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1. Summary 
 
Melanoma is the most deadly form of skin cancer and the incidence rate is continuously in-
creasing worldwide. Interestingly, neural crest cells and melanoma cells share striking simi-
larities and various developmental programs usually active in the neural crest seem to find 
reuse in melanoma. In the frame of my PhD study I investigated the role of the neural crest-
relevant factor NKAP in melanoma.  
 
The goal of my doctoral thesis was to identify a novel neural crest-associated transcriptional 
regulator involved in melanoma. On the basis of a whole-genome transcriptome analysis, 
NKAP was identified among a set of 53 genes, which were up regulated in neural crest stem 
cells when compared to their early-differentiated derivatives. In order to investigate the role 
of NKAP in melanoma, loss-of-function and gain-of-function studies were performed in hu-
man melanoma cell cultures. As a result, NKAP depleted cells showed reduced adhesive po-
tential and presented with a strong G1/G0 cell cycle arrest in vitro. Moreover, subcutaneous 
injections in NSG mice revealed a drastic increase in the metastatic behavior upon NKAP 
depletion, despite unaffected tumor growth. These results were further substantiated with clin-
ical data retrieved from the TCGA database, highlighting that low NKAP levels in lymph 
node and distant metastases correlate with poor patient survival. On the other side, exogenous 
expression of a fluorescently labeled fusion protein confirmed NKAP’s exclusive localization 
to the nuclear speckles. These findings were further corroborated, as NKAP co-
immunoprecipitated with numerous nuclear speckle proteins involved in RNA splicing and 
processing. Furthermore, NKAP depletion induced a drastic reduction in translational activity. 
Thus, only well-regulated NKAP expression levels guaranteed optimal conditions for protein 
synthesis, whereas aberrant NKAP expression resulted in reduced translation.  
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Consequently, the results of my doctoral thesis indicate that NKAP is a tightly regulated nu-
clear speckle protein involved in co- or post-transcriptional processes. Hence, NKAP deple-
tion results in reduced translational activity and increases the metastatic potential in melano-
ma. Recently, it has been discovered that translational inhibition leads to the activation of an 
alternative translational program, which is associated with increased stemness and tumorigen-
esis. However, whether this is the cause for the increased metastatic proclivity in NKAP de-
pleted melanoma cells has not yet been addressed and requires further investigations.  
  Zusammenfassung 
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2. Zusammenfassung 
 
Malignes Melanom beschreibt die tödlichste Form von Hautkrebs mit einer weltweit stetig 
ansteigenden Inzidenzrate. Interessanterweise teilen sich Neuralleistenstammzellen und Me-
lanomzellen verblüffend viele Eigenschaften, sodass verschiedene entwicklungsbezogene 
Programme die normalerweise in der Neuralleiste aktiv sind im Melanom Wiederverwendung  
finden. Während meiner Dissertation habe ich die Rolle des für die Neuralleiste relevanten 
Faktors NKAP in Melanom untersucht.  
 
Das Ziel meiner Doktorarbeit war es, einen neuen mit der Neuralleiste assoziierten Transkrip-
tionsregulator zu identifizieren, der in Melanom von Bedeutung ist. Anhand einer gesamtge-
nomischen Transkriptomanalyse wurde NKAP in einer Gruppe von 53 Genen entdeckt, wel-
che in Neuralleistenstammzellen, im Vergleich zu ihren früh-ausdifferenzierten Abkömmlin-
gen, erhöhte Expressionen aufwiesen. Um die Rolle von NKAP in Melanom genauer zu un-
tersuchen, wurden in humanen Melanomzellkulturen verschiedene Experimente durchgeführt, 
in denen das Gen entweder ausgeschaltet oder überexprimiert wurde. Die Resultate der in 
vitro durchgeführten Untersuchungen zeigten, dass Zellen mit abwesender NKAP Expression 
eine reduzierte Adhäsion und einen starken G1/G0 Zellzyklusarrest aufwiesen. Zusätzlich 
konnte an subkutan injizierten NSG Mäusen belegt werden, dass der NKAP Knockout das 
Metastaseverhalten verstärkte, obwohl das Tumorwachstum unbeeinträchtigt blieb. Klinische 
Daten aus der TCGA Datenbank untermauerten diese Resultate und zeigten auf, dass tiefe 
NKAP Levels in Lymphknoten- und Fernmetastasen mit schlechteren Überlebenschancen für 
den Patienten korrelieren. Auf der anderen Seite konnte anhand eines von außen zugeführten 
fluoreszierenden Fusionsproteins die exklusive Lage NKAP’s in nukleären Speckles demons-
triert werden. Dieser Befund wurde mittels einer Ko-Immunopräzipitationsstudie zusätzlich 
bekräftigt, welche aufgezeigt hat, dass NKAP mit einer Vielzahl von nukleären Speckle Pro-
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teinen interagiert, die an der RNA Prozessierung beteiligt sind. Des Weiteren konnte gezeigt 
werden, dass das Ausschalten von NKAP eine drastische Reduktion der Translationsaktivität 
auslöste. Zusätzlich konnte verdeutlicht werden, dass eine streng regulierte NKAP Expression 
notwendig ist, um optimale Bedingungen für die Translation zu schaffen, währendem abwei-
chende NKAP Levels zu verminderter Proteinsynthese führen.  
 
Die Ergebnisse meiner Doktorarbeit deuten darauf hin, dass NKAP ein streng reguliertes nuk-
leäres Speckle Protein ist, welches an ko- oder post-transkriptionellen Prozessen beteiligt ist. 
Das Ausschalten von NKAP führt zu einer reduzierten Translationsaktivität und zu einem 
verstärkten Metastasierungspotential. Kürzlich wurde entdeckt, dass die Hemmung der Pro-
teinsynthese ein alternatives Translationsprogramms aktiviert, welches mit einer verstärkten 
Ausprägung von Stammzell- und Krebseigenschaften verbunden ist. Ob dies der Grund für 
das verstärkte Metastasierungsverhalten in Melanomzellen ist, konnte bis jetzt noch nicht ab-
schließend behandelt werden und benötigt weitere Untersuchungen.  
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3. Introduction 
 
3.1. The neural crest 
 
The neural crest is a transient appearing embryonic structure defined by a multipotent migratory stem 
cell population that emerges from the dorsalmost margin of the neural tube [Le Douarin_2003; Baggi-
olini_2015] (Figure 1). By definition, neural crest stem cells have the ability to self-renew and to dif-
ferentiate into various cell derivatives appropriate to their corresponding location in the embryo [Le 
Douarin_2003]. The fourth germ layer, another name for the neural crest, is a phylogenetic invention 
of the craniate family and therefore a common feature in all vertebrate embryos including hagfishes 
and lampreys [Hall_2000]. 
 
	  
 
Figure 01. The neural crest is a migratory multipotent stem cell population. In vivo lineage tracing using 
multicolor labeling of premigratory and migratory neural crest cells revealed that the majority of neural crest 
cells are multipotent [graphical illustration; Mario Bonalli in Baggiolini_2015].  
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3.1.1. The development of the neural crest 
 
Following the chronology of embryonic development, first neural crest cells appear during gastrula-
tion and remain present until late organogenesis [Monsoro-Burq_2005; Basch_2006]. As mentioned, 
the induction of the presumptive neural crest region starts at gastrulation and proceeds during neurula-
tion. When the neural plate is specified, the regions flanking the neural plate start to elevate and form 
the neural folds. With continued elevation, the neural folds converge and build the neural tube. As the 
folding of the neural tube progresses, neural crest progenitors start to specify at the neural plate border 
defined as the region between neural and epidermal ectoderm. Upon closure of the neural tube, neural 
crest progenitors undergo an epithelial-to-mesenchymal transition (EMT) and delaminate from the 
ectoderm. Finally, neural crest cells start to migrate along predefined pathways and settle in various 
distant organs where they differentiate into a multitude of derivatives [Betancur_2010] (Figure 2). 
 
	  
 
Figure 02. Regulatory mechanisms during neural crest development. From induction to migration, the for-
mation of the neural crest succumbs a tight gene regulatory network. During neural crest induction WNT, FGF 
and BMP induce the expression of PAX3 and ZIC1. These factors activate the expression of SNAIL1 and 
FOXD3 to initiate neural crest specification. Subsequently, neural crest cells undergo EMT, delaminate from the 
neural crest and migrate throughout the embryo to reach their sites of specification [Sauka-Spengler_2008].  
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3.1.2. Molecular signaling cues during neural crest induction 
 
The induction of the neural crest mainly occurs in response to instructive signaling molecules emanat-
ing from adjacent tissues, such as the mesoderm or the neural and epidermal ectoderm. As a conse-
quence of the external influence, a class of transcription factors is activated and initiates the separation 
of prospective neural crest cells from other neural plate border cells [Basch_2006]. This tightly con-
trolled transcriptional network allows future neural crest cells to control the acquisition of self-
renewal, multipotency and the competence to respond to later neural crest-specifying signals. Despite 
differences between species, neural crest inducing signals appear similar and comprise secreted lig-
ands, such as bone morphogenetic proteins (BMPs), Wingless-type proteins (WNTs), and fibroblast 
growth factors (FGFs) [Knecht_2002].  
 
While high levels of BMP are necessary for the acquisition of epidermal fate, neural development 
requires BMP inhibition [LaBonne_1998]. Consequently, the neural plate border is exposed to inter-
mediate levels of BMP signals, as a result of diffusing signaling molecules from the ectoderm. Alt-
hough BMP signaling is required for neural crest induction, intermediate levels of BMPs alone, are not 
sufficient to induce neural crest cell markers [Knecht_2002, Nguyen_1998]. Several gain- and loss-of-
function experiments in different species have shown the importance of WNT signaling in neural crest 
development [Garcia-Castro_2002; LaBonne_1998; Lewis_2004]. However, none of the performed 
experiments addressed the role of WNTs in early neural crest induction during gastrulation. Hence, it 
remains unknown whether WNT signaling plays an inductive part at early stages. It is difficult to draw 
a definite conclusion about the role of FGFs in neural crest induction, as the requirement for FGF sig-
naling varies among species. In Xenopus, the mesoderm-derived FGF ligands up regulate the expres-
sion of early neural crest cell marker, SNAIL2 also known as SLUG [Mayor_1997; Villanueva_2002]. 
Nevertheless, in mouse or zebrafish, neural crest cells develop normally despite absent FGF signaling 
[Noden_2005]. Moreover, it is speculated whether local cell-cell signals such as NOTCH/DELTA 
might be involved during the induction of the neural crest [Endo_2002; Glavic_2004; Wil-
liams_1995].  
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3.1.3. Molecular signaling cues during neural crest specification 
 
Under the influence of external neural crest specifying signals during early neurulation, the area be-
tween neural and epidermal ectoderm starts to express so-called neural plate border specifiers. Among 
those there are homeobox transcription factors such as MSX1/2, DLX5, PAX3/7, GBX2 and the zinc 
finger-containing ZIC proteins [Monsoro-Burq_2005; Tribulo_2003; Sato_2005; Hong_2007; 
Luo_2001; Woda_2003]. Upon expression of neural plate border specifiers, presumptive neural crest 
cells acquire competence to respond to later neural crest specifying signals.  
 
The transcriptional network that controls the process of specification in premigratory and delaminating 
neural crest progenitor cells is defined by the expression of so-termed neural crest specifier genes. At 
early neurula stage, neural plate border genes either directly or indirectly regulate the expression of 
neural crest specifiers such as AP2α, SNAIL1/2, ID, c-MYC and TWIST [Meulemans_2004; 
Sato_2005; Tribulo_2003; Nikitina_2009; Sauka-Spengler_2008]. It has been proposed, that during 
the specification process neural crest specifiers play different roles. Thus, SNAIL2 for example has 
been shown to take over key functions during EMT, while c-MYC and ID maintain neural crest cells 
in a multipotent state, mediating critical cell cycle and cell fate decisions [LaBonne_2000; Bar-
rio_2002; Bellmeyer_2003; Kee_2005; Light_2005]. Furthermore, c-MYC and AP2α directly regulate 
ID expression implicating their role in cross-regulating other neural crest specifiers [Nikitina_2008]. 
At the time of delamination, neural crest fate acquisition is defined by the expression of SNAIL2, 
FOXD3, SOX9, ETS1, c-MYB and SOX10, while the latter persists in migrating and differentiating 
neural crest cells. Whereas the winged-helix transcription factor FOXD3 was shown to maintain neu-
ral crest multipotency by preventing early differentiation, the functions of ETS1 and c-MYB, though 
only specific to the cranial crest, are implicated in SOX10 activation [Betancur_2010; Lister_2006; 
Théveneau_2007].  
 
Summarizing, the specification process is a key event during neural crest development, where external 
signals mediated by neural plate border specifiers induce a collective interplay of neural crest specifier 
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genes. These transcription factors in turn orchestrate the expression of downstream effectors that allow 
neural crest cells to acquire their ultimate migratory and multipotent properties.   
 
3.1.4. Molecular signaling cues during neural crest migration 
 
In order to delaminate from the neuroepithelium and emigrate from the dorsal margin of the neural 
tube, premigratory neural crest cells lose their compact organization and acquire motility. This so-
called EMT process affects changes on a cellular level that include switches in cell junctions and ad-
hesion properties as well as cytoskeletal rearrangements. As a consequence of the cellular conversion, 
migrating neural crest cells acquire a flat, mesenchymal morphology and start to form filopodia and 
lamellipodia [Coles_2007].  
 
On a molecular scale, a major characteristic of EMT is defined by the switch in cadherin expression 
that involves down regulation of type I cadherins such as E- and N-cadherin (CDH1/2) and up regula-
tion of type II cadherins as for example cadherin 7 (CDH7). It has been shown that in response to 
BMP signaling, SMAD-interacting protein 1 (SIP1), which is expressed in premigratory and migratory 
neural crest cells, leads to CDH1 repression [Comijn_2001]. Moreover, CDH1 and CDH2 expressions 
are negatively regulated by SNAIL1 and SOX10, respectively [Cano_2000]. On the other hand, 
though a direct gene regulatory interaction has not been demonstrated, it is evident that FOXD3 and 
SOX10 induce the expression of CDH7 and β1 integrin (ITGB1), another factor up regulated upon 
EMT [Cheung_2005]. Although many of the neural crest specifiers persist during migration, the up-
stream modulators may vary among the different time points. Hence, it has been shown that during 
migration SOX10 is directly regulated by FOXD3, AP2α and SOX9 but also receives inputs from the 
WNT signaling pathway [Werner_2007].  
 
As neural crest cells synchronously leave the dorsal neural tube in S Phase, EMT and migration are 
tightly linked to cell cycle. It is proposed that this coordinated interplay between delamination and cell 
cycle progression is regulated by BMP-dependent WNT signaling. It has been demonstrated that 
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WNT-mediated activation of the transcription factor TCF/LEF is crucial for G1/S transition in neural 
crest cells most likely through modulation of cyclin D1 [Burstyn-Cohen_2002].  
 
During migration, semaphorins represent important extracellular signaling molecules guiding neural 
crest cells to the right target site. Semaphorins define the migratory routes as they either attract cells 
by providing a permissive environment for migration or repel cells and thereby create crest-free zones. 
Hence, migrating neural crest cells express the corresponding receptors neuropilin 1/2 (NRP1/2) and 
co-receptors plexin A1 (PLXNA1) [Osborne_2005]. Moreover, ephrins represent a further group of 
signaling molecules that are involved in directing and maintaining the migratory streams [Mel-
lott_2008].  
 
3.1.5. Molecular signaling cues during neural crest differentiation 
 
After neural crest cells have reached their sites of destination, usually, the expression of early neural 
crest specifier genes, such as SNAIL1/2, FOXD3, ID and AP2α is down regulated 
[Meulemans_2004]. However, the SRY-related HMG-box family E (SOXE) transcription factors, 
SOX9 and SOX10 display remarkable exceptions as they persist in specific subgroups of neural crest 
derivatives and appear to be master regulators of terminal differentiation [Kelsh_2006]. Although this 
sustained expression seems paradoxical, it might be explained by the fact that over time transcription 
factors take over multiple functions, as it has been demonstrated for SOX10. Thus, dependent on the 
concentration, low SOX10 levels maintain multipotency in migratory neural crest cells, whereas high 
SOX10 levels inhibit neuronal differentiation and promote melanocytic and glial differentiation 
[Kim_2003; Paratore_2001]. Alternatively, it is conceivable that SOX9 and SOX10 gain novel in-
structive roles during fate determination through acquisition of novel interaction partners. 
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3.1.6. The cranial neural crest 
 
During embryogenesis, the neural crest develops along the neural axis from cranial to caudal in a spa-
tially and temporally deferred manner. Consequently, a neural crest cell turns into the corresponding 
type of derivative depending on the axial level and the time of emigration. As outlined above, the pro-
cess of differentiation involves cell intrinsic as well as extrinsic signaling cues. Therefore, it is evident 
that the surrounding microenvironment has a major impact on the differentiation outcome of an invad-
ing neural crest cell (Figure 3). 
 
	  
 
Figure 03. Axial specificity of the neural crest. The neural crest develops from cranial to caudal in a spatially 
and temporally deferred manner. Cranial neural crest cells (blue) give rise to skeletal structures of the face, car-
diac neural crest cells (green) contribute to the proximal outflow tract of the heart, while vagal neural crest cells 
(yellow) populate the gut and establish the enteric nervous system. Trunk neural crest cells (red) become nerve 
and glia cells of the peripheral nervous system, form cells of the adrenal medulla and give rise to melanocytes 
[graphical illustration; Mario Bonalli_2016]. 
 
In the cranial region, the formation of the pharyngeal (or branchial) arches represents a prerequisite 
structure for the developing craniofacial elements, characterized by a complex interplay of all four 
germ layers including neural crest cells from different cranial levels. Thus, neural crest cells originat-
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ing from the midbrain and rhombomeres 1 and 2 (r1 & r2) give rise to neurons and glia of the trigemi-
nal ganglion as well as the skeleton of the upper and lower jaw. Neural crest cells from r4 generate 
neurons of the proximal facial ganglion and the hyoid bone. Furthermore, postotic crest streams from 
r6 and r7 become neurons of the proximal and jugular ganglia and skeletal components of the post-
pharyngeal arches [Graham_2004; Lumsden_1991; Schilling_1994]. In addition to the location, the 
time of emigration also influences the differentiation process. Hence, early migrating cells populate 
the pharyngeal arches to generate bone, cartilage and connective tissue (skeletal structures), whereas 
the later migrating cells generate neurons and glia of the cranial ganglia [Graham_2004]. In a spatially 
and temporally distinct emigration stream, neural crest cells populate the embryonic epidermis and 
give rise to melanocytes. As epidermal pigment cells are generated similarly along the entire neural 
axis, melanocyte differentiation will be discussed in a separate section [3.1.9.].  
 
Dissecting the molecular circuits in the cranial neural crest reveals that during chondrocyte develop-
ment, SOX9 directly regulates expression of important cartilage markers such as collagen type II α1 
(COL2A1), COL11A2, and cartilage-derived retinoic acid-sensitive protein (CD RAP) 
[Lefebvre_1997; Bridgewater_1998; Xie_1999]. Furthermore, it has been shown that TGF-β-mediated 
suppression of SOX10 is necessary for neural crest cells to generate mesenchymal progenitors 
[John_2011]. On the other hand, SOX10 is crucial in neuronal and glial fate specification and might 
participate in glial end-stage differentiation, as its expression persists within this lineage 
[Kelsh_2006]. It has been demonstrated that SOX10 directly regulates the expression of major com-
ponents of the myelination process, such as protein zero (P0), myelin basic protein (MBP), peripheral 
myelin protein 22, and the gap junction protein connexin 32 (CX32) [Peirano_2000; Bondu-
rand_2001]. In the presumptive trigeminal ganglion, neural crest cells might additionally receive 
NOTCH input signals that favor neuronal and glial lineage specification. Likewise to SOX10, 
NOTCH signaling promotes gliogenesis but inhibits neurogenesis [Nakamura_2000; Ohtsuka_1999]. 
Along this line, glial fibrillary acidic protein (GFAP) might function as direct NOTCH downstream 
effector gene mediated by HES1 and HES5 [Ijuin_2008; Jarriault_1995]. It is assumed that the regula-
tory mechanisms during neuronal differentiation are similar in cranial and trunk neural crest cells. 
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Therefore, neurogenesis will be discussed in the corresponding section [3.1.9.] on trunk neural crest 
differentiation, as most of the studies on neurogenic differentiation have been performed in trunk neu-
ral crest cells.  
 
3.1.7. The cardiac neural crest 
 
Cardiac neural crest cells originate from the posterior region of the otic placode [Kirby_1983]. They 
migrate through the circumpharyngeal ridge and invade the caudal pharyngeal arches 3, 4 and 6. Sub-
sequently, neural crest cells populate the distal outflow tract cushions and from there a small popula-
tion migrates to the proximal outflow tract or to the intraventricular septum where they form a sheath 
around the AV bundle [Kirby_1990]. Under the influence of TGF-β and BMP, crest cells of the distal 
and proximal outflow tract, undergo a mesenchymal differentiation into smooth muscle cells and form 
a condensed structure defined as the aorticopulmonary septation complex. Additionally, cardiac crest 
cells give rise to cardiac ganglia and support the development of the thymus and parathyroid gland 
[Kirby_1983; Bockman_1984]. However, the molecular mechanisms underlying the generation of 
these neural crest-derived structures are not yet fully understood.  
 
3.1.8. The vagal and sacral neural crest 
 
Vagal neural crest cells emigrate from the caudal hindbrain region and invade the foregut. In a rostral-
to-caudal directed migration, vagal neural crest cells populate the entire gut except for the hindgut and 
generate the enteric nervous system (ENS). In a first wave, ENS precursors colonize the myenteric 
(outer) region of the gut, preceding an inward directed radial migration that colonizes the submucosal 
(inner) layer and an outward directed migration to the pancreas that forms ganglia near the islets of 
Langerhans [Lake_2013]. Later processes also include the invasion of sacral neural crest cells into the 
epigastric part of the gut [Avetisyan_2015]. Enteric neural crest-derived cells differentiate into at least 
20 neuronal subtypes or enteric glia and control gastrointestinal peristalsis, regulate blood flow, and 
modulate fluid secretion and absorption [Furness_2006].  
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On the molecular stage, migrating neural crest cells express the receptor tyrosine kinase RET in re-
sponse to retinoic acid synthesized by the paraxial mesoderm, which has been shown to support sur-
vival, proliferation and migration [Simkin_2013]. This process is likely modulated by glial cell line-
derived neurotrophic factor (GDNF) and its receptor GFRA1 through their direct interaction with RET 
[Enomoto_1998; Manié_2001]. Moreover, it has been shown that endothelin-3 (EDN3), a small (21-
aa) vasoactive peptide that binds to a G-protein-coupled heptahelical receptor (EDNRB) is required 
for proper ENS development especially in the hindgut [Nagy_2006]. However, once neural crest cells 
have reached the foregut, there are no extrinsic signaling cues known so far that drive the rostro-
caudal bowel colonization. Therefore, it is assumed that harmonized distribution throughout the gut is 
a consequence of competition for space and trophic factors driven by proliferation [Young_2014]. As 
enteric neural crest derivatives populate the bowel, they prefer to stay in contact with each other, a 
process called chained migration. It is suggested that this process is mediated by human L1 cell adhe-
sion molecule (L1CAM) [Young_2014; Anderson_2010]. Furthermore, it was shown that matrix met-
alloproteinase-2 (MMP2) enhances bowel colonization, most probably by creating gaps in the extra-
cellular matrix, thereby facilitating the migration process [Anderson_2010]. After enteric neural crest 
cells have completed rostrocaudal migration, they start to organize in ganglia, a process that is regulat-
ed by the expression of neural cell adhesion molecule 1 (NCAM1) [Faure_2007].  
 
As mentioned previously, enteric neural crest derivatives give rise to over 20 different subtypes of 
neurons that differ in function, transmitter, neurite patterning, and electrophysiology. Therefore, it is 
conceivable, that a plethora of neurotrophic factors, morphogens, and transcriptional regulators or-
chestrate neuronal subtype specification. However, for most neuronal subtype, specific determinants 
driving their differentiation have not yet been identified [Furness_2006].  
 
3.1.9. The trunk neural crest 
 
In the trunk, neural crest migration is strongly dominated by the physical structures of the somites. 
The segmental organization of the somites guarantees the metameric formation of the peripheral nerv-
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ous system (PNS). Thereby, somite-derived signaling inputs ensure the coordinated development of 
peripheral ganglia and nerves with skeletal structures of the trunk. Somites gather symmetrically along 
each side of the neural tube and the notochord. They are defined as an accumulation of cells from the 
paraxial mesoderm surrounded by an epithelial layer. Subsequently, somites divide into a ventral and a 
dorsal portion termed sclerotome and dermomyotome, respectively [Gammill_2010].  
 
Comparable to the cranial neural crest, trunk neural crest cells leave the neural tube in a rostral-to-
caudal temporally deferred manner and enter a variety of migratory routes. Initially, neural crest cells 
migrate around the ventral side of the somites or in between somites [Loring_1987; Teillet_1987]. 
Upon somite dissociation, neural crest cells begin to invade the sclerotome and migrate ventrolateral-
ly. However, neural crest cells only traverse the rostral aspect of each somitic sclerotome [Bronner-
Fraser_1986]. Finally, in a third migration wave, neural crest cells follow a dorsolateral pathway be-
tween the epidermal ectoderm and dermomyotome [Erickson_1992] (Figure 4).  
 
	  
 
Figure 04. Trunk neural crest cells populate the embryo in different migratory streams. Trunk neural crest 
cells leave the neural tube from cranial-to-caudal in a temporally deferred manner. Initially, neural crest cells 
follow a ventral route and later switch to a ventrolateral pathway. Finally, neural crest cells migrate between the 
epidermal ectoderm and the dermomyotome on a dorsolateral path [graphical illustration; Mario Bonalli_2016]. 
 
During migration, environmental signaling cues guide trunk neural crest cells on predefined routes to 
their target site. Initially, crest cells simply follow blood vessels as they migrate through the interso-
mitic space, a process possibly mediated by ephrin B2 [Davy_2007]. Upon disconnection from the 
somite, the sclerotome becomes accessible to invasive neural crest cells. Sclerotome cells create a 
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permissive and migration-friendly extracellular matrix consistent of fibronectin, laminin and collagen 
[Duband_1987; Newgreen_1980]. Additionally, with dissociation of the sclerotome, neural crest cells 
start to express NRP1, thereby receiving repulsive SEMA3A signals from the dermomyotome and the 
intersomitic space [Schwarz_2009; Roffers-Agarwal_2009]. As a consequence, neural crest cells 
switch from the ventral to the ventrolateral migration path. Simultaneously, neural crest cells begin to 
express NRP2, the receptor of the repellent SEMA3F ligand, which is secreted by the caudal aspect of 
the sclerotome. This leads to the segmental organization of the migratory stream. Finally, it has been 
shown that ephrin and CXCL12/CXCR4 signaling, as well as other extracellular matrix components 
such as F-spondin, T-cadherin, and glycoproteins including aggrecan, versican and tenascin-C might 
influence the migratory behavior of trunk neural crest cells [Krull_1997; Rehimi_2008; Debby-
Brafman_1999; Ranscht_1991; Perissinotto_2007; Dutt_2006; Tucker_1991].  
 
It has been shown that the switch to the dorsolateral pathway does not depend on changes in environ-
mental signaling cues but is neural crest cell autonomous and involves alterations in cell surface recep-
tor expression [Erickson_1995]. During early migration, neural crest cell repulsion from the dermo-
myotome is exerted by the function of the ROBO receptor and its ligand SLIT. However, late migrat-
ing neural crest cells down regulate ROBO expression, thereby losing their responsiveness to repul-
sive signals, which allows them to invade the dermomyotome [Jia_2005]. In addition, the switch from 
repulsion to attraction seems to be further promoted by differentially expressed ephrin receptors in 
early and late migratory crest cells [Harris_2008].  
 
There is conflicting data about, whether the path of migration instructs fate restriction or reflects pre-
determined lineage specification [Erickson_1995; Baggiolini_2015; George_2007]. However, path-
way selection and fate acquisition are tightly coupled in neural crest cells. Thus, ventrally migrating 
neural crest cells are repelled by the notochord and gather at the dorsal aorta to form neurons and glia 
of the sympathetic ganglia as well as chromaffin cells of the adrenal medulla [Thiery_1982]. Under 
the influence of BMP2, a factor that is secreted by the dorsal aorta, neural crest cells differentiate into 
cholinergic neurons mediated by the basic helix-loop-helix transcription factor MASH1 [Guil-
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lemot_1993]. However, neuronal differentiation is suppressed by glial growth factor (neuregulin), 
which directs differentiation towards a glial fate [Shah_1994; Shah_1996]. This mutually exclusive 
fate acquisition is a time dependent process, as neurogenesis usually occurs prior to gliogenesis. Addi-
tionally, it has been shown that NOTCH signaling instructs glial differentiation at the expense of a 
neuronal fate [Morrison_2000]. In the adrenal medulla, neural crest cells either develop into sympa-
thetic ganglia or into adrenomedullary cells, as they encounter glucocorticoids secreted by cortical 
cells of the adrenal gland [Anderson_1986].  
 
Neural crest cells taking the ventrolateral pathway invade and remain within the sclerotome, where 
they form sensory neurons and glia of the dorsal root ganglia and Schwann cells of the ventral roots 
[Kasemeier-Kulesa_2005]. In order to become sensory neurons, neural crest cells depend on WNT/β-
catenin signaling (Hari_2002). The differentiation process is transcriptionally regulated by the basic 
helix-loop-helix protein neurogenin-2 (NRG2) that promotes expression of tyrosine receptor kinases 
TRKB and TRKC [Anderson_2001; Ma_1999]. Furthermore, it was shown that the POU-domain tran-
scription factor BRN3A, a lineage specific marker for sensory neurons, is responsible for the mainte-
nance of the sensory fate even in the presence of BMP2 [Greenwood_1999].  
 
Neural crest cells that enter the dorsolateral pathway populate the epidermal ectoderm and give rise to 
melanocytes [Erickson_1995]. During migration, presumptive melanocyte progenitor cells that arise 
from the dorsomedial region of the neural tube express the receptor tyrosine kinase KIT. KIT-
expressing neural crest cells migrate exclusively in the dorsolateral pathway and appear with a seem-
ingly restricted fate towards a melanocytic fate [Wilson_2004]. Upon epidermal invasion, neural crest 
cells encounter WNT signaling proteins that inhibit neuronal development and promote melanocyte 
differentiation [Dorsky_1998]. Additionally, it has been shown that EDN3/EDNRB signaling is im-
portant during melanocyte differentiation. However, it is rather necessary for the dispersal and surviv-
al of melanocyte progenitors than for the initial specification process [Greenstein_1994; Lahav_1996]
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3.1.10. Postmigratory neural crest cells 
 
It has been shown that cells with neural crest stem cell-like properties are present throughout different 
developmental stages and even persist until late adulthood. Thus, a self-renewing neural crest stem 
cell-like population with differentiation potential was first identified in E14.5 rat sciatic nerve tissue 
using the neural crest stem cell marker p75NTR [Morrison_1999]. Succeeding this discovery, multipo-
tent p75NTR-positive cells with self-renewal capacity were isolated from the fetal and even more strik-
ing from the adult ENS [Bixby_2002; Kruger_2002]. To this day, postmigratory neural crest-like stem 
cells have been isolated from most if not all neural crest target organs, including sciatic nerve, ENS, 
DRG, bone marrow, skin, and heart [Morrison_1999; Bixby_2002; Kruger_2002; Hagedorn_1999; 
Nagoshi_2008; Wong_2006; Tomita_2005; Shakhova_2010] (Figure 5). Despite their differentiation 
and self-renewing potential, NCSCs display intrinsic differences with variable responses to microenvi-
ronmental signals dependent on their location and the developmental stage. While at early stages, 
WNT and BMP signaling regulates self-renewal of migratory NCSCs, postmigratory NCSCs lose their 
responsiveness to WNT and BMP and proliferation is regulated by the EGF signaling cascade mediat-
ed by small Rho GTPases [Kléber_2005; Fuchs_2009]. Furthermore, it was shown through BrdU in-
corporation experiments that the self-renewal capacity of neural crest-like stem cells decreases with 
age. Moreover, the differentiation potential from adult NCSCs differs substantially from the one of 
fetal NCSCs and gets seemingly restricted towards a distinct cell type [Bixby_2002; Kruger_2002]. 
Nonetheless, the sustained presence in adult tissue and the easy accessibility as for example in the skin 
makes postmigratory NCSCs a conceivable target for future therapeutic approaches in regenerative 
medicine.  
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Figure 05. Neural crest stem cells in adult tissue. During adulthood, neural crest cells reside at their post-
migratory locations and largely share the self-renewal and differentiation potential of their embryonic counter-
parts. In adults, cells with neural crest stem cell-like features have been isolated in the gut, cornea, heart, bone 
marrow, skin and dorsal root ganglia [Shakhova_2010]. 
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3.2. Melanocyte biology 
 
Melanocytes are the pigment cells in our body and responsible for the production of melanin. Pigment 
cells arise from melanoblasts and, with exception of those in the retina, are of neural crest origin. Mel-
anocytes are primarily responsible for our skin and hair color as they are located in the basal layer of 
the epidermis and in hair follicles. However, they can also be found in the uvea, inner ear, meninges, 
bones, and heart [Barden_1983; Markert_1956; Nichols_1969; Theriault_1970].  
 
3.2.1. Melanocyte development 
 
There are three transcriptional master regulators that dictate melanocyte development consistent of the 
basic helix-loop-helix leucine-zipper microphthalmia-associated transcription factor (MITF), PAX3, 
and SOX10. Loss of any of the above mentioned, results in failure of melanocytic development 
[Thomas_2008]. Furthermore, the forkhead box transcription factor FOXD3 regulates melanocyte 
differentiation through suppression of the melanocytic lineage at the expense of neurogenesis and 
gliogenesis. Thereby, FOXD3 acts as a transcriptional repressor that directly down regulates MITF 
expression [Ignatius_2008].  
 
3.2.2. Microphthalmia-associated transcription factor (MITF) 
 
Soon after emigration from the neural tube and well before entering the dorsolateral pathway, MITF is 
expressed in prospective melanocyte precursor cells. MITF expression is driven by the transcription 
factors SOX10 and PAX3 [Bondurand_2000]. In addition, MITF is up regulated by WNT3A in mela-
nocytes [Takeda_2000]. It has been suggested that the WNT down stream effector, LEF1 binds to the 
MITF promoter in response to nuclear translocation of  β-catenin [Dorsky_2000]. MITF and LEF1 
then act synergistically to increase dopachrome tautomerase (DCT, also known as TYRP2) transcrip-
tion [Yasumoto_2002]. Down regulation of FRZB-1, a secreted frizzled-related protein that competes 
with frizzled receptors for WNT-binding might as well be involved in WNT-mediated up regulation of 
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MITF [Jin_2001]. It has also been demonstrated that activation of KIT initiates phosphorylation of 
MITF and concomitant increase in transcriptional activity [Goding_2000]. Moreover, cyclic AMP 
(cAMP) signaling can up regulate MITF and induce melanogenesis. Nevertheless, this seems to be 
rather important in adult melanocytes but not for the initial activation of MITF expression [Ji_2005].  
 
MITF expression is crucial for lineage specification and survival of melanoblasts [Kumasaka_2004; 
Lister; 1999; Nakayama_1998; Opdecamp_1997]. This might partially be explained by the observa-
tion that MITF up regulates TBX2, a member of the family of T-box transcription factors known to 
function in maintenance of cell identity [Carreira_2000]. MITF further controls melanocyte growth 
and survival by regulating BCL2, p21Cip1, DIA1, and INK4A [MCgill_2002; Carreira_2005; Car-
reira_2006; Loercher_2005]. Additionally, MITF directly regulates many of the genes required for 
melanogenesis, including tyrosinase, tyrosinase-related protein 1 (TYRP1), and DCT by binding to E-
box and M-box elements in their conserved regulatory regions [Aksan_1998]. Finally, MITF regulates 
the expression of premelanosome protein (PMEL, also called SILVER), protein melan-A (MLANA, 
also called MART-1), absent in melanoma 1 protein (AIM1), melanocortin 1 receptor (MC1R) and 
KIT [Baxter_2003; Du_2003; Du_2002; Aoki_2002; Tsujimura_1996]. 
 
3.2.3. Melanogenesis 
 
Melanin, the principal product of melanocytes, is an effective absorber of light and dissipates over 
99.9% of the UV radiation [Meredith_2004]. Secondly, melanin is a potent scavenger for free radicals, 
thereby protecting skin cells from high levels of reactive oxygen species that would otherwise damage 
DNA [Meredith_2006]. Once synthesized, melanin is stored in lysosome-related organelles, termed 
melanosomes, which are transported along dendrites and delivered to adjacent keratinocytes [Wasmei-
er_2008]. Generally, melanin is produced by oxidation of the amino acid tyrosine with subsequent 
polymerization. There are three basic types of melanin. The most common are brown and black 
eumelanin, which chemically differ from each other in their pattern of polymeric bonds [Mere-
dith_2006]. Pheomelanin, responsible for the red hair phenotype, is distinct from eumelanin as it in-
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corporates benzothiazine into its oligomer structure [Greco_2011]. Neuromelanin is a dark polymer 
pigment and can be found in catecholaminergic neurons in the brain. However, the exact function of 
neuromelanin has not yet been described [Fedorow_2005].  
 
Melanogenesis is a tightly regulated process including a multitude of intrinsic and extrinsic factors 
that guarantee a concerted interplay between melanocytes and keratinocytes in response to external 
stimuli, such as UV radiation. Hence, aberrant melanin synthesis due to deficient melanogenic en-
zymes causes pigmentation disorders such as albinism or cutaneous hyper- and hypopigmentation 
[Lin_2007]. Melanogenesis is initiated upon activation of MC1R mediated by melanin stimulating 
hormone (αMSH) and adrenocorticotropic hormone (ACTH). This leads to the transcriptional activa-
tion of tyrosinase and tyrosinase-related proteins, TYRP1 and DCT [Abdel-Malek_1995]. Tyrosinase 
is responsible for the conversion of L-tyrosine to dopaquinone, which serves as substrate for both, 
eumelanin and pheomelanin [Cooksey_1997]. Internal cyclization leads to the conversion of dopaqui-
none to dopachrome and DOPA. Dopachrome is then further rearranged to 5,6-dihydroxyindole (DHI) 
and to a lesser extent to 5,6-dihydroxyindole-2-carboxylic acid (DHICA). Enzymatic turnover from 
dopachrome to DHICA is catalyzed by DCT. Finally, DHI and DHICA are further oxidized and poly-
merized to produce eumelanin. The oxidation of DHICA is enzymatically controlled by TYRP1 or 
tyrosinase [Edge_2006] (Figure 6).  
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Figure 06. Synthesis of eumelanin is enzymatically controlled by tyrosinase, DCT and TYRP1. At the onset 
of eumelanin synthesis tyrosinase converts L-tyrosine into dopaquinone, which is internally converted into do-
pachrome and DOPA. Dopachrome is then rearranged to DHI and with the catalytic support from DCT to DHI-
CA. Finally, DHI and DHICA are oxidized to eumelanin under the enzymatic control of TYRP1 or tyrosinase  
[D’Ischia_2015]. 
 
3.2.4. Melanocyte stem cells 
 
The skin represents one of the most regenerative organs in the body. Every day millions of epidermal 
skin cells as well as hair are generated and both of which have to be repigmented in an identical man-
ner. In order to overcome this daily challenge, keratinocyte and melanocyte stem cells in concert have 
to succumb a fine-adjusted regeneration regime that governs self-renewal and differentiation. Alt-
hough, the coloration process is slightly different between skin and hair, the principles are largely the 
same- melanin has to be transferred from a melanocyte to a newly produced keratinocyte.  
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Figure 07. Melanocyte stem cells localize to the hair bulge region. Keratinocyte and melanocyte stem cells 
have been localized to the hair bulge region, whereas differentiated melanocytes are found in the dermal papilla. 
While in humans differentiated melanocytes can also be found in the epidermis, the mouse epidermis is free of 
melanocytes [Picardo_2015]. 
 
Previously, keratinocyte and melanocyte stem cells have been localized to the bulge region of the hair 
follicle [Nishimura_2002; Oshima_2001] (Figure 7). Melanocyte stem cells were identified as DCT 
positive and slow cycling BrdU-incorporating cell population that features general stem cell character-
istics, such as self-renewal and multipotency [Nishimura_2002; Cotsarelis_1990]. In a gene expres-
sion profile analysis, differentiated melanocytes from the bulb were compared to bulge melanocyte 
stem cells. Surprisingly, melanocyte stem cells were only positive for DCT and PAX3 but negative for 
tyrosinase, PMEL, TYRP1, KIT, MITF, SOX10 and MC1R [Osawa_2005]. These results indicate that 
despite of their neural crest origin, melanocyte stem cells have a quite distinct expression profile from 
that of differentiated melanocytes or embryonic melanoblasts.  
 
Investigations on the underlying molecular mechanisms controlling melanocyte stem cell maintenance 
and differentiation have revealed that MITF and PAX3 bind to the same enhancer element in the DCT 
promoter, which is located nearby a LEF1-binding site. Even though PAX3 promotes MITF expres-
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sion, it is a strong repressor of DCT. Thus, PAX3 and MITF act as competitors on the DCT promoter. 
This competition is released as in response to WNT activation β-catenin binds to the LEF1-target site. 
In other words, low WNT signaling activity maintains the stem cell in an undifferentiated state, 
whereas activated WNT signaling relieves PAX3-mediated repression of the DCT promoter, which 
induces terminal differentiation [Lang_2005]. In contrast to WNT-induced differentiation, TGF-β 
signaling retains melanocyte stem cells in a rather quiescent and undifferentiated state [Nishi-
mura_2010]. Furthermore, it was demonstrated that disruption of the canonical NOTCH signaling 
pathway prevents melanocyte stem cells from self-renewing, which concomitantly leads to hair gray-
ing [Wang_2011].   
  
Although the stem cell source responsible for hair shaft pigmentation was recently detected in the hair 
bulge, the location of the epidermal melanocyte stem cell compartment is still not identified. One op-
tion is that the epidermis either shelters its own, so far unidentified stem cell niche or it receives mela-
nocytes from the bulge region likewise to the hair follicle. In contrast to humans, mouse skin is usually 
unpigmented. In K14-SLF mice however, ectopic expression of KIT ligand in keratinocytes leads to 
epidermal melanocyte colonization, analogues to human skin. It has been observed that melanocyte 
stem cells emigrate from the bulge region and populate stem cell niches in the epidermis. Although 
this does not definitively prove the mutual origin of melanocytes, it is at least an intriguing indication 
that the bulge region might serve as a common source for melanocytes of the epidermis and the hair 
follicle [Nishimura_2002].   
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3.3. Neurocristopathies 
 
Neurocristopathies are defined as a diverse class of pathologies that arise from cells that commonly 
derive from the neural crest. The expression was coined by the physician Robert P. Bolande in 1974, 
who tried to denote a group of different diseases having a common origin in the neural crest [Bo-
lande_1974]. Due to the fact that the neural crest originates a plethora of different cell types and tis-
sues, diseases arising from the neural crest are particularly diverse in clinical presentation. They in-
clude congenital syndromes as well as acquired neoplastic disorders affecting endocrinological or 
neurological organs, skin, heart or the digestive tract [Bolande_1997]. The following sections describe 
only a small selection of neurocristopathies and are by no means exhaustive.  
 
3.3.1. Waardenburg syndrome 
 
Waardenburg syndrome is a rare, usually autosomal dominant hereditary disease that is mainly the 
result of cranial crest dysgenesis. The disease is characterized by dystopia canthorum, unilateral or 
bilateral hearing impairment, heterochromia iridis, synophrys, white forelock, and patchy hypopig-
mentation. Severe forms further comprise microcephaly, mental retardation, and skeletal malfor-
mations [Read_1997]. Furthermore, Waardenburg syndrome can be accompanied by other neu-
rocristopathies, such as Hirschsprung’s disease or piebaldism [Shah_1981]. Waardenburg’s disease 
has been shown to result from mutations in the PAX3, SOX10, EDN3, EDNRB, MITF, and SLUG 
genes. These genes primarily affect migration and differentiation of melanoblasts but also glial cells 
[Pingault_2010]. At present there is no disease-curing treatment available. Therapy is mainly directed 
towards specific symptoms and involves cosmetic corrections and treatment of deafness, which is in 
correspondence with the treatment of any other form of irreversible deafness [www.rarediseases.org].  
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3.3.2. Hirschsprung’s disease 
 
Hirschsprung’s disease describes a heterogeneous group of disorders characterized by absent or dys-
functional enteric innervation in the hindgut region ultimately leading to a megacolon in the anteced-
ent parts of the bowel. In most cases the defect involves only the myenteric and submucosal plexuses 
of the most distal colon and does not extend above the rectosigmoid colon [McKeown_2013]. The 
aganglionic or hypoganglionic colon segment is narrowed and spastic due to the lack of inhibitory 
signals from the intrinsic nervous system, while external excitatory signals cause constriction and fi-
nally constipation [Kubota_2002]. Hirschsprung’s disease is usually diagnosed shortly after birth be-
cause of the presence of megacolon or because of the delayed departure of the meconium (first stool), 
which normally passes within the first 24 hours [Kapur_2009]. Pathophysiologically, the most accept-
ed theory suggests a defect in the rostrocaudal migration of neural crest derived cells 
[Druckenbrod_2009]. It is further debated whether erroneous differentiation or increased apoptotic 
events might contribute to the onset of the disorder [Uesaka_2010]. The RET gene has been identified 
as a major susceptibility gene as it was mutated in 80% of all mutations associated with Hirsch-
sprung’s disease [Emison_2010]. However, further disease-causing mutations have been found in 
EDNRB, EDN3, GDNF, and L1CAM genes, or when part of the Waardenburg syndrome, also in the 
SOX10 gene locus. Nonetheless, the incidence of these mutations is at much lower rate [Amiel_1996; 
Heanue_2007; Griseri_2009; Bondurand_2007]. At present, the only available treatment involves 
surgical removal of the dysfunctional bowel. Instead, cell transplantation therapy was proposed as an 
alternative to surgical resection. However, cellular resubstitution treatments have not yet found their 
way into clinical application and require further investigations [Metzger_2009].  
 
3.3.3. DiGeorge syndrome 
 
The DiGeorge syndrome, another term for 22q11.2 deletion syndrome, consists of agenesis or hypo-
plasia of the thymus and parathyroid glands, conotruncal abnormalities of the heart, and craniofacial 
dysmorphism [Kobrynski_2007]. Affected patients often suffer from chronic recurrent infections, due 
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to the absent or hypoplastic thymus, which concomitantly leads to an impaired T-cell response [Mag-
gadottir_2013]. Cardiac malformations generally comprise tetralogy of Fallot, interrupted aortic arch, 
truncus arteriosus, ventricular septal defect, transposition of the great vessels, and right aortic arch 
[Keyte_2012]. Moreover, the non-functional parathyroid gland causes hypocalcemia due to low levels 
of parathyroid hormone. This frequently leads to convulsions in newborns and serves, besides present 
heart defects, as a first indication of the disease. Cranial abnormalities may include a long face, hyper-
telorism, malar flattening and velopharyngeal incompetence with or without cleft palate [Hacihamdi-
oglu_2015]. Patients might additionally suffer from learning difficulties, psychiatric disorders and 
bear a significantly elevated risk to develop schizophrenia [Van Amelsvoort_2004]. Although the 
deletion can be inherited in an autosomal dominant manner, in most cases the mutation is acquired de 
novo. As a consequence of the incomplete genetic penetrance the syndrome is characterized by a 
marked variability in clinical expressions [Ryan_1997]. Therefore, early diagnosis of DiGeorge syn-
drome can be difficult and is commonly suspected in patients with more than one symptom present 
[Fernandez_2005]. Due to the presence of numerous chromosome-specific low copy number repeats 
or segmental duplications, the 22q11 region is very unstable and therefore prone to rearrangements 
during germ cell formation [Edelmann_1999]. The waste majority of the patients have a 3 Mb micro-
deletion, which affects approximately 40 – 50 genes, many of which have not been well characterized 
[Kobrynski_2007]. The exact molecular pathomechanism has proven to be of highest complexity and 
therefore has not yet been entirely understood. It is well conceivable that several of the deleted genes 
contribute to the entire manifestation of the syndrome. Nevertheless, TBX1 has been supposed as one 
of the major driver responsible for many, still not for all of the symptoms present in DiGeorge syn-
drome [Packham_2002]. Furthermore, it has been proposed that TGF-β signaling plays an important 
role during the onset of the disease. Hence, conditional ablation of TGF-β receptor II (TβRII) in neural 
crest cells mimics the clinical appearance of DiGeorge syndrome in mice. It was shown that TGF-β 
signaling controls expression of CRK like proto-oncogene, adaptor protein (CRKL), a gene that is 
commonly affected by the 22q11.2 deletion. Accordingly, CRKL depletion in mice causes a pheno-
type reminiscent of the human DiGeorge syndrome [Wurdak_2004]. To this day, there is no cure 
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known for the 22q11.2 deletion syndrome. Therapy is generally directed towards individual symptoms 
using standard methods [Hacihamdioglu_2015]. 
 
3.3.4. Giant congenital melanocytic nevus 
 
Giant congenital melanocytic nevi (GCMN) are benign hyperplastic melanocytic lesions present at 
birth or within the first few month of life that reach a diameter >20 cm in adult life. In general, mela-
nocytic nevi describe accumulations of nevus cells clustered as nests in the epidermis, dermis or in 
other tissues. GCMN usually present as brown lesions with flat or rugose surface, well-demarcated 
borders and hypertrichosis. Although any localization in the skin can be affected, GCMN are most 
commonly found in parts of the trunk, head or neck [Lyon_2010; Kincannon_1999]. Apart from the 
clinical and psychological implications, the most significant feature of GCMN is the associated risk to 
develop other malignancies such as melanoma, rhabdomyosarcoma, peripheral nerve sheath tumor or 
in rare cases neurocutaneous melanocytosis [DeDavid_1997; Hoang_2002; DeDavid_1996]. The ex-
act pathomechanism for GCMN has not yet been completely resolved. It is suggested that during em-
bryonic development melanoblasts acquire somatic mutations that induce excessive prenatal prolifera-
tion. Consequently, giant congenital nevus cells have been primarily reported with gain-of-function 
mutations in the neuroblastoma retrovirus-associated DNA sequence (N-RAS) locus, which leads to 
permanent stimulation of the mitogen-activated kinase (MAPK) pathway [Bauer_2007]. Along this 
line, ectopic expression of the constitutive active N-RASQ61K oncogene in the melanocytic lineage of 
mice results in dermal melanocytic hyperplasia and occasionally in melanoma [Ackermann_2005; 
Shakhova_2012]. At the moment, surgical intervention represents the only available treatment. How-
ever, patients suffering from GCMN might additionally require psychological support [Viana_2013].  
 
3.3.5. Neoplastic neurocristopathies 
 
In contrast to congenital neurocristopathies, acquired neurocristopathies emerge later in life, and 
among others, include neural crest-derived tumorigenic transformations. Accordingly, neoplastic neu-
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rocristopathies comprise malignancies from peripheral and cranial nerves (e.g. peripheral nerve sheath 
tumor), sympathetic nerves (e.g. neuroblastoma), chromaffin cells of the adrenal medulla (e.g. pheo-
chromocytoma), parafollicular cells of the thyroid gland (e.g. medullary thyroid carcinoma), or cells of 
the melanocytic lineage (e.g. melanoma), which will be discussed in detail in the following sections 
[Maguire_2015]. 
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3.4. Melanoma 
 
Melanoma is a neural crest-derived neoplasia that is generally defined as cancer of the melanocytic 
lineage [Gray-Schopfer_2007]. However, the origin of melanoma is highly controversial. It is assumed 
that melanoma cells arise from melanocytes or nevus cells, but hypothetically they might also derive 
from melanocyte stem cells, adult neural crest-like stem cells, or even from glial progenitor cells pre-
sent in the peripheral nerve sheath. Thus, it is well conceivable that melanoma originates from various 
different cell types that are not primarily restricted to the melanocytic lineage [Debbache_unpublished 
data]. Therefore, melanoma might rather be used as an umbrella term that, regardless of its cellular 
origin, describes a specific clinicopathological disease pattern.  
 
3.4.1. Epidemiology 
 
Melanoma is the most fatal form of skin cancer and advanced-stage cutaneous melanoma has a median 
survival time of less than 1 year. Unfortunately, the incidence of melanoma is continuously increasing 
worldwide. Indeed, the incidence rate in the Caucasian population augments annually by 3-7% [Par-
kin_2001]. The rationales may be found in the better and earlier detection of melanomas and enhanced 
public awareness. However, it may also be attributed to a change in the sun-seeking behavior, which 
goes along with increased exposure to natural and artificial UV radiation [Elwood_1997]. Typically, 
primary melanomas occur in the skin (cutaneous; 91.2%) but they can also be found in the mouth 
(mucosal; 1.3%), eye (ocular; 5.2%), or without a known primary tumor (2.2%) [Chang_1998; 
McLaughlin_2005]. Yet another special form of melanoma describes the acral lentiginous subtype that 
affects non hair-bearing surfaces, such as palms, soles, nail beds, or oral mucosa [Erdei_2010] (Figure 
8). 
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Figure 08. Clinical classification of melanoma. Melanomas are clinically classified according to their localiza-
tion in the body. Cutaneous melanomas affect the skin and represent the most common form among all subtypes. 
Acral lentiginous melanomas are less frequent and occur in non hair-bearing regions of the skin. Mucosal and 
ocular melanomas also represent rare melanoma subtypes and emerge from melanocytes located in the mouth 
and eye, respectively [adapted from Rager_2005; Disky_2008; Swagata_2011; Mellen_2013] 
 
According to studies from different developed countries, the incidence for cutaneous malignant mela-
noma in both genders ranks among the seven most common cancers or higher [Jemal_2011; Fer-
lay_2013; Parkin_2001]. Not surprising, the incidence rate for melanoma is highest in fair-skinned 
people, yet extremely rare among the black population, which in most cases present with the acral 
lentiginous subtype [Adegbidi_2007; Asuquo_2009]. The median age of melanoma patients at time of 
diagnosis is 52 years. In comparison, this is almost a decade before most other solid tumors arise (e.g. 
breast, colon, lung or prostate) [Hayat_2007; Tas_2011; Erdei_2010; Van der Velden_2009]. While, 
surgical intervention at early stages seems to prevent progression in most cases, patients with deep 
primary tumors and regional lymph node infiltration frequently develop distant metastases. Hence, 
median survival of patients with distant metastases is only 6-9 months, and the 5-year survival rate is 
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less than 5% [Houghton_2002]. General differences regarding gender singularities mainly concern the 
anatomical distribution of the lesions. Thus, in women melanoma is more often detected in the lower 
extremities, whereas in men lesions are more common in the head, neck and trunk region of the body 
[Bulliard_1997; Naldi_2005; Katalinic_2003]. Furthermore, it was shown that women have a survival 
advantage over men, as the mortality rate in male patients is twice as high as in female patients 
[Schmidt_2006]. 
 
3.4.2. Melanoma risk factors 
 
Exposure to UV radiation is well accepted to be the major causative factor for melanoma [El-
wood_1997]. UV exposure is tightly associated with the geographical location, which determines the 
distribution of the melanoma incidence. Additionally, the risk strongly underlies the pattern of sun 
exposure with highest risks for intermittent or cumulative UV exposure. The risk further depends on 
the frequency of excessive sun exposure and inherited susceptibility to its effects [Solomon_2004; 
Gandini_2005b]. However, the relationship between UV exposure and genetic factors is not well un-
derstood, since a UV footprint (specific UV-induced DNA damage pattern) is not always detected in 
melanoma tumors [Thomas_2006]. UVA as well as UVB are both considered as putative factors pro-
moting skin carcinogenesis. Hence, independent of the applied UV spectrum, indoor tanning elevates 
the odds ratio for cutaneous malignant melanoma by 1.74 [Lazovich_2010]. The risk to develop mela-
noma at different body sites is associated with the amount and pattern of sun exposure. Consequently, 
recreational sun exposure with intermittent exposition strongly predicts melanoma on less frequently 
sun-exposed body sites such as the trunk. Occupational sun exposure that implies a continuous pattern 
increases the risk to develop melanoma on the head and neck. And finally, total sun exposure is asso-
ciated with a higher risk of melanoma on the limbs [Chang_2009].  
 
There are other risk factors besides UV exposure that influence the melanoma incidence rate, body 
localization and histopathological characterization of the lesions. These risk factors are associated with 
fair skin, blonde or red hair color, lifestyle, environmental factors, gender, social class, genetic predis-
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position, or might be disease-related (e.g. benign or atypical nevi, xeroderma pigmentosum) [Mil-
ler_2006; Erdei_2010]. Moreover, risk factors might diverge among continents and different ethnic 
groups. Hence immunosuppression, inflammation, and albinism have been identified as specific risk 
factors in the African population [Asuquo_2009; Seleye-Fubara_2005].  
 
3.4.3 UV-induced pathogenesis 
 
Apart from causing DNA damage, UV radiation is engaged in many diverse cellular processes in the 
skin including Vitamin D synthesis, local production of growth factors, melanin synthesis, and immu-
nosuppression [Gilchrest_1999]. The ultraviolet spectrum ranges from 200 – 400 nm and is divided 
into three categories based on the wavelength. While 95% of UVA and 1-10% of UVB reach the 
earth’s surface, almost 100% of UVC is absorbed by the atmosphere and the ozone layer. Generally, 
UV radiation is absorbed in the skin by light sensitive macromolecules, such as proteins, lipids and 
nucleic acids. Thereby, UVB often causes direct damage to DNA, while UVA rather generates reac-
tive oxygen species causing indirect oxidative DNA damage [Chen_2015]. As a consequence, UVA 
and UVB leave a specific mutational signature on the DNA dependent on the mechanism of damage. 
In particular, UVA-induced reactive oxygen species often generate 7,8-dihydro-8-oxoguanine (8-
oxoG) lesions, which are susceptible to miss-repair and lead to G→T or G→A transversions [Gariby-
an_2010]. In contrast, photochemical reactions induced by UVB cause cyclobutane pyrimidine di-
mers, which as a result of incorrect repair lead to C→T and CC→TT transitions [Brash_1982]. Alt-
hough most mutations remain without consequences for the cellular integrity, mutations within a gene 
that regulates apoptosis, cell cycle progression, DNA damage response, or similar may cause tumor-
igenic transformation.  
 
3.4.4 Pathohistologic classification and tumor staging of cutaneous melanoma 
 
In 1969, the first classification of primary cutaneous melanoma was established implementing detailed 
observations and descriptions of clinical and histopathological features. Until present, this scheme 
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forms the foundation of today’s classification system and comprises the following clinical subtypes: 
superficial spreading melanoma (SSM), lentigo maligna melanoma (LMM), and nodular malignant 
melanoma (NMM) [Clark_1969]. By the time the classification scheme was expanded with other sub-
types, such as acral lentiginous melanoma, mucosal lentiginous melanoma, spindle cell melanoma, 
desmoplastic melanoma and spitzoid melanoma [McGovern_1983] Weissinger_2014; Lee_2006]. 
SSM is the most common clinical subtype and accounts for over 70% of cases diagnosed in the Cau-
casian population. It presents as an irregularly shaped, flat or slightly elevated brown lesion with mott-
led pigmentation often more than 6 mm in diameter. Lentigo maligna in situ (LM) is a slow growing 
patch of discolored skin with irregular borders and pigmentation. LM often undergoes slow progres-
sive changes and turns into LMM once it has acquired invasive behavior. NMM presents as a rapidly 
enlarging lump that mostly affects areas of the head and neck. One third of NMM is non-pigmented 
and might be ulcerated. While certain subtypes such as SSM, LMM and acral lentiginous melanoma 
follow the common ABCDE (asymmetry, border irregularity, color variation, diameter more than 6 
mm, evolving) warning signs, others like NMM might not be detected using the ABCDE rules 
[McCourt_2014].  
 
This classification system allows for the identification of clinically and histologically distinctive mel-
anoma subtypes. However, this segregation does not allow for the discrimination of subtypes accord-
ing to their clinical course or overall prognosis. Previously, Breslow’s thickness was the most im-
portant prognostic factor for melanoma, measuring the depth from the basement membrane of the 
epidermis to the deepest identified melanoma tumor cell [Breslow_1970]. Nonetheless, Breslow’s 
thickness was not part of the pathohistological classification, therefore a prognostic diagnosis was not 
possible [Duncan_2009]. For this reason the American Joint Committee on Cancer (AJCC) set up a 
new classification scheme that in part is based on the TNM staging system. The criteria that form the 
basis of the AJCC staging scheme include size or thickness of the tumor, mitotic rate and ulceration 
(T), number of lymph nodes affected (N), serum LDH levels and the presence and location of distant 
metastases (M). Stages I and II are discriminated by the size of the tumor, presence of ulcerations and 
mitotic rate, while in both stages regional lymph node and distant metastases are absent. Stage III is 
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defined by the presence of lymph node but not distant metastases, whereas in stage IV distant metasta-
ses are present. The AJCC staging system allows the segregation of patients based on their overall 
survival and is thereby much more predictive with respect to prognosis. Nevertheless, the AJCC clas-
sification system has its limitations, as the scheme does not allow predictions regarding susceptibility 
or outcome of a specific treatment [Balch_2004].  
 
3.4.5. Melanoma progression model 
 
Classically, melanoma progression is depicted as a linear model, following a strict series of events that 
ultimately ends in a stage of metastatic disease. This model emphasizes the multistep transition from 
melanocytes to melanoma based on observations in cutaneous pigmented lesions and was first pro-
posed by Clark et al. in 1984. The first stage (I) in Clark’s model of melanoma progression is defined 
by the formation of a benign precursor lesion (benign nevus or mole) from a melanocyte. This benign 
lesion then turns into a dysplastic nevus (II) that is larger in size and histopathologically reveals first 
cellular atypia. The next stage (III) is referred to as the radial growth phase or melanoma in situ char-
acterized by a thin, radially growing lesion that expands within or close to the epidermis. The vertical 
growth phase (IV) is initiated with the breakthrough of the basement membrane and the formation of 
larger nests of dividing cells in the dermis. Upon dermal invasion melanoma cells get in contact with 
blood or lymph vessels, which ultimately allows intravasation and formation of metastatic lesions at 
distant sites (V). Clark’s model further suggests that progression through each step is driven by the 
acquisition and accumulation of genetic or epigenetic changes [Clark_1984; Clark_1991; Mil-
ler_2006; Damsky_2013; Bennett_2016].  
 
Nowadays, it is assumed that melanoma progression is much more complex and less linear as initially 
proposed by Clark et al. [Damsky_2011; Damsky_2013]. Thus, about 65-70% of melanomas develop 
de-novo in normal skin with no visible precursor lesion. In contrast, only 25-30% of melanomas are 
nevus-associated and less than half of them arise from dysplastic nevi [Bevona_2003; Lin_2015] (Fig-
ure 9). This indicates that in most cases melanoma forms de-novo and not from senescent nevi, which 
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is in contrast to the kinetics that were previously proposed by Clark et al. [Clark_1984]. Along this 
line, the lifetime risk of a particular nevus to undergo malignant transformation is only 1 in 7’000 
[Hüsemann_2008]. Although melanocytic nevi are associated with increased risk for melanoma, the 
presence of multiple nevi might rather represent a symptom of an underlying genetic predisposition or 
a measure of frequent UV exposure [Gandini_2005a].  
 
	  
 
Figure 09. Origins of metastatic melanoma and melanoma progression. Melanoma either arises within a pre-
existing melanocytic nevus, which is generally associated with a BRAFV600E mutation or without a visible prima-
ry lesion. Hence, up to 12% of the metastases found, have no identifiable cutaneous precursor lesion. Nonethe-
less, it is assumed that during the course of melanoma progression the genetic complexity increases [adapted 
from Damsky_2011]. 
 
Clark’s course of progression predicts that metastasis only occurs after all previous steps have been 
completed. However, up to 12% of patients with metastatic melanoma do not have a clinically identi-
fiable primary tumor [Clark_1984; Giuliano_1980; Reintgen_1983]. Interestingly, melanocytes can be 
detected in lymph nodes from normal, non-melanoma patients. These melanocyte clusters are referred 
to as nodal nevi and resemble benign melanocytic nevi in the skin. Although it is difficult to exclude 
that these cells are remnants of the embryonic colonization period, it is speculated that nodal nevus 
cells represent early descendants of benign melanocytic lesions [Bautista_1993; Carson_1996]. This 
led to the hypothesis that benign nevus cells are able to dissociate from the primary lesion long before 
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a tumor becomes clinically apparent [Hüsemann_2008; Rhim_2012; Damsky_2013]. After dissemina-
tion, melanoma precursor cells remain in a dormant state before progressing to a macrometastatic le-
sion. Premalignant dissemination might be a possible explanation why melanoma recurs in certain 
patients after excision of the primary tumor and why it recurs more often at distant sites [Balch_1993].  
 
In conclusion, malignant transformation from a melanocyte to melanoma has traditionally been de-
scribed using the Clark model. Although, this model best depicts SSM, it helps to understand the 
course of other melanoma subtypes. However, in most cases melanoma progression is much more 
complex and does not follow a linear and stepwise process initially proposed by Clark et al.  
 
3.4.6. Molecular pathomechanisms in cutaneous melanoma 
 
The course of neoplastic transformation from a melanocyte to malignant melanoma with metastasizing 
potential is usually initiated through acquisition of driver mutations in loci of proto-oncogenes. The 
MAPK pathway is the most prevalently affected signal transduction pathway that drives cell cycle 
progression and survival in melanoma (Figure 10). Thus, 95% of acquired nevi carry activity-
enhancing mutations in members of the MAPK pathway, most (80%) of them in the v-raf murine sar-
coma viral oncogene homolog B (BRAF) locus [Pollock_2003; Poynter_2006]. Despite activation of 
the MAPK pathway, nevi are typically equipped with a remarkably low proliferative potential and 
progression to melanoma is rare. The absence of progression is associated with a mechanism termed 
oncogene-induced senescence [Chandeck_2010]. It is suggested that permanent stimulation of the 
MAPK pathway increases inhibitor of cyclin-dependent kinase 4 (p16INK4A) expression and activates 
acidic β-galactosidase, which finally results in proliferative cessation and senescence [Gray-
Schopfer_2006; Michaloglou_2005; Peeper_2011]. Consequently, the acquisition of further mutations 
in cell cycle regulating genes such as cyclin-dependent kinase inhibitor 2A (CDKN2A), cyclin-
dependent kinase 4 (CDK4) or transformation-related protein p53 (TRP53) are necessary to transform 
a benign nevus into a malignant melanoma [Box_2008; Sharpless_2003].  
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In general, melanoma has a very high mutational burden relative to other cancers, with a median of 
>10 mutations/Mb [Alexandrov_2013; Lawrence_2013]. Although the majority of genetic alterations 
associated with melanoma development are of somatic nature, not all mutations are de-novo acquired. 
Hence, a positive family history and the underlying presence of heritable risk genes is an important 
component of disease occurrence. Approximately 10% of melanoma cases are associated with a genet-
ic predisposition. Increased familial susceptibility has been reported in conjunction with mutations in 
so-called high penetrance melanoma predisposition genes such as CDKN2A, CDK4, BRCA1 associ-
ated protein-1 (BAP1), protection of telomeres protein 1 (POT1), and telomerase reverse transcriptase 
(TERT) [Read_2015].  
 
	  
 
Figure 10. Molecular pathomechanisms in melanoma. In the vast majority of melanomas mutations affect 
components of the MAPK pathway. In a phosphorylation-dependent cascade growth-promoting signals are trans-
ferred from the cell surface to the nucleus. Most mutations in cutaneous melanomas cause constitutive activation 
of the BRAF or N-RAS kinases. However, in mucosal and acral lentiginous melanoma the receptor tyrosine 
kinase KIT is most commonly mutated, whereas in uveal melanomas mutations in the GNAQ/11 locus have been 
most frequently found to activate the MAPK pathway. Other mutations often lead to the activation of the 
PI3K/AKT pathway, which decreases apoptosis, prolongs cell survival and promotes cell cycle progression. 
Furthermore, inactivating mutations in cell cycle regulators, such as CDKN2A often confer resistance to onco-
gene-induced senescence and stimulate cells to re-enter the cell cycle. As the master transcriptional regulator of 
melanocytes, MITF is often affected in the course of melanoma progression. Hence, while increased MITF lev-
els are associated with increased tumor growth, reduced MITF levels promote invasiveness [Lo_2014]. 
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3.4.7. Mitogen-activated protein kinase signaling pathway in melanoma 
 
Under physiologic conditions, the MAPK pathway, also called extracellular signal-regulated kinase 
(ERK) pathway stimulates cell growth, survival and migration. In a phosphorylation-dependent man-
ner external signals are transduced from the cell surface to the nucleus [Fecher_2008]. Hence, extra-
cellular ligands bind to receptor tyrosine kinases that subsequently activate RAS, a membrane-
associated GTPase. Receptor tyrosine kinases that interact with RAS comprise c-KIT, epidermal 
growth factor receptor, platelet-derived growth factor receptor, vascular endothelial growth factor 
receptor, and fibroblast growth factor receptor. Once localized to the membrane, GTP-bound RAS 
transfers the signal to two main downstream targets, RAF and phosphatidylinositol-3-kinase (PI3K) 
[Giehl_2005]. RAS signaling activity depends on so-called GTPase-activating proteins (GAPs) such 
as neurofibromin 1 (NF1) or RAS GTPase-activating protein 2 (RASA2). GAPs strongly increase 
RAS GTPase activity and promote the conversion of RAS into its inactive GDP-bound form. Follow-
ing the MAPK pathway, activation of RAS initiates a phosphorylation-dependent cascade that in-
cludes RAF, MAPK/ERK kinase (MEK; MAPKK; MAP2K), and ultimately ERK (MAPK). Whereas 
RAF and MEK have narrow substrate specificity, ERK catalyzes a broad spectrum of cytoplasmic and 
nuclear factors. The effects of ERK activation include increased proliferation, tumor suppressor inac-
tivation and down regulation of CDK inhibitors [Kortylewski_2001]. Furthermore, ERK activation 
leads to increased survival through modulation of MITF and protection against FAS-induced apoptosis 
[Widlund_2003; Wilson_1999]. Lastly, ERK promotes invasion and metastasis due to extracellular 
matrix remodeling and angiogenesis [Smalley_2003; Giuliani_2004; Cohen_2002].  
 
Although MAPK signaling is usually not present in melanocytes, constitutive activation of the MAPK 
signaling pathway due to activating point mutations is very common in melanoma. Consequently, 
melanomas are separated according to their mutations into BRAFmut, RASmut, NF1mut, or triple wild 
type [Krauthammer_2015; TCGA_2015]. The BRAF proto-oncogene, which encodes for a ser-
ine/threonine protein kinase is the most prevalently affected member of the MAPK pathway. Thus, 
about 40-60% of melanomas harbor activating mutations in the BRAF locus, most (90%) of which are 
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V600E/K substitutions [Kumar_2003; Houben_2004]. While BRAF normally exerts its function as a 
homo- or heterodimer with another RAF kinase, the mutated form acts as a self-sufficient monomer 
with permanent signaling activity [Solit_2010]. Interestingly, non-chronically sun-damaged melano-
mas bear a high frequency of BRAF mutations, while chronically sun-damaged melanomas, acral or 
mucosal melanomas rarely present with BRAF mutations [Curtin_2005]. These subtypes are usually 
associated with KIT mutations or cyclin D1 (CCND1) and CDK4 gene amplifications [Curtin_2006; 
Bastian_2000]. In about 15% of melanomas, mutations occur in the N-RAS GTPase locus, typically 
characterized by Q61K/L/R transversions that confer increased GTP-binding capacity [Fecher_2008; 
Liu_2014]. Normally, BRAF and N-RAS mutations occur in a mutually exclusive manner, as they 
both target the same pathway. Additionally, 12% of melanomas show autosomal dominant mutations 
in NF1. Mutations in NF1 cause reduced RAS GTPase activity, thereby increasing RAS signaling 
activity [Ratner_2015). Further mutations have been found in RASA2, which acts likewise to NF1 by 
activating the RAS GTPase. Consequently, mutations cause increased RAS-GTP binding, followed by 
activation of the MAPK pathway. RASA2 mutations are likely to act synergistically with NF1, as they 
mostly occur in NF1-mutant tumors that are wild type for BRAF or N-RAS [Krauthammer_2015].  
 
3.4.8. PI3K/AKT signaling pathway in melanoma 
 
The PI3K/AKT pathway is commonly initiated by the phosphorylation of phosphatidylinositol-4,5-
bisphospate (PIP2) to phosphatidylinositol-3,4,5-triphosphate (PIP3) through receptor tyrosine kinases 
or RAS, which ultimately leads to AKR murine transforming retrovirus protein (AKT; also termed 
protein kinase B) activation [Cully_2006]. Increased AKT activity prolongs cell survival through inac-
tivation of BCL2 antagonist of cell death (BAD) and promotes cell cycle progression by increasing 
CCND1 expression. Moreover, AKT affects many other survival and cell-cycle genes through activa-
tion of the forkhead (FKHR) transcription factor [Cantley_1999; Wu_2003]. PI3K/AKT signaling 
activity is well controlled by the phosphatase and tensin homolog (PTEN) tumor suppressor that keeps 
PIP3 levels low, thereby preventing AKT activation.  
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In general, mutations in PI3K/AKT pathway components are rare in melanoma. Nonetheless, inacti-
vating mutations of the PTEN tumor suppressor have been reported in up to 25% of melanomas 
[Wu_2003]. The importance of the PI3K/AKT pathway in melanoma was further substantiated exper-
imentally, as suppression of AKT3 resulted in reduced survival and growth of human melanoma im-
planted in immunodeficient nude mice [Stahl_2004]. 
 
3.4.9. Role of cell cycle regulators in melanoma 
 
Cell cycle regulators represent the guardians of genomic integrity during cell division and guarantee 
well-controlled conditions to allow cell cycle progression. Consequently, cell cycle regulators function 
as important tumor suppressors that prevent exuberant cell growth and cancer formation. In melanoma 
cell cycle regulators play a crucial role as for example 25-40% of familial melanomas are associated 
with mutations in the CDKN2A gene [Hussussian_1994; Aitken_1999; Goldstein_2000]. CDKN2A 
encodes for two tumor-suppressor proteins, p16INK4A and alternative reading frame (p14ARF). The 
p16INK4A protein blocks G1-S cell cycle transition through inhibition of CDK4 and CDK6 in response 
to DNA damage or increased oncogenic activity [Goldstein_2006]. On the other hand, p14ARF is acti-
vated upon DNA damage or dysfunctional downstream effectors, such as the retinoblastoma (RB) 
protein. Consequently, p14ARF either induces cell cycle arrest or apoptosis. The p14ARF protein is part 
of the core regulatory machinery that controls TRP53 protein levels [Goldstein_2006]. TRP53 repre-
sents a tumor suppressor gene that is activated in response to DNA damage as well as oncogenic, gen-
otoxic or oxidative stressors [Box_2008; Vousden_2009]. Normally, the E3 ubiquitin ligase mouse 
double minute 2 (MDM2) triggers TRP53 ubiquitination, thereby instigating its destruction in the pro-
teasome. Upon activation, p14ARF binds MDM2, which induces its dissociation from TRP53. As a 
result, TRP53 accumulates and causes a G2-M cell cycle arrest, allowing for the repair of damaged 
DNA or induction of apoptosis [Pomerantz_1999].  
 
Even though CDKN2A loss of function is not able to initiate melanoma formation alone, it might con-
tribute to the onset of melanoma as a consequence of increased sensitivity towards carcinogens [Serra-
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no_1996]. Thus, it has been demonstrated that depletion of CDKN2A in human melanocytes is suffi-
cient to overcome BRAF- or H-RAS-induced senescence, while CDKN2A ablation in melanocytic 
hyperplasia-harboring mice leads to melanomagenesis [Michaloglou_2005; Serrano_1997; Acker-
mann_2005]. In comparison to CDKN2A, mutations in the CDK4 locus occur at much lower rate 
[Hussussian_1994; Aitken_1999; Goldstein_2000]. Mutated CDK4 oncoproteins usually lack respon-
siveness to p16INK4A inhibition, which results in constant kinase activation [Puntervoll_2013]. Alterna-
tively, increased CDK4 kinase activity has also been reported in association with gene amplifications 
[Hodis_2012; Krauthammer_2015; Muthusamy_2006]. In about 20% of melanomas deleterious muta-
tions cause TRP53 loss of function. Contrarily, TRP53 inhibitors, like MDM2 are frequently up regu-
lated [Marine_2005; Muthusamy_2006; Polsky_2001]. Hence, TRP53 depletion or MDM2 overex-
pression have been shown to accelerate melanocyte transformation in vitro as well as in melanoma 
mouse models [Bardeesy_2001; Goel_2009; Serrano_1997].  
 
Summing up, cell cycle regulators represent crucial tumor suppressors and play a central role during 
melanoma formation. Dysfunctional or aberrantly behaving cell cycle proteins spur cell cycle progres-
sion regardless of genomic integrity. Consequently, uncontrolled cell division and genetic instability 
lead to the acquisition of additional mutations and further fuel the vicious circle of tumorigenic trans-
formation.  
 
3.4.10. Microphthalmia-associated transcription factor in melanoma 
 
MITF, the master regulator of melanocytic differentiation and pigment production, has gained recog-
nition as lineage-specific oncogene through its extended role in melanoma development. MITF is ex-
pressed in >80% of melanomas and is present throughout all progression stages [King_2001; Ag-
narsdóttir_2012; O’Reilly_2001]. Elevated MITF levels are correlated with decreased overall patient 
survival and have been shown to promote melanoma growth in synergy with activated MAPK signal-
ing [Garraway_2005; Du_2004]. In 20% of melanomas, chromosomal amplifications represent the 
source of increased MITF activity, whereas activating point mutations, as for example present in 
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E318K substitutions, are relatively rare and mostly occur in association with familial melanoma [Cro-
nin_2009; Bertolotto_2011; Yokoyama_2012]. MITF is heterogeneously expressed within a tumor, 
showing cells with high, low or even absent MITF [Konieczkowski_2014; Müller_2014; Sensi_2011]. 
Interestingly, MITF-negative cells are predominantly regulated by WNT5A and TGF-β [Eich-
hoff_2011]. In analogy to a rheostat, MITF regulates distinct biological processes dependent on its 
expression level. Hence, high MITF levels promote differentiation, while moderate MITF levels drive 
proliferation. On the other side, low MITF levels induce migration and stem cell-like behavior, where-
as lack of MITF leads to senescence [Hoek_2008; Goding_2011; Vandamme_2014]. MITF further 
promotes cell survival by activating the expression of anti-apoptotic genes like BCL2A1, BCL2 and 
BIRC7 [Hartman_2015; Hartman_2013]. Finally, high MITF levels endow melanoma cells with in-
creased resistance to MAPK pathway inhibitors [Johannessen_2013]. Thus, MITF over expression in 
BRAFV600E melanoma cells induces resistance towards RAF, MEK, or ERK inhibitors [Roesch_2015].  
 
3.4.11. Readoption of neural crest features in melanoma 
 
The neural crest and melanoma share striking similarities, best exemplified by their exceptional migra-
tory behavior. In order to gain neural crest properties, it is likely that melanoma cells reactivate signal-
ing cues and transcriptional networks from their developmental predecessors. Thus, melanoma cells 
express a plethora of markers reflecting the entire neural crest differentiation spectrum. Consequently, 
melanoma presents as a highly heterogeneous tumor, suggesting that within the tumor there is a sub-
population of cells with neural crest stem cell-like features. This subpopulation has the capacity to 
self-renew and to give rise to other, more differentiated cell types, which eventually have the potential 
to dissociate from the primary tumor and form distant metastasis.  
 
3.4.12. SOX10 in melanoma 
 
As outlined in previous chapters the transcription factor SOX10 plays a pivotal role in neural crest 
development [3.1.]. SOX10 is further required for melanocyte differentiation and maintenance of mel-
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anocyte stem cells [3.2.1.]. Hence, homozygous depletion of SOX10 in the melanocytic lineage causes 
hair graying due to deprivation of the melanocytic stem cell pool [Potterf_2001]. However, SOX10 is 
not only important in neural crest and melanocyte development, it is also expressed in the vast majori-
ty of giant congenital nevi and melanoma. Furthermore, it was shown that SOX10 expression levels 
are increased upon malignant transformation and that N-RASQ61K is able to activate SOX10 expression 
[Shakhova_2012]. In an experimental set up using the Tyr::N-RASQ61KINK4A-/- melanoma mouse 
model it was demonstrated that SOX10 haploinsufficiency completely prevents the formation of giant 
congenital nevi and melanoma. On the other hand, SOX10 haploinsufficiency did not interfere with 
normal functions of neural crest derivatives [Shakhova_2012]. These results indicate differential 
SOX10 level requirements in melanocytes, nevus cells and melanoma cells. Therefore, SOX10 repre-
sents an interesting target for novel therapy approaches [Shakhova_2014]. 
 
3.4.13. WNT signaling in melanoma 
 
Likewise to SOX10, WNT signaling is highly relevant in neural crest development [3.1.], melanoblast 
specification [3.1.9.] and maintenance of the adult melanocyte stem cell pool [3.2.4.]. Albeit WNT 
signaling plays a major role in melanomagenesis, its role in melanoma is complex and sometimes ap-
pears contradictory. This becomes evident, as there are two major WNT signaling pathways with dis-
tinct functional implications. In melanoma, the canonical signaling pathway mediated by β-catenin is 
activated upon binding of WNT1 and WNT3A ligands to their corresponding receptors, frizzled 1 and 
7 (FRZD1 and FRZD7) [Weeraratna_2005; Webster_2015]. Activation of the canonical WNT signal-
ing pathway is critical for melanocyte transformation and helps to overcome cellular senescence. 
Hence, β-catenin is frequently expressed in human nevi and melanoma [Bachmann_2005; Kageshi-
ta_2001; Maelendsmo_2003, Omholt_2001]. Mechanistically, it is suggested that β-catenin activates 
MITF, thereby promoting cell growth and survival [Damsky_2011; Widlund_2003]. On the other side, 
canonical WNT signaling circumvents oncogene-induced senescence through repression of CDKN2A 
[Delmas_2007]. Paradoxically, high β-catenin expression is associated with reduced metastases and 
correlates with better prognosis for melanoma patients [Bachmann_2005; Chien_2009]. It is suggested 
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that canonical WNT signaling in conjunction with MITF expression promotes a more differentiated 
state that allows proliferation. However, β-catenin-dependent signaling seems to suppress the acquisi-
tion of invasive properties thereby preventing metastasis formation. It is assumed that the switch from 
a proliferative state, to a more motile, invasive state is associated with the activation of the non-
canonical pathway and down regulation of the canonical pathway. Thus, it was demonstrated that 
WNT5A initiates ubiquitination and proteasomal degradation of β-catenin, thereby down regulating 
the canonical pathway. This leads to the suppression of LEF1 and concomitantly to the switch to a 
more invasive phenotype [Topol_2003]. To conclude, WNT signaling plays a central role in malignant 
melanocyte transformation and confers high plasticity to melanoma cells allowing them to switch be-
tween proliferative and invasive phenotypes.  
 
3.4.14. TGF-β  signaling in melanoma 
 
It is well accepted that in epithelial cells TGF-β acts as a growth inhibitor and tumor suppressor during 
early-stage carcinogenesis [Oshimori_2015; Tian_2011]. Functionally, TGF-β exerts its suppressive 
function through up regulation of cyclin-dependent kinase inhibitors (p21, p15, p27Kip1 and 
p57Kip2), while repressing proliferation drivers such as c-MYC [Perrot_2013]. Apart from the cyto-
static effect, TGF-β signaling regulates the expression of several pro-apoptotic genes [Pardali_2006]. 
In contrast to its role as a tumor suppressor in early cancerogenesis, TGF-β promotes proliferation and 
dissemination in advanced tumors. Additionally, TGF-β signaling favors peri-tumoral angiogenesis, 
EMT and immune evasion, thus acting as a tumor driver [Perrot_2013].  
 
Similar to epithelial cells, TGF-β causes a growth arrest in melanocytes, whereas melanoma cells are 
no longer responsive to the anti-proliferative effect of TGF-β [Rodeck_1994; Kragasakis_1999]. 
However, the exact underlying mechanisms inducing this switch are not well understood but might be 
due to differential activation of transcriptional programs [Oshimori_2015; Tian_2011]. Melanoma 
cells secrete TGF-β in an autocrine and paracrine manner, while TGF-β ligands further induce their 
own expression in a positive feedback loop [Lasfar_2010]. This is of clinical relevance, as enhanced 
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TGF-β secretion correlates with increased tumor thickness and disease progression [Reed_1994]. As 
outlined previously [3.4.10.], TGF-β suppresses MITF expression, which is associated with acquisi-
tion of neural crest stem cell-like features such as the invasive behavior [Hoek_2006; Javelaud_2011; 
Pierrat_2012]. Along this line, it was shown that ectopically applied TGF-β ligands activate EMT 
transcription factors such as SNAIL1, TWIST, and GLI family zinc finger 2 (GLI2) and induces inva-
siveness of melanoma cells under in vitro conditions [Alexaki_2010; Javelaud_2011; Menon_2013]. 
Unpublished data from our lab further demonstrate that depletion of the TGF-β downstream target, 
SMAD4 efficiently counteracts melanomagenesis in the Tyr::N-RASQ61KINK4A-/- melanoma mouse 
model. On the other side, interference with the TGF-β pathway inhibitor, SMAD7, activates the TGF-
β signaling cascade, thereby accelerating melanoma cell dissemination and metastasis formation 
[Tuncer_unpublished]. Although TGF-β-induced EMT in melanoma appears reminiscent of the de-
lamination process in the neural crest, it needs to be further investigated to which extent they share a 
common mechanistic background.  
 
3.4.15. NOTCH signaling in melanoma 
 
There are four evolutionarily conserved NOTCH receptors that play an essential role during neural 
crest and melanocyte development [Gordon_2009]. The NOTCH signaling cascade is initiated through 
direct interactions of the NOTCH receptor with DELTA-like and JAGGED ligand proteins on neigh-
boring cells. This interaction induces a two-step cleavage process, in which the extracellular portion is 
first cleaved by ADAM10 and ADAM17 proteases preceding the second cleavage by the presenilin
γ-secretase complex ultimately leading to the release of the active NOTCH intracellular domain 
(NICD) [Brou_2000; Mumm_2000; Sotillos_1997]. The liberated NICD translocates to the nucleus, 
where it binds to the transcriptional repressor complex CBF1/RBP-jk, Suppressor of Hairless, LAG-1 
(CSL) [Kopan_2009]. The NICD replaces the repressor complex, which consequently leads to the 
transcriptional activation of CSL target genes, such as Hairy/Enhancer of Split (HES) and Hairy/E 
(spl)-related with YRPW (HEY) [Kopan_2009; Bedogni_2014]. 
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Even though NOTCH signaling plays a pivotal role during development, NOTCH expression is low or 
undetectable in mature melanocytes and nevi [Bedogni_2008; Pinnix_2009; Zhang_2012]. Nonethe-
less, NOTCH1 NICD expressing melanocytes significantly accelerate cell growth in vitro and show 
better survival under growth limiting conditions [Pinnix_2009]. Albeit NOTCH1 NICD expression 
alone is not able to induce melanoma tumors in mice, NOTCH signaling promotes malignant trans-
formation of primary human melanocytes [Pinnix_2009]. NOTCH1 expression is elevated in 50-60% 
of melanomas and 65% of melanoma cell lines [Bedogni_2008; Zhang_2012]. Melanoma cells often 
depend on NOTCH1 expression for their growth and survival, while NOTCH1 signaling has also been 
shown to promote aggressiveness in primary melanoma [Liu_2006]. Hence, blockade of NOTCH1 
activity in melanoma cells results in cell death, whereas melanocytes are not affected [Qin_2004]. In 
this context, NOTCH1 expression is elevated upon activation of the AKT/PI3K pathway, mediated 
through the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-ΚB) transcription fac-
tor [Bedogni_2008]. On the other side, it is likely that in a positive feedback loop NOTCH1 activates 
the AKT/PI3K pathway [Bedogni_2014]. Although most studies in melanoma focus on the NOTCH1 
receptor, other NOTCH receptors also play a role in melanomagenesis. Thus, NOTCH4 for example 
promotes vasculogenic mimicry in aggressive melanoma, while NOTCH3 is specifically up regulated 
in melanoma upon co-culturing with endothelial cells [Hardy_2010; Howard_2013]. Moreover, 
NOTCH3 activity is associated with enhanced melanoma cell migration [Howard_2013].  
 
First clinical trials using a  γ-secretase inhibitor revealed melanoma among the most frequently ob-
served tumors in patients with prolonged stable disease. This suggests that melanoma may indeed be 
more sensitive to γ-secretase inhibitor therapies [Tolcher_2012]. Considering the importance of the 
NOTCH signaling cascade in melanoma growth and progression, targeting the NOTCH pathway in-
deed represents a valuable alternative for future therapy approaches. 
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3.4.16. Role of enhancer of zeste homologue 2 in melanoma 
 
Besides genetic modulations, aberrant epigenetic activity often leads to developmental disorders and is 
associated with oncogenic transformation [Reik_2007; Sharma_2009]. Enhancer of zeste homologue 2 
(EZH2), a subunit of the polycomb repressive complex 2 represents a major epigenetic modifier. 
EZH2 catalyzes trimethylation of lysine 27 in histone 3 (H3K27me3), which leads to chromatin con-
densation and subsequent transcriptional repression of target genes [Margueron_2011; Ciferri_2012]. 
During embryonic development and in tissue-specific stem cells, EZH2 prevents early lineage re-
striction through transcriptional repression of differentiation genes. However, in neural crest stem cells 
EZH2 does not interfere with differentiation or proliferation, but rather induces the acquisition of a 
mesenchymal fate [Schwarz_2014].  
 
	  
 
Figure 11. Role of EZH2 in melanoma. The epigenetic modifier EZH2 is a methyltransferase that represses 
gene expression through trimethylation of lysine 27 in histone 3. While EZH2 plays a crucial role during neural 
crest development, melanoma is often associated with aberrant EZH2 expression. Thus, EZH2 promotes tumor 
initiation as well as metastasis formation in melanoma. Blocking EZH2 function in melanoma using a preclinical 
EZH2 inhibitor completely abolished metastases formation and therefore represents a powerful strategy for novel 
therapy approaches [graphical illustration; Mario Bonalli in Zingg_2015]. 
 
In many cancer types including melanoma, EZH2 is highly expressed and associated with poor prog-
nosis [Sauvageau_2010; Bachmann_2006; McHugh_2007]. Likewise to its function in embryonic 
tissue and adult stem cells, EZH2 promotes proliferation and growth in tumors [Sauvageau_2010]. 
Thus, loss of EZH2 in human melanoma cells partially interferes with proliferation and the invasive 
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capacity [Fan_2011; Luo_2013a; Luo_2013b]. In addition, conditional deletion of EZH2 in the mela-
nocytic lineage using the murine Tyr::N-RASQ61KINK4A-/- melanoma model drastically reduces the 
number of melanoma tumors and prolongs survival of the animals. Furthermore, EZH2 ablation in 
already established melanoma tumors efficiently blocks disease progression, indicating that EZH2 is 
crucial for the initiation and progression of metastatic melanoma [Zingg_2015]. Therefore, blocking 
EZH2 activity might represent a powerful strategy for novel therapy approaches (Figure 11).  
 
3.4.17. Melanoma stem cells and tumor heterogeneity 
 
Melanoma often presents with remarkable intratumoral heterogeneity, histopathologically as well as 
genetically [Berger_2012; Hodis_2012; Anaka_2013]. Hence, apart from melanocytic markers, mela-
noma cells express neuronal, glial, and mesenchymal markers, reflecting the entire neural crest library 
[Banerjee_2008; Civenni_2011; Cruz_2003; Laga_2010; Mete_2010; Parente_2013]. Although mela-
noma is assumed to be a clonal event, tumors subsequently evolve and acquire heterogeneity in re-
sponse to genomic instability and selective pressure [Bennett_2008; Grichnik_2006]. These findings 
are of particular clinical relevance, since increased clonal diversity contributes to the metastatic poten-
tial and promotes therapy resistance. As a consequence, tumor heterogeneity is linked with poor prog-
nosis in melanoma patients [Civenni_2011].  
 
Besides more specified cell populations within the melanoma tumor, there is a particular cell type that 
strongly resembles undifferentiated neural crest stem cells. This multipotent cell type is characterized 
by the expression of the neural crest stem cell markers CD271(p75NTR) and SOX10 [Civenni_2011]. 
Upon transplantation into recipient mice, isolated CD271(p75NTR)-positive but not CD271(p75NTR)-
negative melanoma cells are able to form tumors [Boiko_2010; Civenni_2011]. These 
CD271(p75NTR)-positive cells faithfully mimic the heterogenic cellular composition of the parental 
tumor after transplantation. Moreover, CD271(p75NTR)/SOX10 cells correlate with higher metastatic 
potential and worse prognosis [Civenni_2011]. 
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In analogy to the neural crest, CD271(p75NTR) marks a cell population with self-renewal and multipo-
tent differentiation capacity in melanoma, suggesting the presence of so-called cancer stem cells.
Melanoma stem cells are crucially involved in the establishment of tumor heterogeneity, which is as-
sociated with increased metastatic potential, therapy resistance and poor prognosis. Hence, the surface 
marker CD271(p75NTR) might be a valuable target in future diagnostics and prognostics, while elimi-
nating melanoma stem cells represents a potential approach in prospective treatment strategies 
[Ward_2007; Civenni_2011].  
 
3.4.18. EMT in melanoma 
 
EMT describes an embryonic program that defines a reversible transversion from an epithelial cell 
with tight intercellular adhesion and apical-basal polarity to a more mesenchymal cell type with stem-
ness features and increased cellular motility [3.1.4.]. EMT is driven by a network of embryonic EMT-
inducing transcription factors, including members of the SNAIL1, TWIST, or ZEB families [Kal-
luri_2009]. Besides its essential role in developmental processes as for example during neural crest 
delamination, EMT is also observed in wound healing or cancer progression [Yan_2010; Kal-
luri_2009]. Hence, aberrant expression of EMT transcription factors is a common event in various 
cancer types and has originally been found in carcinoma, a tumor of the epithelial lineage. In cancer, 
EMT transcription factors trigger neoplastic transformation, stemness, and metastatic dissemination 
[Peinado_2007; Vega_2004; Mejlvang_2007; Mani_2008; Morel_2008]. Consequently, expression of 
EMT transcription factors in cancer patients is associated with poor prognosis and high risk of metas-
tasis formation [Caramel_2013].  
 
Functionally, EMT is thought to be regulated analogously in embryogenesis and cancerogenesis, char-
acterized through down-regulation of adhesion molecules like E-cadherin and up regulation of devel-
opmentally important transcription factors such as SNAIL1, SNAIL2, TWIST and ZEB1/2 [Kal-
luri_2009]. However, in melanocytes SNAIL2 and ZEB2 function as tumor suppressors by activating 
an MITF-dependent differentiation program [Gupta_2005]. On the other side, ZEB1 and TWIST1 are 
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up regulated in response to MAPK pathway activation and induce oncogenic transformation [Cara-
mel_2013]. This indicates that melanoma cells do not undergo a classical EMT, which might be ex-
plained by their non-epithelial origin. Nonetheless, melanocytes express E-cadherin in order to form 
contacts with neighboring keratinocytes in the basal layer of the epidermis. These cell-cell communi-
cations maintain melanocyte homeostasis by suppressing proliferation and promoting differentiation. 
Hence, down regulation of E-cadherin, which represents a hallmark of EMT, is associated with in-
creased proliferation in melanoma [Hsu_2000]. Furthermore, melanoma cells increase the expression 
of N-cadherin, which is assumed to support the acquisition of stem cell-like features and dermal inva-
sion, thereby facilitating the interaction with dermal fibroblasts and vascular endothelial cells that 
express the same cadherins [Li_2001].  
 
It has been estimated that approximately one million cells per gram of tumor mass dissociate from the 
primary tumor per day [Butler_1975]. However, the presence of tumor cells in the blood cannot be 
used as a prediction criterion for a metastatic event to occur [Fidler_1970]. Therefore, the EMT con-
cept is controversially discussed in cancer, as it neglects the terminal components of the metastatic 
cascade such as adhesion, extravasation, survival, and growth at a distant site [Tarin_2005; 
Talmadge_2010]. Hence, apart from acquiring invasive properties, the capacity to survive and propa-
gate growth in a foreign microenvironment has proven equally important for the establishment of dis-
tant metastases. In contrast to EMT, this process is assumed to be associated with loss of mesenchy-
mal and reactivation of epithelial characteristics and is therefore termed mesenchymal-epithelial-
transition (MET) [Polyak_2009; Yao_2011].  
 
To sum up, the EMT model serves well to describe the initial but not the entire metastatic process in 
melanoma. This emphasizes the critical role of the terminal phase in tumor progression, which most 
likely represents a reversal of the EMT process and allows adhesion, extravasation, survival and 
growth at distant sites. In melanoma, cells only partly undergo classical EMT, which might be due to 
their non-epithelial origin. Moreover, it is still nebulous to which extent melanoma cells undergo MET 
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at distant sites in order to establish macrometastases. Thus, further investigations are required to prove 
the applicability of the EMT/MET paradigm in melanoma.  
 
3.4.19. Melanoma therapy 
 
Although melanoma is not among the most prevalent types of skin cancer, it has a considerably higher 
propensity to metastasize, therefore leading to a disproportionate high number of skin cancer-related 
deaths. Therefore, early detection prior to metastasis formation followed by surgical resection corre-
lates with a high survival rate. However, once metastasis has occurred, surgical excision only yields 
about 10% five-year survival rate [Bhatia_2009]. Apart from surgery, radiotherapy is mostly applied 
locally in unresectable lesions but has proven little effect on metastatic melanomas [Bhatia_2009]. In 
metastatic melanoma, dacarbazine was considered the best treatment option for a long time, although 
the response rate was only about 15-20% [Bajetta_2002]. Dacarbazine or dimethyltriazeno-imidazol 
carboxamide (DTIC) represents a DNA-alkylating chemotherapeutic agent [Eggermont_2004]. Other 
single agent chemotherapies comprise cisplatin, nitrosoureas, vindesine and the microtubule-
disrupting agent taxane. However, their response rate is less efficient in comparison to dacarbazine 
[Gogas_2004; Bajetta_2002; Bhatia_2009].  
 
The lack of satisfying treatment options in metastatic melanoma highlights the exigence for novel 
therapy approaches. As the majority of melanoma patients harbor activating mutations in members of 
the MAPK pathway, the identification of these mutations has offered novel opportunities to develop 
oncogene-specific drugs that target the MAPK pathway. In the past few years the US food and drug 
administration (FDA) approved two inhibitors, vemurafenib and dabrafenib that specifically target 
mutated BRAF. Both BRAF inhibitors present with better overall responses in comparison to dacarba-
zine. Vemurafenib achieves a 48-53% response rate with 6% showing a complete response, while 
dabrafenib receives a 59% response rate in melanoma patients with BRAFV600E/K mutations [Chap-
man_2011; Ascierto_2013; Hauschild_2012]. However, in most patients, treatment efficacy has only 
short duration, as the median progression free survival ranges from 5.1 to 6.8 months [Sosman_2012; 
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Hauschild_2012]. Vemurafenib and dabrafenib are contraindicated in melanomas without BRAF mu-
tation. Moreover, the MEK inhibitors, trametinib and cobimetinib have been approved for 
BRAFV600E/K mutated melanomas and achieve response rates similar to BRAF inhibitors [Flaher-
ty_2012a; Eroglu_2016]. MEK inhibitors are not allowed in wild type BRAF or in patients that were 
previously treated with BRAF inhibitors. Although BRAF and MEK monotherapies have shown 
promise, the responses are not long lasting due to acquired resistances. In order to overcome limita-
tions in single drug treatments, the combination of BRAF and MEK inhibitors has markedly improved 
the response rate and progression free survival. Hence, simultaneous application of BRAF and MEK 
inhibitors has become the standard care for patients with BRAF mutated advanced melanoma [Flaher-
ty_2012b].  
 
Melanomas heterogeneously express a multitude of different tumor antigens and are frequently infil-
trated with cytotoxic T-lymphocytes (CTLs). CTLs are primed in the lymph node by dendritic cells to 
recognize a particular antigen. Once CTLs reencounter their cognate antigen upon tumor infiltration, 
they get activated and exert cytotoxicity towards antigen-expressing tumor cells [Schatton_2014]. 
Consequently, increased numbers of tumor-infiltrating T-cells correlate with better prognosis for mel-
anoma patients [Azimi_2012, Erdag_2012]. However, with advanced progression, melanoma cells 
evolve under selective pressure and undergo immunosuppressive adaptations rendering the T-cell re-
sponse ineffective [Schatton_2014].  
 
In a first approach to manipulate the patient’s own immune system, high-dose interleukin 2 (IL-2) was 
intravenously infused in order to activate and prompt natural killer cells to attack cells without major 
histocompatibility complex class 1 (MHC1) expression [Mule_1984; Bajetta_2002]. Furthermore, IL-
2 has been shown to stimulate proliferation and maturation of T cells [Boyman_2012]. Although IL-2 
treatment has a response rate of 16-17%, it is associated with serious side effects resulting in increased 
morbidity [Schwartz_2002]. Combinational treatment of IL-2, interferon alpha (IFN-α), and dacarba-
zine improved the response rate to 31% [Bajetta_2006].  
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Recently, fundamental discoveries have been achieved regarding the molecular mechanism how mela-
noma cells abscond from the immune system, paving the way for novel approaches in immunotherapy.  
Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) typically acts in the lymph node as a negative 
immune checkpoint regulator by blocking potentially autoreactive T-cells [Rudd_2009; Alegre_2001; 
Rudd_2003]. CTLA-4 and CD28 compete as coreceptors for CD80/86 ligand binding on antigen pre-
senting cells. While CD28 mediates T-cell proliferation, differentiation and cytokine production, 
CTLA-4 inhibits T-cell activation, thereby limiting the immune response [Krummel_1995].  
In contrast to CTLA-4, PD-1 inhibits T-cell proliferation in peripheral tissues in a later phase of the 
immune response [Fife_2008]. PD-1 binds PD ligand 1 and 2 (PD-L1/2), which are more widely ex-
pressed as for example on leukocytes, non-hematopoietic cells, and on parenchymal cells upon induc-
tion by inflammatory cytokines (IFN-γ) [Chen_2004; Parry_2005; Chen_2012; Latchman_2004].  
 
Melanoma and many other tumors have found ways to evade the immune system by expressing im-
munosuppressive receptors such as CTLA-4 or PD-1. Hence, blockage of the immune checkpoint 
pathways using inhibitory antibodies represents a novel form of immunotherapy in melanoma. Ipili-
mumab belongs to the group of humanized monoclonal antibodies that stimulate T-cell activity by 
blocking CTLA-4 receptor interaction with CD80/86 [O’Day_2010; Melero_2007; O’Day_2007; 
Peggs_2006]. It has been reported that CTLA-4 blockade with ipilimumab significantly augments T-
cell diversity in the peripheral blood [Robert_2014]. The response rate in stage III and IV melanoma 
patients is 11.1%, while side effects are observed in 15% of patients [Wolchok_2010; Farolfi_2012]. 
Pembrolizumab and nivolumab represent humanized monoclonal antibodies that target the PD-1 re-
ceptor. In a phase III trial, pembrolizumab reached a response rate of 33-34% with a 1-year survival 
rate of 68-74% [Farolfi_2012]. Preliminary data suggest combinatorial inhibition of CTLA-4 and PD-
1 increases the efficacy over single drug application [Buchbinder_2016]. Further trials will follow to 
confirm the benefits of the double treatment.  
 
While first trials have revealed response rates of up to 70% for combinatorial BRAF and MEK inhibi-
tion, tumor relapse occurs within a fairly short period of time. This stands in contrast to immune 
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checkpoint inhibitors that offer significant durability, even though their response rates are rather low 
[Schadendorf_2015; Robert_2015b; Ribas_2013; Hodi_2010]. Consequently, there are interests in 
combining these two treatments, as it has been shown that MAPK inhibitors increase the number of 
tumor-infiltrating CD8+ T cells. Furthermore, experiments using murine melanoma models have 
demonstrated prolonged survival in mice treated with BRAF/MEK and PD-1 inhibitors [Hu-
Lieskovan_2015]. However, further follow up studies and clinical trials will determine whether com-
bination therapy effectively leads to a high response rate with a long lasting effect.  
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3.5. NKAP 
 
Human NKAP is located on the X chromosome and encodes for a 415 amino acid long highly charged 
and basic protein with a pI of 10 [Chen_2003; Burgute_2014; Worlitzer_2014]. NKAP is present 
ubiquitously in various tissues but is particularly expressed in spleen, skin, testes, kidney and lung 
[Burgute_2014]. Furthermore, NKAP is highly expressed in adult mouse subventricular zone neural 
progenitor cells [Worlitzer_2014]. From flies to humans, NKAP is well conserved throughout the 
evolution, while the human and mouse protein share 86% sequence homology [Burgute_2014]. Epon-
ymously, NF-ΚB activating protein (NKAP) was initially identified to stimulate the NF-ΚB pathway. 
In a NF-ΚB-luciferase reporter assay using 293 cells, NKAP overexpression induced NF-ΚB activa-
tion in a dose-dependent manner [Chen_2003]. More recent studies reported that NKAP modulates the 
NOTCH signaling pathway through interaction with HDAC3 and CBF1 interacting co-repressor 
(CIR), both components of the NOTCH co-repressor complex. This interaction seems to be pivotal in 
different phases of T-cell and natural killer T (NKT) cell development [Pajerowski_2009; Hsu_2011; 
Thapa_2013]. Thus, conditional ablation of NKAP in early T-cell development using LCK-cre trans-
genic mice revealed that NKAP is necessary at the double negative 3 (DN3) to double positive (DP) 
transition, as well as for post-positive selection maturation of single-positive thymocytes [Pa-
jerowski_2009; Hsu_2011]. Specific NKAP depletion in stage 0 invariant NKT (iNKT) cells using the 
PLZF-cre mouse line prevented proliferation of iNKT cells and blocked differentiation into ROR-γt-
expressing NKT17 cells. However, despite dramatically reduced cell number, differentiation into 
NKT1 and NKT2 cells was still possible [Thapa_2016]. Moreover, NKAP is required for the mainte-
nance and survival of hematopoietic stem cells (HSCs). Inducible ablation of NKAP using the Mx1-
cre mouse line leads to hematopoietic failure and loss of the HSC pool within days [Pa-
jerowski_2010].  
 
In an extensive yeast two-hybrid screening approach, NKAP has been found as a core component of 
the splicing complex and interaction partner of RNA binding proteins. Functionally, NKAP has thus 
been implicated in RNA metabolism and splicing [Giot_2003; Hegele_2012]. RNA processing factors 
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and elements of the splicing machinery tend to accumulate in so-called nuclear speckles [La-
mond_2003; Hall_2006; Raska_1995]. Proteins that localize to nuclear speckles are often associated 
with an arginine/serine-rich domain (RS domain) of variable length and therefore referred to as SR 
proteins. The RS domain has been shown to be important for nuclear speckle localization but also 
functions as a protein interaction domain [Caseres_1997; Hedley_1995, Li_1991]. In addition to the 
RS domain, SR proteins principally contain one or two RNA recognition motifs (RRM) that provide 
RNA binding specificity [Graveley_2000]. Proteins that lack the RRM are defined as SR-related (or 
SR-like) proteins. Despite absent RRM, SR-related proteins might be involved in RNA processing 
[Long_2009]. In general, SR and SR-related proteins represent crucial regulators of constitutive and 
alternative splicing of precursor messenger RNA (pre-mRNA) [Lin_2009; Long_2009]. Hence, in vivo 
depletion of the SR proteins SRSF1 and SRSF2 dramatically reduces the synthesis of nascent RNA 
[Lin_2009]. 
 
NKAP has been characterized as a SR-related protein that contains a N-terminal RS domain, a central 
basic domain and a C-terminal domain of unknown function termed DUF926. In correspondence with 
other SR-related proteins, NKAP localizes to nuclear speckles but lacks the RRM [Burgute_2014]. 
However, it has been shown that unlike to other SR proteins, NKAP’s nuclear speckle localization 
depends on the basic domain, whereas the RS domain has no impact on the subnuclear distribution. 
Although, NKAP is not required for the organization of nuclear speckles, NKAP overexpression dra-
matically increases the size and number of nuclear speckles [Burgute_2014]. Previously, the mRNA-
bound proteome has been described in human embryonic kidney (HEK) cells and NKAP has been 
identified as a novel RNA binding protein [Baltz_2012]. Subsequently, NKAP was shown to interact 
with various RNA binding factors such as heterogeneous nuclear ribonucleoproteins (hnRNPs), splic-
ing factors and RNA helicases. Although NKAP has no RRM, it has the ability to interact with pre-
mRNA as well as with spliced mRNA and has no preferential binding motif such as the 5’-cap or
other particular regions of the mRNA [Burgute_2014]. Crosslinking and immunoprecipitation fol-
lowed by RNA sequencing (CLIP-Seq) revealed that NKAP mostly associates with exonic regions of 
pre-mRNA. NKAP further binds to various non-coding RNAs (ncRNAs), most abundantly to small 
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nuclear RNAs (snRNAs) and ribosomal RNAs (rRNAs). More specifically, NKAP interacts with U1 
and U4 snRNAs, which contribute to the formation of complex B during splicing. Furthermore, NKAP 
has been found associated with specific spliceosomal complexes such as the B* complex, C complex 
and P complex [Burgute_2014] (Figure 12). Along this line, it was shown that the ratio between 
GAPDH pre-mRNA and spliced GAPDH mRNA was significantly increased upon NKAP knockdown 
[Burgute_2014]. Consequently, NKAP’s regulatory function might be mediated through its role in 
snRNA biogenesis and the assembly of the spliceosome. However, NKAP’s specific function in RNA 
processing remains obscure and requires further investigations. 
 
	  
 
Figure 12. NKAP is a RS-related speckle protein involved in RNA processing and splicing. NKAP is a 415 
amino acid long, highly basic protein that has been shown to exclusively localize to nuclear speckles. It directly 
binds to RNA and interacts with various RNA processing factors. Hence, NKAP knockdown leads to the accu-
mulation of unprocessed RNA, whereas mature mRNA levels decrease. However, NKAP’s exact molecular 
function during RNA splicing is not yet completely resolved [Burgute_2014].  
 
Apart from its role in RNA splicing, NKAP functions as a transcriptional repressor and interacts with 
components of the NOTCH co-repressor complex. Thereby, the basic domain is important for the in-
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teraction with CIR, whereas the DUF926 domain is required for the binding to HDAC3 [Pa-
jerowski_2009]. In this context, it was shown that the DUF926 domain is necessary for transcriptional 
repression, whereas the other domains have no influence on transcription. Therefore, it is suggested 
that NKAP’s repressive function is mediated by HDAC3 [Pajerowski_2009]. As a transcriptional reg-
ulator of the NOTCH signaling pathway, NKAP directly interacts with chromatin in order to repress 
NOTCH target genes. Experiments using ChIP followed by real-time quantitative PCR for the 
NOTCH target site in the SKP2 promoter revealed that NKAP associates with a NOTCH-regulated 
promoter [Pajerowski_2009]. Another study using ChIP-sequencing in NKAP over expressing HeLa 
cells confirmed that NKAP precipitates with chromatin but mostly interacts with centromere and other 
heterochromatic sequences [Burgute_2014].  
 
So far, NKAP has not been associated with melanoma nor with any other kind of cancer. Nevertheless, 
NKAP plays a pivotal role in diverse cellular processes and has been implemented in mRNA splicing 
and transcriptional repression. However, NKAP’s molecular mode of action is hypothetical and the 
link between mRNA splicing and transcriptional repression is still missing. Interestingly, the NICD 
and many NOTCH regulators including CIR, CSL, SKIP, SMRT and MAML are also distributed in a 
punctate nuclear pattern [Hsieh_1999]. This indicates that the NOTCH co-repressor complex at least 
partially operates in nuclear speckles. Therefore it is tempting to speculate that NKAP serves as a me-
diator between mRNA splicing and transcriptional repression of NOTCH target genes.  
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3.6. Nuclear speckles 
 
Nuclear speckles represent compartments that form within the nucleoplasm in regions containing little 
or no DNA and are therefore also referred to as interchromatin granule clusters [Thiry_1995]. Gener-
ally, nuclear speckles appear as 20-50 irregularly shaped structures that vary in size [Spector_2011]. 
Nuclear speckles are highly dynamic and there is a continuous exchange of individual speckle compo-
nents with the surrounding nucleoplasm [Misteli_1997; Kruhlak_2000; Phair_1995]. Along this line, 
nuclear speckles are supposed to act as storage, assembly, and modification compartments that supply 
splicing factors to active transcription sites [Lamond_2003]. Hence, it has been shown that nascent 
pre-mRNA preferentially localizes outside of nuclear speckles as fibrillary structures, termed peri-
chromatin fibrils [Cmarko_1999]. Therefore, it is assumed that mRNA transcription, co-transcriptional 
splicing and exon junction complex (EJC) assembly does not occur within nuclear speckles but in the 
perispeckle region [Daguenet_2012]. In addition to pre-mRNA splicing factors, including small nucle-
ar ribonucleoproteins (snRNPs) and SR proteins, several kinases and phosphatases have been localized 
to nuclear speckles [Fu_1995; Brede_2002; Colwill_1996; Ko_2001; Sacco-Bubulya_2002; Trinkle-
Mulcahy_1999; Trinkle-Mulcahy_2001]. Phosphorylation and dephosphorylation has thus been as-
sumed as an important regulatory mechanism that controls the shuttling of nuclear speckle compo-
nents [Misteli_1998; Mermoud_1994]. Upon transcriptional inhibition, splicing factors accumulate 
predominantly in enlarged, rounded speckles, while diffuse speckles disappear [Melcak_2000; Spec-
tor_1991; O’Keefe_1994]. Furthermore, nuclear speckles do not contain factors primarily involved in 
ribosome subunit biogenesis or tRNA production [Spector_2011]. To conclude, nuclear speckles rep-
resent highly dynamic compartments within the nucleoplasm that are involved in storage, assembly, 
and modification of splicing factors. Hence, nuclear speckles provide splicing factors to active tran-
scription sites, which are located in the perispeckle region.  
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3.7. RNA splicing and spliceosome assembly 
 
Following transcription, primary RNA transcripts are processed into mature messenger RNA. This 
process includes 5’-capping, 3’-polyadenylation and RNA splicing. Unprocessed primary RNA tran-
scripts, so-called pre-mRNAs, usually contain several protein-coding exons, which are intercepted by 
non-coding introns. During RNA splicing, the non-coding introns are cleaved out and exons are reli-
gated [Berget_1977; Chow_1977]. The splicing reaction is catalyzed by five U snRNPs (U1, U2, U4, 
U5, and U6) that together form the large spliceosome complex [Lerner_1980; Jurica_2003] (Figure 
13). Each snRNP consists of one stable snRNA bound by several proteins, plus additional less stably 
associated splicing factors. These snRNAs recognize conserved consensus sequences within the intron 
[Mount_1982]. Most commonly, intron splice sites start with a GU dinucleotide and end with AG. 
These consensus sequences are known to be critical, as nucleotide substitution results in inhibition of 
splicing. The branch point represents a second conserved sequence within introns and is located be-
tween 18-40 nucleotides upstream of the 3’ end [Burge_1999]. Spliceosome assembly follows a pre-
cise sequence of short-lived intermediate stages termed E, A, B, B*, and C complexes. In brief, intron 
excision from a nascent pre-mRNA transcript occurs in two steps, both requiring two distinct trans-
esterification reactions. Initially the 5’ splice site is cleaved and the cut end of the intron folds back in 
order to bind to an adenosine residue at the branch point thereby forming a lariat. Subsequently, a new 
phosphodiester bond ligates the two adjoining exons, while the intercalated intron is released as a 
product of the reaction [Burge_1999; Will_2011; Matera_2014]. Recently another type of spliceosome 
has been identified that processes a minor category of introns, therefore referred to as the minor 
spliceosome complex. This complex consists of the snRNPs U11, U12, U4atac, and U6atac, which 
represent functional analogs of the U1, U2, U4 and U6 snRNPs, respectively. The snRNP U5 remains 
unaltered in the minor spliceosome complex. Consequently, introns bound by the minor spliceosome 
complex are defined as U12-type introns, while the major spliceosome complex binds to U2-type in-
trons [Tarn 1997; Patel_2003].  
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Figure 13. RNA splicing requires the assembly of the large spliceosome complex. In general, unprocessed 
primary mRNA transcripts consist of several protein-coding exons that are interspersed with non-coding introns. 
During the mRNA maturation process introns are cleaved out and the exons are religated. This process requires 
the formation of a spliceosome complex, which follows a strict sequence of short-lived intermediate stages 
termed E, A, B, B*, and C. The spliceosome complex consists of 5 U snRNPs, while each snRNP contains 1 
snRNA bound by several proteins [Matera_2014].  
 
Alternative splicing describes the process that is responsible for the generation of multiple isoforms 
from a single gene, thereby creating high protein diversity despite a low number of genes 
[Wang_2008; Nilsen_2010]. In this process, particular exons of a gene may or may not be included in 
the final transcript [Black_2003]. The expression of a particular transcript might vary substantially 
among different tissues or distinct developmental stages [Wang_2008; Matera_2014]. Thus, alterna-
tive splicing is tightly regulated through trans-regulatory proteins that bind to cis-regulatory elements 
on the primary transcript. However, the splicing code containing all cis-regulatory sequences has not 
yet been fully deciphered [Barash_2010]. Moreover, signaling factors that regulate alternative splicing 
are poorly understood [Lynch_2007]. Hence, prediction tools for alternatively spliced transcripts are 
so far not available [Barash_2010]. While alternative splicing helps explaining how new genes are 
created during evolution, a large proportion of human genetic disorders results from abnormal varia-
tions in splicing [Matlin_2005]. Additionally, abnormal splicing variants are implicated in cancer de-
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velopment, whereas splicing factor genes are frequently mutated in various cancer types 
[Skotheim_2007; He_2009; Fackenthal_2008; Sveen_2015]. 
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4. Goals of the thesis 
 
As outlined in the introduction, there is compelling evidence that distinct genetic programs, usually 
active during the development of the neural crest are reactivated in melanoma [Civenni_2011; Eich-
hoff_2011; Shakhova_2012; Zingg_2015; Cheng_2015]. Therefore, in the initial phase of my doctor-
ate, I planned to identify novel transcriptional regulators that are involved in neural crest stem cell 
maintenance, to subsequently determine their roles in melanoma. On the basis of the obtained results I 
aimed to focus on one particular factor to further dissect its functional contributions to the formation 
and metastatic progression of melanoma.    
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5. Preliminary investigations 
 
The experiments described in this section were performed by Dr. Sandra Varum and served as the 
basis for my PhD thesis project. 
 
In order to identify putative transcriptional regulators that are relevant in neural crest stem cell 
maintenance, a preliminary experiment was performed using in vitro cultured neural crest cells 
[Sommer_2001; Sommer_2002] In brief, neural tubes of E8.75 mouse embryos were isolated and 
plated under hypoxic conditions in fibronectin-coated dishes, in the presence of a permissive medium. 
These conditions allow the dissociation of migratory neural crest cells from the neural tube. Following 
the emigration, neural crest cells were primed for differentiation into specific cell fates, namely auto-
nomic neurons, glia and mesenchymal progenitors. Therefore, previously identified instructive growth 
factors were subjected to neural crest cells for 6 hours in order to prime for a specific cell fate at the 
expense of other lineages. BMP2 was applied to generate autonomic neurons, TGF-β induced mesen-
chymal progenitors, and heregulin and forskolin promoted gliogenesis. The obtained populations were 
characterized based on canonical markers, such as SOX10 and GFAP for glia, MASH1 and neurofil-
ament for autonomic neurons and smooth muscle actin for mesenchymal progenitors to confirm the 
high grade of homogeneity.  
 
A whole-genome transcriptome analysis was performed, comparing multipotent neural crest stem cells 
to their corresponding early-stage derivatives. Genes that were down regulated upon differentiation 
were considered as putative stemness gatekeepers. Thus, the obtained results revealed four transcrip-
tional regulators among a set of 53 genes that were at least 2.8-fold down regulated in early-
differentiated derivatives compared to neural crest stem cells (P>0.05). These transcriptional regula-
tors include lin-9 homolog (LIN9), lin-28 homolog A (LIN28A), single stranded DNA binding protein 
2 (SSBP2), and NKAP (Figure 14).  
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Figure 14. A genome-wide transcriptome analysis reveals 7 transcriptional regulators. To identify potential 
transcriptional regulators involved in the maintenance of neural crest stemness, a whole genome transcriptome 
analysis was performed comparing neural crest stem cells to early-specified neural crest derivatives. Neural crest 
stem cells were primed for 6 h with respective instructive growth factors in order to obtain early-differentiated 
neural crest cells. Genes that were 2.8-fold down regulated (P>0.05) upon differentiation were considered as 
putative stem cell genes. The analysis revealed 4 transcriptional regulators consistent of LIN9, LIN28A, SSBP2, 
and NKAP, among a set of 53 differentially expressed genes. Additionally, the gene expression dataset was 
evaluated using the online available algorithm MARA. This extended data analysis further suggested members 
of the NF-Y family as potential target factors.  
 
To broaden the spectrum of potential neural crest stem cell factors, the gene expression dataset was 
evaluated using an online available algorithm termed motif activity response analysis (MARA) pro-
vided by the Biozentrum Basel. Comparative transcriptomic signatures of two or more cell popula-
tions serve as the basis for MARA to identify key transcription factors that drive the observed expres-
sion state changes. MARA reconstructs transcription regulatory dynamics using computational meth-
ods by incorporating comparative genomic information and positional preferences of transcription 
factors relative to the transcription start site in the prediction of regulatory sites [The FANTOM con-
sortium_2009]. Among others, the extended data evaluation using MARA identified the nuclear tran-
scription factor Y family (NF-YA, NF-YB, NF-YC) with differential activities in neural crest stem 
cells and their early-differentiated counterparts. 
 
I would like to remark that the evaluation of the whole genome transcriptome array including MARA 
further revealed the transcription factors SALL4 and YY1. It is the current objective of two other 
members in the Sommer group to unravel their roles in melanoma.  
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6. Results 
 
6.1.1. The neural crest-relevant transcriptional regulator NKAP plays a role in melanoma 
 
On the basis of the whole-genome transcriptome analysis comparing neural crest stem cells to early-
differentiated derivatives, seven transcriptional regulators were identified including LIN9, LIN28A, 
SSBP2, NKAP, NF-YA, NF-YB, and NF-YC [5.]. Since numerous developmental signaling cues and 
transcription factors of the neural crest find reuse in melanoma, I planned to screen the newly discov-
ered neural crest-associated transcriptional regulators in melanoma. Therefore, I utilized the previous-
ly characterized human melanoma cell culture M010817, which is well established in the Sommer 
group [Hoek_2006; Zipser_2011]. The cells were obtained from a 37 years old female patient and 
contain an N-RASQ61R mutation. M010817 represents a fast proliferating melanoma cell culture with 
low invasive capacity under in vitro conditions. Nonetheless, their metastatic potential after subcuta-
neous injection in NSG mice is considerably high. M010817 cells were provided by the URPP bi-
obank, UZH and in vitro manipulations using these cells have been successfully performed in earlier 
experiments [Civenni_2011; Shakhova_2012; Zingg_2015].  
 
Cell cycle analysis using propidium iodide is a simple and robust method to examine the proliferation 
status of in vitro-cultured melanoma cells. Uncontrolled cell growth represents a major hallmark in 
melanoma and generally in tumor biology. Hereby, cancer cells often activate cell intrinsic growth 
stimulating factors and signaling pathways to continuously spur cell division. However, this illustrates 
their dependence on the growth promoting machinery and concomitantly highlights their vulnerability. 
Hence, genetic modulations that affect the functional integrity of one of these components, conse-
quently interferes with proliferation. Therefore, I subjected a selected assortment of small interfering 
RNAs (siRNAs) to M010817 cells targeting the previously identified neural crest-associated factors 
and assessed their impact on the cell cycle.  
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Figure 15. The RNAi screening approach reveals NKAP to play a role in melanoma. To test the role of the 
newly discovered target genes in melanoma, the cell cycle profile was assessed after subjecting a set of siRNAs 
(55 nM) to the human melanoma cell culture M010817. (A-F) The knockdown efficiencies were confirmed 
using RT-qPCR. (G-L) Cells were stained with propidium iodide and subsequently the cell cycle profile was 
analyzed using flow cytometry. Computational evaluation was performed on the FlowJo 7.6 software using the 
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Dean-Jett-Fox algorithm. In case a statistical analysis was performed, the unpaired student’s t-test was applied 
and data are represented as mean ± s.e.m. of n=3. 
 
To evaluate the efficiency of the knockdowns, the expression of the corresponding genes was deter-
mined using RT-qPCR. The obtained knockdown efficiencies were sufficient (70-90%) for LIN9, 
SSBP2, NKAP, NF-YC, moderate (40-65%) for NF-YB, and low (65-85%) for NF-YA (Figures 15A-
F). The RT-qPCR results further revealed that LIN28A is not expressed in M010817, which was later 
confirmed by RNA sequencing (data not shown). Thus, LIN28A was excluded from further investiga-
tions.   
 
The results from the cell cycle analysis revealed that, both siRNAs targeting NKAP induced a signifi-
cant G1/G0 cell cycle arrest. Transient depletion of the residual genes either resulted in minor cell 
cycle alterations or the applied siRNAs had no consistent effect on the cell cycle. Therefore, it is likely 
that these factors do not affect proliferation or it might be that the achieved knockdown was not suffi-
cient to induce a significant change in the cell cycle profile. Furthermore, the observed inconsistencies 
might be a consequence of siRNA off target effects (Figures 15G-L). According to the results of this 
preliminary screening approach, I decided to further study the role of NKAP in melanoma.  
 
6.1.2. NKAP is expressed in primary human melanoma cell cultures 
 
Previously, NKAP has been reported to be required for T cell development and for the maintenance 
and survival of hematopoietic stem cells. However, NKAP has not yet been described in the context of 
melanoma or other kinds of cancer. To expand the field of view on NKAP’s role in melanoma, I tested 
NKAP protein expression in different primary human melanoma cell cultures by immunoblot analysis. 
In accordance with previous findings that NKAP is ubiquitously expressed, all tested melanoma cell 
cultures expressed NKAP protein at detectable levels [Burgute_2014]. Although NKAP theoretically 
weighs 47 kDa, it effectively runs with a molecular weight of approximately 60 kDa when separated 
by SDS-PAGE. This observation is in analogy with earlier reports and is suggested to be a cause of the 
exceptionally high content of basic and charged residues, or yet unknown posttranslational modifica-
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tions [Burgute_2014; Worlitzer_2014]. As shown in a former study, melanoma cell cultures can be 
classified into a proliferative or an invasive state, according to their phenotype-specific gene expres-
sion profile [Widmer_2012]. The URPP biobank, UZH has previously characterized the provided pri-
mary human melanoma cell cultures as follows; M000921, M130427, M980514, M130429, and 
M010817 are proliferative, whereas M121224 and M130219 are invasive. Interestingly, NKAP ex-
pression is markedly reduced in invasive cells as compared to proliferative cells. This indicates that 
NKAP is either required for proliferation or NKAP down regulation might be necessary to promote 
invasiveness (Figure 16A).  
 
	  
 
Figure 16. Low NKAP levels correlate with poor patient survival. (A) Immunoblot analysis of NKAP ex-
pression in different human melanoma cell cultures. M000921, M130427, M980513, M130429, and M010817 
were previously characterized as proliferative, whereas M121224 and M130219 are annotated as invasive cell 
cultures. (B-C) Clinical data were retrieved from the TCGA database in order to assess the correlation between 
NKAP expression and patient survival. Therefore, a comparative analysis was performed assessing the survival 
of patients that provided samples with highest (top 15%) and lowest (bottom 15%) NKAP expression. P-values 
were calculated using the Log-rank (Mantel-Cox) test. (D-E) To address the role of NKAP in melanoma, stable 
NKAP loss-of-function M010817 cells were generated using shRNA and CRISPR-CAS9. The absence of the 
protein was confirmed by immunoblot.  
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6.1.3. Decreased NKAP expression is linked to poor patient survival 
 
In order to interrogate whether NKAP plays a clinical role in melanoma patients, I assessed the overall 
patient survival based on NKAP expression using the The Cancer Genome Atlas (TCGA) database. 
TCGA represents a publicly available data collection that catalogues about 33 different cancer types, 
including melanoma. The database comprises patient information and data from collected patient ma-
terial, which was analyzed by gene expression profiling, copy number variation profiling, single nu-
cleotide polymorphism (SNP) genotyping, genome wide DNA methylation profiling, microRNA pro-
filing, and exon sequencing. For data analysis and statistical evaluations I used the TCGA browser 
v0.9, an online available program developed by Dr. Phil Cheng. To address whether NKAP expression 
correlates with melanoma patient outcome, I compared the survival data of patients that provided 
highest (top 15%) and lowest (bottom 15%) NKAP-expressing samples. To better distinguish the ef-
fect of NKAP on different phases of melanomagenesis, primary tumors and lymph node/distant metas-
tases were analyzed separately. Differential NKAP expression in primary tumors had no significant 
influence [P=0.6972] on patient survival (Figure 16B). However, patients with low NKAP expression 
in lymph node and distant metastases had a significantly (P=0.0026) shorter survival. NKAP low pa-
tients had a median survival of 0.9 years, whereas the NKAP high patients had a median survival of 
>10 years (Figure 16C). Consequently, these data demonstrate that NKAP has a beneficial impact on 
the outcome of melanoma patients. Furthermore, these data suggest that NKAP only interferes with 
patient survival once melanoma has metastasized.  
 
6.1.4. CRISPR-CAS9 and shRNA efficiently ablate NKAP expression 
 
To keep a closer eye on NKAP’s function in melanoma I planned to generate a stable knockdown 
using RNA interference. Therefore, I used the primary human melanoma cell culture M010817, which 
presents among the strongest NKAP expressing cell cultures, as shown in (Figure 16A). I applied a 
lentiviral construct to deliver shRNA plus GFP marker. In order to increase the knockdown efficiency 
I sorted for cells with high GFP expression using fluorescence-activated cell sorting (FACS). The 
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knockdown efficiently reduced NKAP expression in M010817, which was confirmed by RT-qPCR 
(data not shown) and immunoblotting (Figure 16D).  
 
Additionally, to exclude the effect of remaining NKAP activity and shRNA off-target effects, I gener-
ated a complete NKAP knockout in M010817 cells using the clustered regularly interspaced short 
palindromic repeats (CRISPR)-CAS9 technique. The RNA-guided CRISPR-CAS9 method defines a 
powerful genome-editing tool that allows fast generation of knockout cell cultures. Originally, 
CRISPR-CAS9 has been found as a prokaryotic adapted immune defense mechanism that confers 
resistance to foreign genetic elements. Thereby, the CAS nuclease recognizes and cuts exogenous 
genetic material that is bound by a CRISPR spacer [Barrangou_2007; Marraffini_2008; Red-
man_2016]. In genome engineering, the single guide RNA (sgRNA) recognizes and binds to its com-
plementary sequence on the genome. Generally, sgRNAs contain a target specific CRISPR RNA se-
quence (crRNA) and a trans-activation RNA (tracrRNA) that recruits the CAS9 nuclease to the target 
site. In order to exert nuclease activity, CAS9 requires a protospacer adjacent motif (PAM) consistent 
of the three base pairs 5’-NGG-3’, which are located directly after the sgRNA recognition sequence. 
Upon binding to the sgRNA, CAS9 introduces a double strand break into the DNA, which is usually 
repaired by non-homologues end-joining (NHEJ). Errors during the repair process lead to random 
integration of so-called indel mutations at the target site. This often causes the formation of a frame 
shift and consequently to the introduction of a premature stop-codon, which results in the abrogation 
of the gene product [Jinek_2013; Ran_2013].  
 
Although the NKAP gene locus encodes four alternatively processed transcripts, only one is translated 
into a protein. Hence, to completely abolish protein expression I decided to target the NKAP gene at 
exon 1 of the protein-coding transcript. Using the online available Optimized CRISPR Design tool I 
generated an sgRNA (TGATGAACATACACCAGTGG) with a quality score of 69 out of 100, pre-
dicting a low chance for off-target binding. Subsequently, M010817 cells were simultaneously trans-
fected with an sgRNA expressing vector and a construct that encodes the CAS9 nuclease and a GFP 
reporter. Ultimately, GFP positive cells were seeded as single colonies and screened for NKAP protein 
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expression by Western blot analysis. The complete disappearance of the presumed bands in two se-
lected clones, clearly demonstrates the loss of NKAP expression (Figure 16E). The knockout was fur-
ther confirmed by Sanger sequencing, revealing the presence of a premature stop-codon in all samples 
tested (data not shown).  
 
6.1.5. Loss of NKAP affects cell adhesion in vitro 
 
As a first observation, NKAP deficient M010817 cells display an evident adhesion phenotype in cul-
ture. After trypsinization, NKAP depleted cells remain in suspension as clumps and adhere to the cell 
culture dish in a temporally deferred manner (Figure 17A). To confirm this observation, I conducted 
an adhesion assay followed by a crystal violet staining to quantitatively assess the adhesive potential 
of NKAP deficient M010817 cells. Therefore, I seeded 500’000 cells in normal 6-well cell culture 
plates and determined the area covered by cells and the number of cells in suspension after a 12 hours 
incubation period. As expected, the area covered by NKAP deficient M010817 cells was dramatically 
reduced, whereas the number of cells in suspension was significantly elevated as compared to control 
cells (Figure 17B-C). Additionally, to exclude enhanced cellular detachment due to increased apop-
totic events, I stained floating cells with trypan blue and examined the live-dead cell ratio (Figure 
17C). However, the live-dead cell ratio was not significantly altered between control and knockout 
cells, indicating that the increased number of cells in suspension is not a consequence of a higher 
apoptotic rate. Hence, these results suggest that NKAP effectively interferes with the adhesive capaci-
ty of M010817 cells.    
 
6.1.6. NKAP deficiency increases invasiveness in vitro 
 
To test whether NKAP deficiency also affects invasiveness in vitro, I performed a Boyden chamber 
invasion assay. Previous experiments have shown that regardless of the treatment, M010817 cells 
become hardly invasive under in vitro conditions and cannot be used in Boyden chamber assays. Con-
sequently, I generated a stable NKAP knockdown in the primary human melanoma cell culture 
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M050829 using two different shRNAs. M050829 cells possess proliferative as well as invasive prop-
erties and have been used previously in invasion assays. The results of the invasion assay revealed that 
either of the two applied shRNAs significantly (P>0.05) enhanced the invasive capacity of M050829 
cells (Figure 17D-E). Summing-up, these findings demonstrate that NKAP depletion leads to en-
hanced invasiveness, suggesting that NKAP acts suppressively on invasion in vitro.  
 
	  
 
Figure 17. NKAP depletion affects adhesion in vitro. (A) Bright-field image of M010817 NKAP knockout and 
control cells. Scale bars, 50 µm. (B-C) To assess the adhesion capacity of M010817 knockout and control cells, 
500’000 cells were seeded in a 6-well-plate and incubated for 12 h. To determine the relative area (%) covered 
by cells, 5 random regions were analyzed using the CellProfiler 2.0 software. (D) To determine the invasive 
capacity of M050829 NKAP knockdown and control cells, a Boyden chamber invasion assay was performed. 
Microscopic image of invading cells fluorescently labeled with Hoechst 33342. Scale bars, 100 µm. (E) The 
exact number of invading cells was quantified with the CellProfiler 2.0. software. (B, C, E) For statistical analy-
sis the unpaired student’s t-test was applied and the data are depicted as mean ± s.e.m. of n=3. 
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6.1.7. Stable NKAP depletion induces a G1/G0 cell cycle arrest in vitro 
 
As mentioned previously, transient NKAP depletion in M010817 cells induced a G1/G0 cell cycle 
arrest in vitro [6.1.1]. To confirm these results, I analyzed the cell cycle profile of stably transfected 
NKAP knockdown and NKAP knockout M010817 cells. Furthermore, I conducted a growth curve 
analysis to assess the proliferative potential of these cells. Analogous to transiently transfected cells, 
stable NKAP knockdown as well as complete NKAP ablation induced a drastic G1/G0 cell cycle ar-
rest (Figure 18A). Along this line, the growth curve analysis revealed that NKAP deficiency signifi-
cantly reduced proliferation, circumstantiating the previously obtained results (Figure 18B).  
 
6.1.8. Forced adhesion does not rescue the G1/G0 cell cycle arrest 
 
Generally, adhesion to the extracellular matrix is a precondition in normal cells to allow cell cycle 
progression. If cellular attachment to solid substrate is disrupted, normal cells are not able to complete 
cell division and arrest in the G1 phase of the cell cycle [Otsuka_1975; Matsuhisa_1981; 
Benaud_2001]. This prompted me to investigate whether the G1/G0 cell cycle arrest in NKAP deplet-
ed cells is mediated through reduced cellular adhesion. Therefore, I seeded cells in fibronectin-coated 
cell culture dishes to force their attachment to the plate surface. Subsequently, I determined their cell 
cycle profile and performed a growth curve analysis to assess their proliferative behavior. Expectedly, 
fibronectin treatment rescued the adhesion phenotype, as the attachment rate for NKAP depleted and 
control cells was equal (data not shown). However, although NKAP deficient cells were forced to 
adhere, their cell cycle profile remained unaltered (Figure 18C). The results of the growth curve analy-
sis further substantiated that despite adhesion, NKAP depleted M010817 cells present with impaired 
proliferation (Figure 18D). This indicates that NKAP deficiency effectively interferes with prolifera-
tion in vitro and that decreased cellular adhesion is most likely not the cause of the induced G1/G0 cell 
cycle arrest. 
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Figure 18. NKAP depletion induces a G1/G0 cell cycle arrest. (A) After EdU and propidium iodide incorpo-
ration, a cell cycle analysis of NKAP knockout, knockdown and control M010817 cells was performed using 
flow cytometry. (B) To assess the proliferative potential of NKAP knockout, knockdown and control M010817 
cells, a growth curve analysis was performed over 5 days. (C) After NKAP knockout and control M010817 cells 
were seeded in fibronectin-coated dishes their cell cycle profile was determined according to the descriptions in 
(A). (D) KNAP knockout and control M010817 cells were cultured in fibronectin-coated dishes and a growth 
curve analysis was performed over 5 days. (E) NKAP knockout and control M010817 cells were co-cultured in a 
1:1 ratio and their cell cycle profile was assessed as described in (A). (A, C, E) For statistical analysis the un-
paired student’s t-test was applied and the data are depicted as mean ± s.e.m. of n=3. 
 
6.1.9. Cell intrinsic mechanisms induce the cell cycle arrest in NKAP depleted cells 
 
Cell replication is a tightly controlled process that relies on intrinsic as well as extrinsic signaling cues. 
To address whether the cell cycle arrest is due to decreased secretion of growth promoting signaling 
molecules, I planned to determine the cell cycle profile of co-cultured NKAP wild type and knockout 
M010817 cells. Hence, NKAP wild type and knockout cells were co-incubated in a 1:1 ratio for two 
days prior to cell cycle analysis. If co-culturing rescues the proliferation defect in NKAP knockout 
cells, the mixed and the pure wild type population present with similar cell cycle profiles. However, if 
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co-culturing has no effect on NKAP knockout cells, the cell cycle profile appears as an intermediate 
product of both, wild type and knockout cells. The cell cycle distribution is thereby biased towards the 
faster proliferating wild type population (63%), which outnumbers the knockout population (37%) 
after two days in culture. The results of the cell cycle analysis however revealed that the cell cycle 
profile of co-cultured wild type and knockout cells is significantly distinct from purely cultured 
M010817 wild type cells. Moreover, considering the growth advantage of NKAP wild type M010817 
cells, the estimated G1/(S+G2) ratio of 1.17 (1+0.37·(1.47-1) perfectly coincides with the effectively 
measured G1/(S+G2) ratio of 1.15 (Figure 18E). Consequently, these results demonstrate that co-
culturing does not rescue the cell cycle arrest and suggest that NKAP depletion impedes cell prolifera-
tion through cell intrinsic mechanisms and not through reduced secretion of growth promoting factors.   
 
6.1.10. NKAP deficiency enhances metastasis formation in vivo 
 
To examine the effect of NKAP deficiency under in vivo conditions, I subcutaneously injected 
M010817 NKAP knockout cells into immune-compromised NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) 
mice. I sacrificed the mice 4 weeks after injection and determined the weight of the primary tumors. 
Despite the in vitro induced G1/G0 cell cycle arrest after NKAP depletion, there was no significant 
difference in tumor growth in vivo (Figure 19A-B). Additionally, to assess the metastatic potential of 
NKAP deficient cells, I collected the lungs of injected animals and analyzed the metastatic burden by 
RT-qPCR. Therefore, I measured the relative mRNA expression of two independent human house-
keeping genes (GAPDH, PPIA) in homogenized lung tissue and normalized against the murine house-
keeping gene USF1. An earlier report has described a similar approach to quantify human circulating 
tumor cells (CTCs) in the blood system of previously injected mice [Gorges_2012]. In order to deter-
mine the metastatic load in mouse lungs, I used the same primers for the human housekeeping genes 
as suggested in the report. To evaluate the specificity of the primers, I additionally analyzed the lungs 
of non-injected mice. Hence, the specificity of the primers was clearly confirmed, as GAPDH and 
PPIA expression levels in injected animals were significantly higher as compared to uninjected ani-
mals. Ultimately, the results of the RT-qPCR analysis revealed that GAPDH and PPIA expression was 
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significantly elevated in mice injected with NKAP depleted cells (Figure 19C-D). Thereby, the extent 
of the metastatic burden does not coincide with the size of the primary tumor, as in vivo tumor growth 
remained unaffected upon NKAP depletion.  
 
	  
 
Figure 19. NKAP depletion increases the metastatic potential in vivo. (A) Macroscopic image of primary 
tumors 4 weeks after subcutaneous injection of 300’000 NKAP knockout and control M010817 cells in NSG 
mice (n=3). Scale bar, 10 mm. (B) Weights of the tumors depicted in (A). (C-D) To examine the metastatic bur-
den in the lungs of mice described in (A), RT-qPCR was used to determine human GAPDH and human PPIA 
levels in homogenized lung tissue. Relative mRNA expression levels were normalized to murine USF1. (E) 
Superficial GFP-positive lesions and corresponding bright-field images from lungs of mice injected with NKAP 
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knockdown and control M010817 cells. Scale bars, 100 µm. (B, C, D) For statistical analysis the unpaired stu-
dent’s t-test was applied and the data are depicted as mean ± s.e.m. of n=3. 
 
In a second experiment, NKAP knockdown cells labeled with a GFP reporter were injected into NSG 
mice to qualitatively assess the incidence of metastatic cells in the lung. Therefore, I isolated the lungs 
of previously injected mice four weeks after injection and visualized superficially located metastases 
using a fluorescence-coupled binocular. Corroborating the results described above, the number of me-
tastases in mice that were injected with NKAP knockdown cells was dramatically increased (Figure 
19E). However, the exact number of metastatic lesions per lung could not be determined, as with 
depth the emitted GFP signal slowly merges with the surrounding background noise.  
 
6.1.11. NKAP associates with EMT, cell adhesion and cytoskeleton remodeling 
  
To determine downstream effector genes that are differentially expressed upon NKAP depletion, I 
performed RNA sequencing (RNA-seq) to compare the gene expression profile of NKAP knockout, 
knockdown and control M010817 cells. In total 2954 genes were differentially expressed in NKAP 
knockout cells, and 1863 genes had altered expression in NKAP knockdown cells when compared to 
control cells (fold change >1.4-fold, FDR corrected P<0.05). Overlapping the two signatures revealed 
910 commonly regulated genes (Figure 20A). To further assess the pathways that are functionally 
affected upon NKAP depletion, I conducted a gene ontology pathway enrichment analysis using the 
MetaCoreTM platform (Figure 20B). Interestingly, the MetaCoreTM analysis proposed enriched path-
ways associated with EMT, cell adhesion, and cytoskeleton remodeling. However, most genes en-
gaged in the proposed pathways, change their expression in a way that stands in contrast to the ob-
served phenotype. A prominent example following this paradoxical phenomenon is fibronectin 1 
(FN1), an extracellular protein that helps cells attach to the surrounding matrix. Although fibronectin 
is four times up regulated in NKAP deficient cells, their adhesion capacity remains low. Thereby, up 
regulation of FN1 might be a compensation mechanism to overcome the adhesion defect induced by 
NKAP depletion. The reason for decreased adhesion however could not be determined by RNA-seq.  
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Figure 20. NKAP deficiency affects EMT, cell adhesion and cytoskeleton remodeling. (A) RNA sequencing 
was performed to establish a comparative transcriptomic analysis of NKAP knockout, knockdown and control 
cells. The overlap reveals 910 differentially expressed genes (log2Ratio>0.5, P<0.05, FDR≤0.05). (B) These 
genes (910) were further analyzed using the MetaCoreTM pathway enrichment algorithm. The top eight hits are 
represented in the table.  
 
6.1.12. NKAP over expression in M010817 cells is weak 
 
In order to revert the phenotype observed in NKAP depleted cells, I generated a lentiviral over expres-
sion construct containing an HA_NKAP fusion protein under the control of the CMV promoter. The 
vector further comprises an eGFP reporter regulated by the SV40 promoter. Next, M010817 NKAP 
knockout and control cells were infected and selected with Puromycin to obtain a pure population. In 
addition, infected cells were sorted for high GFP to guarantee accurate expression of the exogenous 
protein. However, exogenous protein levels were fairly weak, despite all the measures taken and 
abundant eGFP expression, as confirmed by immunoblot analysis (Figure 21A). Hence, this indicates 
that high NKAP expression is poorly tolerated, and M010817 cells are either able to silence the CMV 
promoter or high NKAP expression induces apoptosis. 
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6.1.13. NKAP over expression only partly rescues the NKAP depletion phenotype in vivo 
 
Although exogenous NKAP levels were low, the range of expression was similar to the endogenous 
protein. Therefore, I planned to address whether exogenous NKAP expression is able to revert the in 
vivo phenotype evoked by NKAP depletion. To this end, I subcutaneously injected NKAP reconstitut-
ed M010817 cells, described in the previous section, into NSG mice and harvested primary tumors and 
lungs for further evaluation four weeks post injection. In accordance with previous findings, NKAP 
reconstitution had no effect on tumor growth (data not shown). However, the metastatic burden was 
substantially reduced upon NKAP over expression (Figure 21B-C). Although a clear trend is observa-
ble, the differences were not significant due to the high variability in the non-reconstituted control 
group. Nonetheless, these results clearly demonstrate that the increased metastatic proclivity of 
M010817 cells is indeed a consequence of NKAP depletion and that NKAP reconstitution at least 
partly reverts this phenotype.  
 
6.1.14. NKAP appears with a punctuated pattern within the nucleus 
 
As shown by Western blot analysis, the achieved expression levels for exogenous NKAP were low in 
M010817 cells. However, the method does not allow a conclusion about the expression intensity on a 
single cell level. Hence, it might be that NKAP is expressed in all cells on a similarly low level or it 
might be that NKAP is high in a small subset of the population, while it is absent in the rest. To ad-
dress this question, I performed an immunocytochemistry staining of M010817 cells over expressing 
HA_NKAP using a monoclonal anti-HA antibody. The anti-HA staining nicely illustrates the localiza-
tion of the exogenous HA_NKAP protein to the nucleus in a punctuated manner (Figure 21D). How-
ever, although all cells were strongly GFP positive, only a small fraction expressed the HA-tagged 
protein, whereas in residual cells the expression was completely absent (data not shown). Hence, 
M010817 cells are able to silence the CMV promoter, independently of the GFP reporter, in order to 
shut down NKAP expression.  
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Figure 21. NKAP localizes to nuclear speckles. (A) To revert the NKAP depletion-mediated phenotype, 
NKAP knockout M010817 cells were reconstituted with a HA_NKAP fusion protein and a eGFP reporter. The 
expression of the exogenous protein was confirmed by immunoblotting. (B) Reconstituted cells were subcutane-
ously injected into NSG mice and the metastatic burden was assessed as described in (Figure 19C-D). (C) Im-
munofluorescent staining for the HA-tag and internal eGFP expression in reconstituted NKAP knockout 
M010817 cells. Scale bars, 10 µm. (D) Immunofluorescent staining for SC-35 and internal eGFP expression in 
NKAP knockout M010817 cells reconstituted with a HA_NKAP_eGFP fusion protein. Scale bars, 10 µm. (B, C) 
For statistical analysis the unpaired student’s t-test was applied and the data are depicted as mean ± s.e.m. of 
n=3. 
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6.1.15. NKAP localizes to the nuclear speckles 
 
Since M010817 cells were able to silence NKAP expression independently of the eGFP reporter, I 
created a HA_NKAP_eGFP fusion protein with the intention to directly link the intensity of the GFP 
signal with protein expression. Furthermore, the eGFP tag allows the exact subcellular localization of 
the protein. Accordingly, I transfected M010817 NKAP knockout and control cells with a lentiviral 
construct containing the fusion protein under the control of an SV40 promoter. I subjected the trans-
fected cells to Puromycin selection and sorted for high GFP expression as described above. A previous 
study performed in HEK cells suggests NKAP as a component of the RNA processing machinery and 
has shown its localization to the nuclear speckles [Burgute_2014]. To test whether NKAP behaves 
similar in M010817 cells, I conducted an immunofluorescence staining to co-label GFP positive cells 
with the nuclear speckle marker serine/arginine-rich splicing factor 2 (SRSF2). SRSF2 is required for 
the formation of the earliest splicing complex and interacts with various spliceosomal components 
[Fu_1993]. The staining revealed the accumulation of the eGFP reporter in multiple small nuclear 
spots that exclusively colocalize with SRSF2 (Figure 21E). Consequently, these findings illustrate that 
the exogenously expressed NKAP fusion protein localizes to nuclear speckles in M010817 cells, 
thereby confirming previous data that suggest NKAP as a speckle protein involved in RNA processing 
[Burgute_2014]. Usually, speckles appear as irregularly shaped nuclear structures localized in the 
interchromatin space [Spector_2011]. However, the SRSF2 antibody staining supports previous data 
demonstrating that nuclear speckles increase in number and appear as homogenous, round spots upon 
NKAP over expression [Burgute_2014]. Thus, it is assumed that excessive NKAP synthesis leads to 
the accumulation of the protein in nuclear speckles, which have been proposed as a storage place for 
RNA processing factors. Interestingly, inhibition of the transcription machinery leads to a similar ac-
cumulation of nuclear speckle proteins in enlarged rounded spots [Melcak_2000].  
 
Unfortunately, the exogenous fusion protein was only present in the minority of the cell population, 
and the number of GFP positive cells decreased drastically over time in culture. This clearly indicates 
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that M010817 cells poorly tolerate NKAP over expression and silencing is required for the mainte-
nance of the cellular integrity.  
 
6.1.16. NKAP interacts with nuclear speckle components 
 
A previous report demonstrated the interaction of NKAP with components of the NOTCH co-
repressor complex such as CIR and HDAC3. Interestingly, both factors partially localize to nuclear 
speckles [Pajerowski_2009]. A later study showed that NKAP co-precipitates with RNA binding pro-
teins, i.e. hnRNPs, RNA helicases and splicing factors [Burgute_2014]. To gain more insights into the 
mechanistic function of NKAP in M010817 cells, I sought to investigate its interaction partners. 
Therefore, I performed a co-immunoprecipitation study in collaboration with Sergio Leone (group of 
PD Dr. Raffaella Santoro) in HA_NKAP expressing M010817 cells using a monoclonal anti-HA anti-
body. Subsequently, the eluate was processed for LC-MS/MS analysis. The results of the mass spec-
trometry analysis revealed that the majority of the proteins identified associate with nuclear speckles 
and include hnRNPs, RNA helicases, splicing factors, and other RNA-binding proteins (Table 1). In-
terestingly, NKAP also co-precipitated with stress response factors that at least partly exert their func-
tion in nuclear speckles. Consequently, the data obtained by mass spectrometry confirm earlier co-
immunoprecipitation studies and demonstrate that NKAP interacts with nuclear speckle and RNA 
processing proteins in M010817 cells. Although, the interaction with CIR and HDAC3 was not af-
firmed, NKAP co-precipitated with pinin (PNN). PNN binds to the transcriptional repressor C-
terminal binding protein (CtBP), a component of the NOTCH co-repressor complex, and thereby pre-
vents CtBP-mediated transcriptional repression. Hence, NKAPs’ interaction with PNN suggests a 
connection with the NOTCH co-repressor complex, however the functional significance of this inter-
action remains speculative.  
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Table 01. NKAP interacts with nuclear speckle proteins involved in RNA processing. (A) To determine 
NKAP interaction partners, a co-immunoprecipitation study was performed in HA_NKAP over expressing 
M010817 cells using a monoclonal anti-HA-antibody. Subsequently, the eluate was processed for LC-MS/MS 
analysis. The table depicts NKAP interaction partners localized in nuclear speckles.  
 
6.1.17. CIR knockdown does not phenocopy NKAP depletion 
 
As mentioned before, CIR localizes to nuclear speckles and interacts with NKAP, as confirmed by co-
immunoprecipitation [Pajerowski_2009]. Likewise to NKAP, CIR regulates transcription as a compo-
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nent of the NOTCH co-repressor complex [Hsieh_1999]. However, CIR has also been proposed to 
modulate splice site selection during alternative splicing of pre-mRNAs [Maita_2004]. To further 
investigate the relationship between NKAP and the NOTCH co-repressor complex, I decided to ad-
dress the role of CIR in M010817 cells. Therefore, I transiently depleted CIR expression in M010817 
cells using two different siRNAs. Subsequently, I performed an adhesion assay and determined the 
cell cycle profile using EdU incorporation. As confirmed by RT-qPCR, the siRNAs achieved an 80%, 
and 72% reduction in CIR expression, respectively (Figure 22A). However, transient CIR depletion 
had neither an effect on cell adhesion nor on the cell cycle, implying that CIR deficiency does not 
mimic the NKAP phenotype in M010817 cells (Figure 22B-D). Consequently, these data suggest that 
NKAP’s role in cellular attachment and cell cycle progression is not mediated by CIR.  
 
	  
 
Figure 22. CIR deficiency does not phenocopy NKAP depletion. (A) M010817 cells were transiently trans-
fected with two siRNAs (55 nM) targeting CIR. The knockdown was confirmed using RT-qPCR. (B-C) To as-
sess the adhesive capacity of transiently transfected cells described in (A), an adhesion assay was performed as 
described in (Figure 17B-C). (D) To determine the cell cycle profile of CIR knockdown M010817 cells (A), a 
cell cycle analysis was performed according to previous instructions (Figure 18A). (B-D) For statistical analysis 
the unpaired student’s t-test was applied and the data are depicted as mean ± s.e.m. of n=3. 
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6.1.18. NKAP depletion reduces translational activity 
 
This and earlier studies have shown NKAP’s subcellular localization to nuclear speckles, where it 
interacts with a plethora of RNA processing factors. Hence, it is well conceivable that NKAP is in-
volved in the co- or post-transcriptional processing of pre-mature RNA. If NKAP depletion truly af-
fects RNA processing, unprocessed RNA would accumulate, whereas the concentration of mature 
RNA would decrease. Consequently, translation drops in response to reduced substrate levels. To test 
this hypothesis, I pulsed M010817 NKAP knockout and control cells with O-propargyl-puromycin 
(OP-puro) and assessed the incorporation rate using fluorescence activated cell analysis. OP-puro is a 
functional analog of puromycin and is efficiently incorporated into newly synthesized peptides. Sub-
sequently, OP-puro is fluorescently labeled, whereas the intensity of the signal directly correlates with 
the translational activity. As a negative control I used M010817 control cells pre-incubated with cyclo-
heximide, a potent protein synthesis inhibitor. As a result, the median OP-puro incorporation was 5 
times (P>0.001) reduced in cycloheximide treated cells, confirming the specificity of the signal (Fig-
ure 23A-B). The FACS analysis further revealed that the OP-puro incorporation was 2.4-fold and 1.6-
fold decreased in both NKAP knockout clones tested. These results demonstrate that NKAP depletion 
leads to impaired transcriptional activity, which suggests that NKAP is required in co- or post-
transcriptional processes. 
 
6.1.19. NKAP expression levels are tightly regulated to allow optimal transcriptional activity 
 
As described earlier, exogenous NKAP was only expressed in a small fraction of the cell population, 
whereas it was silenced in the residual fraction. To test whether the translational potential is restored 
in M010817 cells expressing the exogenous HA_NKAP_eGFP fusion protein, I examined their trans-
lational activity using OP-puro incorporation followed by flow cytometric analysis. To assess the dif-
ference between silenced and strong NKAP expression, I compared the OP-puro incorporation rate of 
lowest (10%) and highest (10%) GFP-expressing cells. Surprisingly, the translational activity was only 
slightly increased (P=0.02) in high NKAP expressing cells when compared to the low group (Figure 
Results	  
90 
23C). Furthermore, I compared their OP-puro incorporation to a third group with intermediate GFP 
expression (10%, optimized). Strikingly, M010817 cells with intermediate NKAP levels showed a 
dramatic increase in translational activity when compared to the low and high group. Hence, these 
results demonstrate that NKAP levels are tightly regulated and that aberrant NKAP expression leads to 
impaired translational activity.  
 
6.1.20. Reduced adhesion is a consequence of impaired protein synthesis 
 
With the results described in the previous sections, it became evident that NKAP deficiency interferes 
with the translational activity. During the course of the preparation procedure for the adhesion assay, 
cells were routinely incubated with trypsin to allow dissociation from the culture dish. Trypsin is a 
serine protease that hydrolyses cell surface proteins, thereby inducing cellular detachment from the 
substrate. Consequently, cells have to replenish their arsenal of surface proteins in order to guarantee 
reattachment to the culture dish. However, if translational activity is impaired, cells attach in a tem-
porally deferred manner due to delayed protein synthesis. To test this assumption, I incubated 
M010817 NKAP knockout and control cells with PBS-EDTA to allow mild detachment from the cul-
ture dish without destroying the surface proteome. Subsequently, I conducted an adhesion assay as 
described earlier in this study [6.1.5.]. Strikingly, the adhesion in the NKAP knockout clone 1 was 
completely restored upon PBS-EDTA treatment, while the adhesive capacity of the NKAP knockout 
clone 2 was dramatically improved (P=0.03) (Figure 23D-E). Hence, these data clearly illustrate that 
impaired cellular adhesion in NKAP depleted cells is a consequence of delayed protein replenishment 
on the cell surface after trypsinization due to the compromised translational activity.  
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Figure 23. NKAP deficiency reduces translation activity. (A-B) Translational activity in NKAP knockout and 
control M010817 cells was assessed after OP-puro incorporation using flow cytometry. As a negative control, 
M010817 control cells were treated with 50 µg/ml cycloheximide. (C) NKAP knockout cells reconstituted with 
the HA_NKAP_eGFP fusion protein were separated according to their GFP expression into a low, medium and 
high group. Subsequently, their translational activity was assessed as described in (A-B). (D-E) The adhesion 
capacity of NKAP knockout and control M010817 cells was assessed after mild detachment using PBS-EDTA. 
The adhesion assay was performed according to the descriptions in (Figure 17A-B). (F) The cell cycle of NKAP 
knockout and control M010817 was determined after mild detachment using PBS-EDTA as described previously 
in (Figure 18A). (B-F) For statistical analysis the unpaired student’s t-test was applied and the data are depicted 
as mean ± s.e.m. of n=3. 
 
6.1.21. Delayed replenishment of the surface proteome partly induces the cell cycle arrest  
 
Since delayed replenishment of the surface proteome due to reduced translational activity led to im-
paired cellular attachment after trypsinization, I sought to investigate whether this might also be the 
reason for the observed cell cycle arrest. Therefore, I plated NKAP deficient M010817 cells after 
PBS-EDTA treatment in order to examine their cell cycle profile using EdU incorporation and subse-
quent flow cytometric analysis. The cell cycle analysis revealed a drastic enhancement of the cell cy-
cle profile in NKAP depleted cells, though the results were still significant when compared to control 
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cells (Figure 23F). Consequently, these results imply that decelerated recovery after trypsinization is 
partly responsible for the G1 cell cycle arrest observed in NKAP deficient M010817 cells. Nonethe-
less, the cell cycle arrest was not completely restored after PBS-EDTA treatment, which indicates that 
NKAP depletion also has an internal effect on cell proliferation.  
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6.2. Contributions 
 
In the course of my PhD study rewiring the role of NKAP in melanoma, I conducted the vast majority 
of the above-described in vivo and in vitro experiments. In brief, my contributions to the study com-
prise xenograft experiments using NSG mice, molecular cloning, generation of NKAP knockdown, 
knockout and overexpressing melanoma cell cultures, immunochemical imaging studies including 
immunocytochemistry and Western blot analysis, RT-qPCR analysis, and cell culture experiments 
including growth curve and cell cycle analysis, adhesion assays, Boyden chamber invasion assays, and 
translational activity assays. Further on, my contributions to the study comprehend the usage of com-
putational and statistical data processing applications such as FlowJo 7.6, CellProfiler 2.0, Imaris, 
GraphPad PRISM 5, ApE 2.0.44, Microsoft Office 2011, Adobe Photoshop CS5, Adobe Illustrator 
CS5, and Adobe InDesign CS5. Furthermore, my contributions include the experimental design, and 
the writing of this report. Finally, I created the graphical abstract of two recently published reports by 
our group [Zingg_2015; Baggiolini_2016]. For these contributions I was included as co-author in the 
publications. 
 
The experimental procedures described in the following paragraph were conducted in collaboration 
with colleagues and co-workers. Co-immunoprecipitation studies were performed together with Sergio 
Leone (group of PD Dr. Raffaella Santoro). Western blots were conducted in cooperation with 
Yudong Zhang. Xenograft studies using NSG mice were performed in collaboration with Dr. Gaetana 
Restivo. Assessing the metastatic burden in lung tissues using RT-qPCR analysis was conducted with 
the help of Johanna Diener. In vitro cell culture assays were done together with Ana Antunes and An-
nika Klug. TCGA data evaluation was performed with the help of Dr. Phil Cheng (group of Prof. 
Mitchell Levesque). Confocal imaging was done in collaboration with Luis Zurkirchen, and CellPro-
filer analysis was performed in cooperation with Kim Ferrari (group of Prof. Bruno Weber).  
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7. Discussion 
 
Initially, NKAP has been described as an activator of NF-ΚB, while later reports proposed NKAP as a 
component of the NOTCH co-repressor complex regulating T cell development and survival and 
maintenance of hematopoietic stem cells [Chen_2003; Pajerowski_2009; Pajerowski_2010]. However 
a recent study identified NKAP as a nuclear speckle protein involved in RNA processing and splicing. 
During my doctoral thesis I investigated the role of NKAP in melanoma and demonstrate that NKAP 
depletion inhibits translational activity and thereby increases the metastatic behavior in melanoma.  
 
7.1.1. The neural crest associated factor NKAP plays a role in melanoma 
 
Previous studies in our lab have shown the reactivation of neural crest specific factors during the 
course of melanomagenesis [Civenni_2009; Shakhova_2012; Zingg_2015]. The goal of my PhD the-
sis was to determine a novel neural crest associated transcriptional regulator involved in melanoma. In 
a preliminary study, the transcriptional profile of early-differentiated neural crest derivatives was 
compared to untreated neural crest stem cells. The whole-genome transcriptome array was initially 
performed to identify novel transcription factors that drive early processes during neural crest differen-
tiation. Whether this approach generally suits the requirements to identify novel key drivers in mela-
nomagenesis remains to be seen. However, fast responding transcriptional adaptations might very well 
be reflected during certain aspects of melanoma progression, endowing cells with high plasticity. 
Therefore, comparing the transcriptional profile of early-differentiated neural crest derivatives to their 
undifferentiated counterparts represents a valid approach to identify novel neural crest associated fac-
tors in melanoma. Hence, on the basis of the whole-genome transcriptome array I determined 7 tran-
scriptional regulators, which were associated with neural crest stem cells and tested their functional 
involvement in melanoma using an RNAi screening approach. The results revealed that 6 out of 7 
genes were expressed in melanoma, which emphasizes the hypothesis that many neural crest associat-
ed genes find reuse in melanoma. The results further demonstrate that NKAP depletion induced a 
strong G1 cell cycle arrest. However, the remaining factors had no consistent impact on the cell cycle, 
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suggesting their function in a different cell biological process. Noteworthy, the achieved knockdowns 
for NF-YA and NF-YB using RNAi were insufficient and the generation of NF-YB knockout cells 
using CRISPR-CAS9 was not successful, highlighting their indispensible role in melanoma. Ultimate-
ly, the results of the RNAi screening approach prompted me to interrogate NKAPs function in mela-
noma.  
 
7.1.2. Functional manipulations were limited to the human melanoma cell culture M010817 
 
To investigate NKAP’s role in melanoma I generated stable NKAP knockdown and knockout cells 
using the human melanoma cell culture M010817. M010817 is a fast proliferating cell culture, en-
dowed with metastatic potential that tolerates a single cell expansion, which is necessary to create a 
knockout clone. To exclude possible side effects elicited by the clonal selection, I mostly performed 
the experiments using 2 NKAP knockout clones and stably transfected NKAP knockdown cells. As 
expected, the evoked phenotypes were usually more pronounced in the NKAP knockout clones when 
compared to the knockdown cells. In addition, I reconstituted knockout cells with a fluorescently 
tagged NKAP fusion protein to revert the phenotype observed after NKAP depletion. However, to 
strengthen the results obtained in M010817 it was the goal to establish further NKAP knockdown and 
knockout cell cultures. Unfortunately, only few cell cultures tolerated a single cell expansion, whereas 
in others the achieved knockdown efficiency was insufficient. Furthermore, the number of available 
cell cultures was strongly restricted, due to their limited metastatic behavior in vivo. Surprisingly, in-
vasive melanoma cell cultures generally presented with a low metastatic proclivity after subcutaneous 
injection in NSG mice. Therefore, most experiments performed in this study were restricted to the 
human melanoma cell culture M010817.  
 
7.1.3. NKAP localizes to nuclear speckles and interacts with RNA processing factors 
 
A previous report has demonstrated NKAP as a SR-related nuclear speckle protein involved in RNA 
processing and splicing [Burgute_2014]. In this study the exclusive localization to nuclear speckles 
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was confirmed using a fluorescently labeled NKAP fusion protein. Furthermore, co-
immunoprecipitation followed by mass spectrometry revealed that NKAP interacts with a plethora of 
RNA processing factors and other nuclear speckle proteins. Hence, it was not surprising that NKAP 
depletion drastically interfered with translational activity, highlighting its presumed role in RNA pro-
cessing. However, the exact mechanisms leading to decreased protein synthesis remain unclear. It is 
possible that likewise to the SR proteins SRSF1 and SRSF2, NKAP depletion reduces the production 
of nascent RNA [Lin_2009]. On the other side, it has already been published that NKAP deficiency 
reduces the levels of processed mRNA [Burgute_2014]. Hence, it remains to be shown whether re-
duced translation in NKAP depleted melanoma cells is a consequence of decreased RNA synthesis or 
a consequence of impaired RNA processing.  
 
7.1.4. Aberrant NKAP expression leads to impaired translational activity 
 
As a first observation, NKAP depleted melanoma cells attached in a temporally deferred manner after 
trypsinization when compared to control cells. What initially appeared as induction of EMT, later 
turned out to be a consequence of delayed replenishment of adhesion molecules on the cell surface 
after trypsinization due to impaired protein synthesis. Hence, when applying a mild dissociation meth-
od without trypsin, NKAP deficient cells presented with normal adhesion properties. Apart from the 
results obtained from the OP-puro incorporation assay, these findings further support that NKAP func-
tions as a pivotal factor in co- or post-transcriptional processes.  
 
However, NKAP reconstitution using a fluorescently tagged fusion protein was not able to revert the 
adhesion phenotype in NKAP depleted cells. Evidently, the cells poorly tolerated excessive NKAP 
expression and silenced the exogenous gene to allow the maintenance of the cellular integrity. These 
data found further supporting evidence as cells with high NKAP levels only presented a slight increase 
in translational activity when compared to low NKAP expressing cells. However, the translational 
activity culminated with intermediate NKAP levels, suggesting that NKAP is a tightly regulated pro-
tein, which is critical for protein synthesis. While NKAP depletion results in reduced translational 
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activity presumably due to decreased RNA levels, it is conceivable that excessive NKAP expression 
impairs translation as a consequence of perturbed RNA processing. Hence, NKAP represents an im-
portant factor that allows the fine-tuning of translation, whereas only well-regulated NKAP levels 
guarantee optimal conditions for protein synthesis.  
 
As shown earlier, inhibition of RNA polymerase II (pol II) leads to the accumulation of RNA pro-
cessing factors in enlarged nuclear speckles. In a similar way, nuclear speckles lose their irregular 
shape in response to NKAP over expression and appear as homogenous, round spots. It is assumed 
that excessive NKAP production leads to the accumulation of the protein in nuclear speckles. None-
theless, it is also possible that NKAP over expression causes perturbations in the RNA maturation 
process, which secondarily leads to a general accumulation of speckle proteins including NKAP. 
However, further experiments will be necessary to answer this question.  
 
Interestingly, a previous study using a luciferase reporter assay demonstrated that NKAP acts as a 
transcriptional repressor. The study examined the ability of a GAL4DBD-NKAP fusion protein to 
repress transcription from a luciferase reporter containing four copies of a GAL4-binding sequence 
upstream of the SV40 promoter [Pajerowski_2009]. As a result, the reporter activity was reduced and 
NKAP assigned a transcriptional repressor. However, the authors did not address whether the reporter 
activity was reduced in response to impaired RNA processing, which concomitantly results in de-
creased translational activity. Hence, it is conceivable that excessive NKAP expression perturbed the 
RNA maturation process, leading to decreased translation of the reporter protein. Along this line, if 
NKAP solely acts as a transcriptional repressor, translation would increase upon NKAP ablation. 
However, the contrary is the case, NKAP depletion induces a strong reduction in translational activity, 
suggesting NKAP as an activator of co- and post-transcriptional processes.  
 
Previously, NKAP has been identified as an activator of NF-ΚB [Chen_2003]. In this study the au-
thors found that NKAP activated NF-ΚB in a dose dependent manner using a NF-ΚB reporter assay. 
However, another report revealed that translational repression mediates activation of NF-ΚB by phos-
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phorylated translation initiation factor 2 (eIF2α) [Deng_2004]. Hence, it can be assumed that with 
increasing NKAP expression translation was continuously impaired leading to the activation of the 
NF-ΚB pathway. However, it remains to be confirmed whether excessive NKAP levels lead to in-
creased phosphorylation of eIF2α. Nonetheless, it would be an act of negligence to presume that im-
paired translation generally activates the NF-ΚB pathway. Thus, despite reduced translational activity, 
the RNAseq data provide no evidence that NKAP depletion leads to the up regulation of known NF-
ΚB downstream targets (data not shown). Consequently, these findings propose that excessive NKAP 
expression induces a stress response during the RNA maturation process, whereas NKAP depletion 
simply reduces the levels of processed RNAs, without inducing a stress response.  
 
All in all, the results of this study propose that NKAP is a tightly regulated protein, which is required 
in co- or post-transcriptional processes. Nonetheless, further investigations will be required to unravel 
the exact mechanistic function of NKAP in RNA processing and splicing.   
 
7.1.5. RNAseq data reveal compensational adaptations in response to decreased adhesion 
 
In order to determine potential NKAP downstream effectors, RNAseq and subsequently a MetaCoreTM 
pathway enrichment analysis was performed. The results revealed enriched pathways associated with 
EMT, cell adhesion and cytoskeleton remodeling. Nonetheless, most genes engaged in the proposed 
pathways, altered their expression in a way that stands in contrast to the observed phenotype. Unfortu-
nately, it is likely that many of the identified genes altered their expression as a compensation mecha-
nism in response to decreased adhesion. Therefore, to better examine NKAP downstream effectors, 
RNAseq should be repeated in cells that are passaged without trypsinization.  
 
7.1.6. NKAP is not involved in alternative splicing 
 
To address if NKAP is involved in alternative splicing, I analyzed the RNAseq data using the DEXseq 
algorithm to identify differentially expressed exons between NKAP knockdown, knockout and control 
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cells (data not shown). However, the results revealed only 152 commonly regulated genes with differ-
entially expressed exons in NKAP knockout and knockdown cells. Thus, these results rather suggest 
that alternative splicing is not affected by NKAP and therefore not the reason for the dramatic reduc-
tion in translational activity upon NKAP depletion. However, these data allow no conclusion about 
NKAP’s involvement in constitutive splicing.  
 
7.1.7. CIR ablation does not phenocopy NKAP deficiency  
 
As demonstrated in a previous study, NKAP interacts with components of the NOTCH co-repressor 
complex, such as CIR [Pajerowski_2009]. However, CIR ablation neither affected the cell cycle nor 
the adhesive property of M010817 cells. These results illustrate that CIR knockdown does not pheno-
copy NKAP depletion. Moreover, NKAP did not co-immunoprecipitate with CIR in M010817 cells, 
suggesting that this interaction does not play a role in M010817 and might be cell type specific. As 
stated previously, the results of this study do not support the assumption that NKAP acts as a tran-
scriptional repressor. Nonetheless, the interactions with components of the NOTCH co-repressor com-
plex might be relevant in a different context. Thus, it can be hypothesized that CIR, as a component of 
the NOTCH co-repressor complex, locally binds to NKAP in order to interfere with its function as an 
RNA processing factor. Consequently, this interaction represents an additional repressive mechanism 
on a post-transcriptional level. However, further experiments will be required to verify this hypothesis.  
 
7.1.8. Despite reduced proliferation in vitro, tumor growth of NKAP depleted cells is not 
affected in vivo 
 
Interestingly, despite the in vitro observed G1/G0 cell cycle arrest, there was no significant difference 
between NKAP knockout and control M010817 cells regarding size and weight of the primary tumor 
after subcutaneous injection into NSG mice. Hence, it might be that in vitro cultured NKAP knockout 
cells are not able to produce enough autocrine growth factors as a consequence of impaired translation, 
and therefore proliferation is reduced. On the other side, subcutaneously injected NKAP knockout 
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cells encounter additional growth promoting factors from the surrounding tumor stroma, which helps 
them to overcome their proliferation deficit observed in vitro.   
 
7.1.9. NKAP depletion increases the metastatic behavior in vivo 
 
In addition to the tumor growth analysis, I assessed the metastatic burden in the lungs of mice that 
were subcutaneously injected with M010817 NKAP knockout cells. Strikingly, despite unaffected 
tumor growth, the metastatic potential was drastically increased upon NKAP ablation as compared to 
control cells. These findings were further supported retrieving clinical data from the TCGA database. 
Hence, while differential NKAP expression in primary tumors had no effect on patient survival, pa-
tients with low NKAP expression in lymph node and distant metastases revealed a significantly short-
er survival. Summing up, these results indicate that NKAP depletion-mediated translational inhibition 
leads to increased metastatic proclivity in melanoma. Nonetheless, the exact underlying mechanisms 
linking translational inhibition with increased metastasis formation in melanoma remain to be re-
solved.  
 
Interestingly, a recent study demonstrated that global repression of protein synthesis induces an alter-
native translational program, which promotes stem cell function and tumorigenesis [Blanco_2016]. 
Therefore, the authors genetically depleted Nop2/Sun domain family, member 2 (NSUN2), a methyl-
transferase catalyzing the methylation of tRNA precursors, in a tumor mouse model and found that 
protein synthesis was globally repressed. However, distinct transcripts escaped this repression and 
established an alternative translational program that stimulates stem cell functions and tumorigenesis. 
Surprisingly, these alterations render the cells more sensitive to cytotoxic stress.  
 
As a matter of fact, these findings are of particular relevance in the context of NKAP deficient mela-
nomas, as it has been shown that stem cell-like features are associated with increased invasiveness 
[Civenni_2011; Goding_2011; Vandamme_2014]. Hence, it might be that NKAP depletion-mediated 
translational inhibition activates an alternative translational stem cell program, which concomitantly 
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increases the metastatic behavior. However, further inquiries are necessary to prove that this transla-
tional escape mechanism also exists in melanoma and that NKAP depleted cells are associated with 
increased stemness. In a second step, further investigations would have to address whether NKAP 
deficiency renders melanoma cells more sensitive to cytotoxic stress.  
 
7.1.10. From neural crest stem cells to melanoma 
 
As mentioned above, it has been shown that repressed protein synthesis induces stem cell function and 
tumorigenesis. Moreover, it has been demonstrated that translation is generally reduced in stem cells 
when compared to more restricted cells [Blanco_2016]. Therefore, it was surprising to find NKAP up 
regulated in neural crest stem cells when compared to their early-differentiated derivatives. However, 
a translation profile has not yet been assessed, and therefore statements about the translation status of 
neural crest cells are purely speculative. Thus, it might be that during early differentiation translation 
drops transiently, in order to increase again during terminal differentiation. Furthermore, it is unclear 
whether NKAP acts context dependent, as the functional relevance of the interaction partners has not 
yet been resolved. It is conceivable that with different interaction partners NKAP gains temporal and 
spatial specificity. Therefore, it might be interesting to address the role of the NOTCH co-repressor 
complex with respect to NKAP function in a developmental context.  
 
7.1.11. Conclusion 
 
In summary, the results of my doctoral thesis demonstrate that the neural crest-associated factor 
NKAP plays an important role in melanoma. Initially, NKAP was identified in a genome-wide tran-
scriptome analysis comparing neural crest stem cells to their early-differentiated derivatives. On the 
basis of this array, it was the goal of my PhD study to identify a novel transcriptional regulator in-
volved in melanoma. Therefore, I performed NKAP loss-of-function and gain-of-function experiments 
using a human melanoma cell culture. The results revealed that NKAP localizes to nuclear speckles 
and interacts with RNA processing factors. The results further illustrated that NKAP depletion induces 
Discussion 
103 
a drastic reduction in protein synthesis, whereas NKAP overexpression is poorly tolerated by the cells 
and also decreases the translational activity. Consequently, these data show that aberrant NKAP ex-
pression results in impaired translational activity and indicate that NKAP is a tightly regulated protein 
required in co- or post-transcriptional processes. Nonetheless, it will be essential to show whether 
reduced translation is a consequence of decreased RNA synthesis or a consequence of impaired RNA 
processing. Strikingly, xenotransplantation experiments revealed that NKAP ablation increases the 
metastatic behavior of injected cells, although tumor growth is not affected. These results were further 
underlined with clinical data retrieved from the TCGA database, highlighting that low NKAP levels in 
lymph node and distant metastases are associated with poor survival in melanoma patients. Conse-
quently, these data suggest that NKAP depletion-mediated translational inhibition increases the meta-
static potential in melanoma. However, whether the initiation of an alternative translational stemness 
program elevates the metastatic proclivity in melanoma requires further investigations.  
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8. Materials and methods 
 
8.1. In vivo analysis 
 
8.1.1. Xenograft experiments 
 
Prior to injections, human melanoma cells were resuspended in 100 µl melanoma growth medium and 
100 µl BD MatrigelTM Matrix (354234 BD Biosciences). If not stated otherwise, 300’000 cells were 
injected subcutaneously into the right side of the back of adult NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) 
mice (Dr. Leonard D. Shultz, The Jackson Laboratory). The mice were sacrificed around 4-5 weeks 
after injection or when signs of pain, like hunched back, apathy, weight loss, scrubby fur or abnormal 
behavior, were observed. After dissection, primary tumors were weighed and the size was determined 
by measuring two diameters, perpendicular to each other, using a caliper. In order to assess the tumor 
volume we applied the following formula V = !! ƒ (length · width)3/2 [Feldmann_2009]. The xenograft 
studies were evaluated and approved by the cantonal veterinary office Zurich.  
 
8.1.2. Quantitative analysis of lung metastases 
 
In order to quantitatively assess the metastatic burden, the expression of human mRNA was measured 
in the lungs of injected mice. In short, dissected lungs were collected in 1.5 ml TRIzol® Reagent 
(15596-026 Invitrogen) and frozen at -80°C. After tissue homogenization and cell lysis, phenol-
chloroform-isoamyl alcohol mixture (77617 Sigma-Aldrich) was used for phase separation. Subse-
quently, Isopropanol was added for precipitation followed by a washing step with Ethanol. In order to 
increase the grade of purification the extracted RNA was subjected to the RNeasy Mini Kit (74106 
Qiagen) including RNase-free DNase (79254 Qiagen) treatment according to the manufacturer’s pro-
tocol. The RNA concentration was determined using a NanoDrop ND-1000 photospectrometer 
(NanoDrop Technologies). The Maxima First Strand cDNA Synthesis Kit (K1672 Thermo Fisher 
Scientific) was applied for the reverse transcription of 1 µg mRNA followed by an RNase H (EN0201 
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Thermo Fisher Scientific) digest in accordance with the supplier’s guidelines. Real-time quantitative 
PCR was performed on a LightCycler® 480 Instrument II using the LightCycler® 480 SYBR Green I 
Master (4887352001 Roche). Each sample was analyzed in technical triplicates and the primers used 
are listed in [Table 2]. Relative mRNA expression of human GAPDH and human PPIA was normal-
ized against murine housekeeping transcript USF1. 
 
Table 02. RT-qPCR primers 
 
    
Gene Species Forward sequence Reverse sequence 
GAPDH Human ATCATCCCTGCCTCTACTGG GTCAGGTCCACCACTGACAC 
PPIA Human TTCATCTGCACTGCCAGGAC TCGAGTTGTCCACAGTCAGC 
USF1 Mouse CAGGGCTCAGAGGCACTACT  GCTCCCTCCCTGCAATACTT 
 
8.2. In vitro analysis 
 
8.2.1. Molecular cloning 
 
Vectors and inserts were subjected to 0.5 U/µl restriction enzymes [Table 3] in the corresponding re-
action buffer. The digest was performed in 20 µl reaction volume for 1 h at 37°C. The reaction mix 
was separated in a 1% agarose gel (A8963,1000 AppliChem) by gel electrophoresis using a Mini-Sub 
cell GT electrophoresis cell (Bio-Rad). The desired DNA fragments were excised from the gel fol-
lowed by a gel purification using the QIAquick Gel Extraction Kit (28706 Qiagen) according to the 
manufacturer’s recommendations. In a 10 µl reaction volume, 200 ng of vector were ligated for 2 h at 
37°C with the corresponding amount of insert using 0.5 U/µl T4 Ligase (EL0011 Thermo Fisher Sci-
entific). Library Efficiency® DH5αTM Competent Cells (18263012 Thermo Fisher Scientific) or, in 
case of Gateway® cloning, OneShot® OmniMAXTM 2 T1R Chemically Competent E. Coli (C854003 
Thermo Fisher Scientific) were transformed by heat shock with 5 µl of the ligation mix according to 
standard protocols. Transformed bacteria were plated under 50 µl/ml Ampicillin (A0166 Sigma-
Aldrich®) or 100 µl/ml Kanamycin (K1377 Sigma-Aldrich®) selection on Luria Broth (LB) agar plates 
overnight at 37°C. Single colonies were cultured in 3 ml liquid LB medium supplemented with 50 
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µl/ml Ampicillin (A0166 Sigma-Aldrich®) or 100 µl/ml Kanamycin (K1377 Sigma-Aldrich®) over-
night at 37°C under constant shaking (220 rpm). The plasmid was purified using the QIAamp DNA 
Mini Kit (51306 Qiagen) according to the supplier’s recommendations. The DNA concentration was 
determined using a NanoDrop ND-1000 photospectrometer (NanoDrop Technologies). The plasmid 
was sent for Sanger sequencing (Microsynth AG) to confirm the sequence. In order to achieve high 
yield transfection-grade plasmid DNA, transformed bacteria were grown in 200 ml LB medium sup-
plemented with 50 µl/ml Ampicillin (A0166 Sigma-Aldrich®) or 100 µl/ml Kanamycin (K1377 Sig-
ma-Aldrich®) overnight at 37°C under constant shaking (220 rpm). The NucleoBond® Xtra Maxi 
(740414.50 Macherey-Nagel) kit was applied for plasmid extraction.  
 
Table 03. Restriction Enzymes  
    
U/µl Name Catalog # Manufacturer 
0.5 BamHI ER0055 Thermo Fisher Scientific 
0.5 ClaI ER0141 Thermo Fisher Scientific 
0.5 HindIII ER0501 Thermo Fisher Scientific 
0.5 KpnI ER0521 Thermo Fisher Scientific 
0.5 SacI ER1135 Thermo Fisher Scientific 
 
8.2.2.  Cell culture 
 
Human melanoma-derived cell cultures were established from surplus material from primary cutane-
ous melanoma and melanoma cell culture excised by surgery. Written consent obtained from all pa-
tients was approved by the local institutional review boards (EK647 & EK800). The utilized human 
melanoma cell cultures listed in [Table 4] were kindly provided by the URPP biobank, UZH and were 
previously characterized [Zipser_2011]. HEK293T cells were purchased from ATCC. Human mela-
noma cell cultures were cultured in melanoma growth medium consistent of RPMI 1640 (42401 
Thermo Fisher Scientific) supplemented with 10% heat inactivated fetal bovine serum (HI FBS, 16140 
Thermo Fisher Scientific), 4 mM L-Glutamine (25030 Thermo Fisher Scientific), Penicillin-
Streptomycin (50 U/ml; 50 µg/ml, 15070 Thermo Fisher Scientific) and GibcoTM Amphotericin B (0.5 
µg/ml, 15290 Thermo Fisher Scientific) as previously described [Shakhova_2012; Zipser_2011]. 
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HEK293T cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM, 11965 Thermo Fisher 
Scientific) supplemented with 10% HI FBS (16140 Thermo Fisher Scientific) and Penicillin-
Streptomycin (50 U/ml; 50 µg/ml, 15070 Thermo Fisher Scientific). All cells were maintained at 37°C 
and 5% CO2. 
 
Table 04. Human Melanoma Cell Cultures  
     
Cell Culture Gender Age Mutation Phenotype 
M980513 F 29 BRAF V600E Proliferative 
M000921 F 52 BRAF V600E Proliferative 
M010817 F 37 N-RAS Q61R Proliferative 
M050829 M 39 N-RAS Q61L Intermediate 
M121224 M 37 BRAF V600E / N-RAS Q61K Invasive 
M130219 M 48 N-RAS Q61R Invasive 
M130427 M 48 N-RAS Q61R Proliferative 
M130429 M 48 N-RAS Q61R Proliferative 
 
8.2.3. NKAP gene silencing by RNA interference in human melanoma cell cultures 
 
In order to temporarily deplete LIN9, LIN28A, NF-YA, NF-YB, NF-YC, NKAP and SSBP2, human 
melanoma cell cultures were transfected with small interfering RNA (siRNA) using FlexiTube 
GeneSolution (Qiagen) packages containing 4 preselected siRNAs [Table 5]. For transfection 25 nM 
siRNA were applied in combination with jetPRIME® transfection reagent (114-07 Polyplus Transfec-
tion) according to the manufacturer’s protocol. The melanoma growth medium was exchanged 24 h 
post-transfection. Unless otherwise stated, the cells were further processed and evaluated 72 h after 
transfection. As control siRNA, the AllStars Negative Control siRNA (SI03650318 Qiagen) was used.  
 
In order to achieve a stable NKAP knockdown, a small hairpin RNA (shRNA) expressing lentiviral 
construct was generated using the MuLE (Multiple Lentiviral Expression) system. Therefore, the 
shRNA sequence [Table 5] together with the U6 promoter was isolated from the TRC1-pLKO-puro 
vector (Mission® Sigma-Aldrich) and introduced into the pMuLE ENTR H1 L1-R5 (#62101 
Addgene) using ClaI and SacI restriction sites. The correct order of the sequence was confirmed by 
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Sanger sequencing (Microsynth AG). The Gateway® LR Clonase® II Enzyme Mix (11791100 Thermo 
Fisher Scientific) was used to combine the shRNA expressing entry vector with the pMuLE ENTR 
SV40 eGFP L5-L2 (#62144 Addgene) and the pLenti X1 Puro DEST (694-6) (#17297 Addgene) vec-
tor according to published instructions [Albers_2015]. For lentivirus production HEK293T cells were 
chemically transfected with 10 µg shRNA expression plasmid and 5 µg psPAX2 (#12260 Addgene) 
and 2.5 µg pMD2.G (#12259 Addgene) using 12.5 mM CaCl2 in Hepes Buffered Saline (HBS) ac-
cording to standard protocols. The medium was exchanged 24 h post-transfection and the virus con-
taining suspension was collected 48 h, 72 h and 96 h after transfection. For lentiviral infection mela-
noma cell cultures were incubated in 50% melanoma growth medium and 50% virus containing medi-
um for 24 h. To increase the infection rate, we supplemented the mix with 5 µg/ml Polybrene® (SC-
134220 Santa Cruz). As soon as the GFP marker was expressed, the selection procedure was started 
with 3 µg/ml Puromycin (ant-pr-1 Invitrogen) for 1 week. Furthermore, cells were sorted for high GFP 
expression using the BD FACSAriaTM III 5L (BD Biosciences) in order to increase the knockdown 
efficiency and to adjust GFP expression over all conditions.   
 
Table 05. RNA interference   
     
Function Gene Clone ID Target sequence Provider 
shRNA NKAP TRCN0000143174 GCATCATTTGAATGCTCAGGT Sigma-Aldrich 
shRNA NKAP TRCN0000145475 GCTGAAGAACCATCAGATTTA Sigma-Aldrich 
siRNA CIR SI04266199 CAGGGCATAACAACAGTGATT Qiagen 
siRNA CIR SI04253501 AACGTGTAAAGAATGGCCTTA Qiagen 
siRNA CIR SI04242553 CAGTAGTGAGAGTGAGAGTAA Qiagen 
siRNA CIR SI04175864 GTCCTGGTAGTTACAAGCAAA Qiagen 
siRNA LIN9 SI02779539 ACGAGTGGTTCTATTCAAATA Qiagen 
siRNA LIN9 SI02649003 TAGGCTTCCAACACCAAATAA Qiagen 
siRNA LIN9 SI02649010 TTCCTTTAGATGTCTCATAAA Qiagen 
siRNA LIN9 SI03034031 AAGCTTATCTAACACGTGGAA Qiagen 
siRNA LIN28A SI03126123 AACGGGACAAATGCAATAGAA Qiagen 
siRNA LIN28A SI04214938 CACCAGATTAGGTTAGGCCTA Qiagen 
siRNA LIN28A SI04321919 TAAAGACTTATTGGTACGCAA Qiagen 
siRNA LIN28A SI04365221 CACGCTGTGAGATCACCGCAA Qiagen 
siRNA NF-YA SI00658238 TAGAGGGTTATTAAACCTTGA Qiagen 
siRNA NF-YA SI05392576 CCGCGAGTCGTTCATTTAACA Qiagen 
siRNA NF-YA SI05392583 ACGGCCGGCACTTGCACTTAA Qiagen 
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siRNA NF-YA SI05392590 AAGCTAGACCTTTGCCTATTA Qiagen 
siRNA NF-YB SI04168836 CAGGTGCATAATATCCTAATT Qiagen 
siRNA NF-YB SI04216485 CTCTGCAATAAACTAAACGTA Qiagen 
siRNA NF-YB SI04312868 CTGGGTTACCAAATATGCAAA Qiagen 
siRNA NF-YB SI04341372 TTGCATGATAACCTAGCTAGA Qiagen 
siRNA NF-YC SI00658301 CAGCCTGTATCAGGCACTCAA Qiagen 
siRNA NF-YC SI04152169 CTCATCGATATTGTTCCAAGA Qiagen 
siRNA NF-YC SI04201673 CAGCTCTACCAGATCCAGCAA Qiagen 
siRNA NF-YC SI05140933 CAGCTGCAGTATATCCGCTTA Qiagen 
siRNA NKAP SI03164056 CACGCTCGCGGTCGCGTTCTA Qiagen 
siRNA NKAP SI04331929 AAGAAGAAGTCTAGCCGTTCA Qiagen 
siRNA NKAP SI04345348 AACTCTGGCCATGCTCTGTTA Qiagen 
siRNA NKAP SI04360412 TTGGCCTAGCCTCCTCGACAA Qiagen 
siRNA SSBP2 SI04141242 CGGGTCCAAATGTGATTCAAA Qiagen 
siRNA SSBP2 SI04154864 CACCAGGATTCTTACATTCTT Qiagen 
siRNA SSBP2 SI04240985 CAGCCCTTCACAGAACTACTA Qiagen 
siRNA SSBP2 SI04323452 TGCAATCATGGATAGGAATAA Qiagen 
 
8.2.4 CRISPR/CAS9-mediated NKAP knockout in human melanoma cell cultures 
 
The CRISPR/CAS9 technique was applied to completely ablate NKAP expression in human melano-
ma cell cultures. Therefore, the online available Optimized CRISPR Design tool 
(http://crispr.mit.edu/) was used to identify a 20 bp long sequence (TGATGAACATACACCAGTGG; 
quality score 69) targeting exon 1 of the NKAP gene. Single-stranded oligonucleotides [Table 6] were 
synthesized (Microsynth AG) and annealed in a TProfessional Basic thermal cycler (Biometra) under 
a slowly cooling temperature gradient from 95°C to 4°C. Double-stranded oligonucleotides were ligat-
ed into the single guide RNA (sgRNA) expressing MLM3636 (#43860 Addgene) vector using Golden 
Gate cloning. Human melanoma cell cultures were transfected with 10 µg MLM3636 and 10 µg 
pCAG-T7-Cas9-P2A-EGFP (kindly provided by the group of Dr. Pawel Pelczar, USZ) by electro-
poration (30 ms, 1 pulse, 1300 V) using a MicroPoratorTM (Digital Bio). Electroporation was carried 
out in melanoma growth medium devoid of antibiotic or antifungal additives. GFP positive cells were 
seeded as single cells into 96-well plates 3 days after transfection using a BD FACSAriaTM III 5L (BD 
Biosciences). In order to select NKAP depleted clones, genomic DNA was isolated according to 
standard protocols using proteinase K (3115828001 Roche) enriched lysis buffer and subsequent iso-
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propanol precipitation. The region encompassing the sgRNA target site was amplified in a PCR reac-
tion using the primers indicated in [Table 6] and send for Sanger sequencing (Microsynth AG). The 
PCR reaction was performed in a T3000 ThermoCycler (Biometra) using the AmpliTaq Gold® 360 
Master Mix (4398881 Applied BiosystemsTM) according to the manufacturer’s guidelines. Additional-
ly, the absence of the protein was confirmed by immunoblot analysis in compliance with previously 
described settings.  
 
Table 06. CRISPR/CAS9  
  
sgRNA oligonucleotides Sequence 
Forward Primer ACACCTGATGAACATACACCAGTGGG 
Reverse Primer AAAACCCACTGGTGTATGTTCATCAG 
Genomic PCR NKAP exon1 Sequence 
Forward Primer ATCTTTCCTATGGTTCCTGTTTCTC 
Reverse Primer CTTTCTCCTTTTCTTGGACCTTTC 
 
8.2.5. Generation of stably expressing HA_NKAP_eGFP human melanoma cell cultures 
 
The lentiviral overexpression construct for the HA_NKAP_eGFP fusion protein is based on the NKAP 
full-length sequence isolated from human melanocyte template cDNA. In brief, mRNA was extracted 
from human melanocytes using the RNeasy Mini Kit (74106 Qiagen) including RNase-free DNase 
(79254 Qiagen) treatment according to the manufacturer’s protocol. The Transcriptor High Fidelity 
cDNA Synthesis Kit (5081955001 Roche) was applied for the reverse transcription of 1 µg mRNA in 
accordance with the supplier’s guidelines. In a PCR reaction, the NKAP full-length sequence was 
amplified from template cDNA using the primers indicated in [Table 7]. The PCR reaction was per-
formed in a T3000 ThermoCycler (Biometra) utilizing the Expand High Fidelity PCR system 
(11732650001 Roche). In a previous step, the HA-tag (TACCCCTACGACGTCCCCGACTAC-
GCCGGATCC) was isolated from the pcDNA_HA vector (kindly provided by the group of PD Dr. 
Raffaella Santoro) and introduced N-terminal to the eGFP of the pMuLE ENTR SV40 eGFP L5-L2 
(#62144 Addgene) using HindIII and BamHI restriction sites. The NKAP full-length cDNA was then 
inserted between the HA-tag and the eGFP sequence using BamHI and EcoRI restriction sites. The 
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correct order of the sequence was confirmed by Sanger sequencing (Microsynth AG). The Gateway® 
LR Clonase® II Enzyme Mix (11791100 Thermo Fisher Scientific) was used to combine the 
HA_NKAP_eGFP overexpression vector with the empty pMuLE ENTR CMV L1-R5 (#62090 
Addgene) vector and the pLenti X1 Puro DEST (694-6) (#17297 Addgene) according to published 
instructions [Albers_2015]. The lentivirus production and subsequent infection of melanoma cell cul-
tures was performed as described above.  
 
Table 07. Overexpression primers 
  
Function Sequence 
Forward Primer TATATAGGATCCATGGCTCCGGTGTCC 
Reverse Primer GCTCGCTCGAGTTATTTGTCATCCTTC 
 
8.2.6. Proliferation assays and cell cycle analysis 
 
In order to address cell growth, 50’000 human melanoma cells were seeded in 6-well plates and the 
cell number was determined daily over 5 days using a Neubauer chamber. To determine the cell cycle 
profile, human melanoma cells were pulsed for 30 min with 10 µM 5-Ethynyl-2’-deoxyuridine (EdU) 
and stained with the Click-iT® EdU Alexa Fluor® 647 Imaging Kit (C10340 Thermo Fisher Scien-
tific). The cells were analyzed by counting 30’000 events using a BD FACSCantoTM II (BD Biosci-
ences) flow cytometer. Data evaluation was performed on the FlowJo 7.6 software.  
 
8.2.7. Adhesion assay 
 
To assess to adhesive capacity of human melanoma cell cultures, 500’000 cells were seeded in 6-well 
plates (140675 Thermo Fisher Scientific) in melanoma growth medium and incubated for 12 hours at 
37°C. The number of cells in suspension was determined with Countess Cell Counting Chamber 
Slides (Thermo Fisher Scientific) using an EVETM Automatic Cell Counter (NanoEnTek). Adherent 
cells were stained with 0.5 % (v/w) Crystal Violet (C3886 Sigma-Aldrich) in 20% Ethanol for 5 min 
at room temperature. In order to quantify the area covered by cells, 5 randomized pictures per well 
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were recorded with a DMI 6000B (Leica) microscope and evaluated using the CellProfiler 2.0 soft-
ware [Carpenter_2006]. 
 
8.2.8. Boyden chamber invasion assay 
 
As a preparation to the invasion assay human melanoma cells were starved for 48 h in melanoma 
growth medium containing only 1% HI FBS (16140 Thermo Fisher Scientific).  Subsequently, 
150’000 cells were subjected to Corning® BioCoatTM Matrigel® Invasion Chamber inserts containing 
HI FBS-free melanoma growth medium. Cells were incubated for 22 h to allow migration along the 
nutrient gradient, where melanoma growth medium containing 10% HI FBS acted as chemoattractant. 
Invaded cells were fixed in 3.7% formaldehyde (F8775-25ML Sigma-Aldrich) for 10 min at room 
temperature and stained with Hoechst 33342 (145533 Sigma-Aldrich). Excised membranes were 
mounted on cover slides, and cells were visualized using a DMI 6000B (Leica) microscope. Cell num-
bers were quantified by the CellProfiler 2.0 software [Carpenter_2006].  
 
8.2.9. Immunocytochemistry 
 
Cells were seeded on NuncTM ThermanoxTM Coverslips 25 mm (174985 Thermo Fisher Scientific) in 
6-well plates and fixed in 3.6% formaldehyde (F8775-25ML Sigma-Aldrich) for 10 min at room tem-
perature. Cells were permeabilized with 0.2% Tween®20 (P2287 Sigma-Aldrich) in phosphate buff-
ered saline (PBS; 10010-056 Thermo Fisher Scientific) for 1 h at room temperature and blocked with 
1% bovine serum albumin (BSA; A9418-5G Sigma-Aldrich) in PBS (10010-056 Thermo Fisher Sci-
entific) for 1 h at room temperature. Immunofluorescent staining was performed using primary anti-
bodies [Table 8] in PBS with 1% BSA over night at 4°C and secondary antibodies [Table 9] were 
applied in PBS with 1% BSA for 1 h at room temperature. Nuclei were visualized with Hoechst 33342 
(145533 Sigma-Aldrich). Cover slips were mounted on glass slides and images were recorded using a 
DMI 6000B (Leica) microscope or an SP8 (Leica) Confocal Laser Scanning Microscope.  
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Table 08. Primary antibodies 
   
      
Antigen Species Type Dilution Catalog # Company 
GFP Chicken Polyclonal 1:200 GFP-1020 Aves Labs. Inc. 
HA-tag Mouse Monoclonal  1:400 ab1424 Abcam 
Human NKAP Goat Polyclonal 1:250 sc-161948 Santa Cruz 
Human SC35 Mouse Monoclonal 1:400 ab11826 Abcam 
 
Table 09. Secondary antibodies 
   
    
Antibody Dilution Catalog # Company 
Alexa Fluor® 546  
Goat anti-Mouse IgG (H+L) 1:400 A-11030 Thermo Fisher Scientific 
Alexa Fluor® 555  
Donkey anti-Goat IgG (H+L) 1:250 A21432 Thermo Fisher Scientific 
Alexa Fluor® 647-AffiniPure  
Donkey anti-Mouse IgG (H+L) 1:250 715-605-150 Jackson ImmunoResearch 
Alexa Fluor® 647-AffiniPure  
Goat anti-Chicken IgY (IgG)(H+L) 1:250 103-605-155 Jackson ImmunoResearch 
Cy3-AffiniPure  
Goat anti-Mouse IgG (H+L) 1:250 115-165-003 Jackson ImmunoResearch 
 
8.2.10. Protein isolation and immunoblot analysis 
 
Cells were resuspended in 400 µl RIPA Lysis and Extraction Buffer (89900 Thermo Fisher Scientific) 
supplemented with Halt Phosphatase/ Protease Inhibitor Cocktail  (78420/87786 Thermo Fisher Scien-
tific) and either processed immediately or stored at -80°C. Protein concentration was determined using 
the PierceTM BCA Protein Assay Kit (23225 Thermo Fisher Scientific) in accordance with the manu-
facturer’s recommendations. The protein solution was prepared by adding 4x Laemmli Sample Buffer 
(1610747 Bio-Rad) followed by denaturation at 95°C for 5 min. If not stated differently, 50 µg of pro-
tein were subjected to a 4-20% Mini-PROTEAN® TGXTM Precast Protein Gel (4561094 Bio-Rad) and 
separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) using 
Tris/Glycine/SDS (1610732 Bio-Rad) running buffer and a Mini-PROTEAN® Tetra Vertical Electro-
phoresis Cell (1658004 Bio-Rad). Proteins were transferred on 0.45 µm nitrocellulose membranes 
(1620215 Bio-Rad) by blotting for 1 h at 110 V in Tris/Glycine transfer buffer (1620734 Bio-Rad) 
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using a Mini Trans-Blot® Cell (1703930 Bio-Rad). Membranes were blocked in Odyssey blocking 
buffer (927-40100 LI-COR) for 1 h at room temperature. Primary antibodies [Table 10] were applied 
in Odyssey blocking buffer (927-40100 LI-COR) overnight at 4°C. The membrane was incubated with 
secondary antibodies [Table 11] in Odyssey blocking buffer (927-40100 LI-COR) for 1 h at room 
temperature. Membranes were scanned and processed using the Odyssey imaging system (LI-COR).  
 
Table 10. Primary antibodies 
   
      
Antigen Species Type Dilution Catalog # Company 
HA-tag Mouse Monoclonal  1:2’000 ab1424 Abcam 
Human NKAP Goat Polyclonal 1:250 sc-161948 Santa Cruz 
Human β-ACTIN Mouse Monoclonal 1:10'000 a5316 Sigma-Aldrich 
Human β-ACTIN Rabbit Monoclonal 1:10'000 4970 Cell Signaling 
 
Table 11. Secondary antibodies    
    
Antibody Dilution Catalog # Company 
IRDye 680 LT Donkey anti-Mouse IgG (H+L) 1:10'000 926-68022 LI-COR 
IRDye 680 LT Donkey anti-Rabbit IgG (H+L) 1:10'000 926-68023 LI-COR 
IRDye 800 CW Donkey anti-Goat IgG (H+L) 1:10'000 926-32214 LI-COR 
IRDye 800 CW Donkey anti-Mouse IgG (H+L) 1:10'000 926-32212 LI-COR 
 
8.2.11. RNA isolation and real-time quantitative PCR 
 
RNA was extracted from cells using the RNeasy Mini Kit (74106 Qiagen) including RNase-free 
DNase (79254 Qiagen) treatment according to the manufacturer’s protocol. RNA concentration was 
determined by the NanoDrop ND-1000 photospectrometer (NanoDrop Technologies) and 1 µg RNA 
was subjected to reverse transcriptase reaction using the Maxima First Strand cDNA Synthesis Kit 
(K1672 Thermo Fisher Scientific) followed by a RNase H (EN0201 Thermo Fisher Scientific) treat-
ment in accordance with the supplier’s guidelines. Real-time quantitative PCR was performed on a 
LightCycler® 480 Instrument II using the LightCycler® 480 SYBR Green I Master (4887352001 
Roche). Each sample was analyzed in technical triplicates and the primers used are listed in [Table 
12]. Relative mRNA expression was normalized against human housekeeping transcript RPL28. 
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Table 12. RT-qPCR primers 
 
    
Gene Species Forward sequence Reverse sequence 
CIR Human GAAAGGAGCCCCACGAGAAA AGTGGGAACCGAACTTGCAT 
LIN28A Human CGGGCATCTGTAAGTGGTTC CAGACCCTTGGCTGACTTCT 
LIN9 Human GGAACGAAAGTTACAGCACGA CAAGCCCTGTCCTATCAAAAGT 
NF-YA Human GAGCCCCTGTATGTGAATGC TGTCATGGCTTCTTCGTCAC 
NF-YB Human GGAAAGATCGCAAAAGATGC GTCTTCCGCTTCTCCTGATG 
NF-YC Human AGACAGAGGTCCAGCAAGGA GGCTGATTGGCTGACTGAAT 
NKAP Human TGAAGATAGCGACAGTGACTCT CAGCCTTTGTTCGATCCTTCC 
RPL28 Human GCAATTGGTTCCGCTACAAC TGTTCTTGCGGATCATGTGT 
SSBP2 Human CTCCTGGGAATTATGTAGGTCCT AGAGCCATTCATGTGATGTGAC 
 
8.2.12. RNA sequencing and gene expression profiling 
 
RNA sequencing including sample preparation was performed by the Functional Genomic Center 
Zurich (FGCZ). In short, the quantity and quality of the isolated RNA was determined with a Qubit® 
(1.0) Fluorometer (Thermo Fisher Scientific) and a Bioanalyzer 2100 (Agilent). The TruSeq Stranded 
mRNA Sample Prep Kit (Illumina) was used in the succeeding steps. Briefly, total RNA samples (1 
µg) were poly(A) enriched and fragmented with divalent cations and elevated temperature. Fragment-
ed RNA was subjected to reverse transcription with addition of Actinomycin that allows RNA but not 
DNA dependent synthesis. In order to achieve strand specificity, dUTP was incorporated instead of 
dTTP during second strand synthesis. A single ‘A’ nucleotide is added to the 3’ ends prior to ligation 
of the TruSeq adapters, which comprise the index for multiplexing. In a PCR reaction, fragments fea-
turing TruSeq adapters were enriched. The quality and quantity of the enriched libraries were validat-
ed by RT qPCR using a LightCycler 96 (Roche) and the Bioanalyzer 2100 (Agilent). The TruSeq SR 
Cluster Kit v3-cBot-HS (Illumina) was used for cluster generation using 8 pM of pooled normalized 
libraries on cBOT. Sequencing was performed on the HiSeq 2500 single end 125 bp (Illumina) using 
the TruSeq SBS Kit v3-HS (Illumina). Gene ontology pathway enrichment analysis was performed 
with MetaCoreTM (Thomson Reuters).  
Material and methods 
117 
8.2.13. Pull-down assays and mass spectrometry 
 
Cell nuclei were isolated using buffer A (10 mM Hepes pH 7.6, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM 
DTT) and a Dounce homogenizer. Subsequently, nuclei were resuspended in buffer 1 (0.3 M sucrose, 
15 mM TRIS-HCl pH 7.5, 60 mM KCl, 15 mM NaCl, 5 mM MgCl2, 0.1 mM EDTA, 0.5 mM DTT, 
0.5% NP40, 1% sodium deoxycholate). Nuclei were subjected to MNase (30 U) treatment in MNase 
buffer (0.3 M sucrose, 85 mM TRIS-HCl pH 7.5, 3 mM MgCl2, 2mM CaCl2) and sonicated for 10 sec. 
From the resulting supernatant 0.5 mg protein was immunoprecipitated overnight at 4°C using anti-
HA-Agarose (A2095 Sigma-Aldrich). Proteins were eluted with 100 µg/ml Influenza Hemagglutinin 
(HA) peptide (12149 Sigma-Aldrich). Proteins were precipitated with 20% trichloroacetic acid (TCA) 
and washed with cold acetone. Dried pellets were dissolved in 30 µl buffer (10 mM TRIS, 2 mM 
CaCl2 pH 8.2), 10 µl acetonitrile, 5 µl trypsin (100 ng/µl in 10 mM HCl) and 5 µl RapiGestTM (Waters 
Inc.). After centrifugation, dried pellets were dissolved in 0.1% formic acid. Mass spectrometry was 
performed at the FGCZ. After transferring the proteins to autosampler vials, 2 µl injection volume was 
analyzed by liquid chromatography tandem mass spectrometry (LC-MS/MS) using a nanoACQUITY 
UPLC® system (Waters Inc.) connected to a Q ExactiveTM Hybrid Quadrupole-OrbitrapeTM Mass 
Spectrometer (Thermo Fisher Scientific). Database analysis was performed using the Mascot Search 
Engine (Matrix Science). Scaffold 4 (Proteome Software) was used to visualize search results for the 
SwissProt_2015_11 database assuming a trypsin digest. 
 
8.2.14. Translational activity assay 
 
In order to address translational activity, human melanoma cells were pulsed for 30 min with 20 µM 
O-propargyl-puromycin (OP-puro) and stained with the Click-iT® Plus OPP Alexa Fluor® 647 Protein 
Synthesis Assay Kit (C10458 Thermo Fisher Scientific). As a negative control human melanoma cells 
were pre-incubated with 50 µg/ml cycloheximide (C1988-1G Sigma-Aldrich). The cells were ana-
lyzed by counting 30’000 events using a BD FACSCantoTM II (BD Biosciences) flow cytometer. Data 
evaluation was performed on the FlowJo 7.6 software.  
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8.3. In silico analysis 
 
8.3.1. TCGA analysis 
 
RNA sequencing and clinical data for melanoma patients were retrieved from The Cancer Genome 
Atlas (TCGA; http://cancergenome.nih.gov/). Statistical data analysis was performed as previously 
described using the TCGA Browser v0.9 online tool (tcgabrowser.ethz.ch:3839/TEST/) 
[Cheng_2015]. For differential expression and survival analysis in primary tumors or lymph nodes and 
distant metastases the dataset was segregated into NKAP high (top 15%) and low (bottom 15%) ex-
pressing patient samples. 
 
8.3.2. Statistical analysis  
 
For xenograft experiments at least 3 mice were injected. The unpaired Student’s t-test was used to 
statistically evaluate the size and weight of primary tumors as well as the metastatic burden in lung 
tissue. In vitro experiments were performed as triplicates. In order to compare to groups the unpaired 
Student’s t-test was applied. P<0.05 was considered as significant. Statistical analysis was done with 
GraphPad PRISM (Graphpad Software Inc.).  
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